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   Cytokine receptor signalling is involved in regulating a number of key biological processes, 
including blood and immune cell development and function. The ability to control such 
signalling, particularly mechanisms to extinguish these signals in a timely manner, are 
essential in order to avoid pathogenic outcomes. The Suppressor of cytokine signalling 
(SOCS) family of proteins represents one mechanism that facilitates this. 
   The Cytokine inducible SH2 domain-containing (CISH) protein was the first member of the 
SOCS family identified. Studies in vitro have suggested the involvement of CISH as a 
negative feedback regulator of signalling by EPO, IL-2, GH and G-CSF. However, at the time 
of commencement of this project in vivo studies on the role of CISH remained limited, with 
no Cish knockout mouse available. This thesis describes the generation and characterization 
of Cish-targeted mice, with an emphasis on examining blood cell development.   
   Mice were generated from ES cells in which the Cish locus was targeted with a lacZ-neo 
cassette. The presence of the inserted lacZ gene allowed Cish expression to be assessed by β-
galactosidase staining. Expression was observed from 11.5 days post-conception in the fetal 
liver and continued in the brain and vertebrae and at later time points during fetal 
development in the abdomen, digits, tail and forelimb. Expression of Cish was widespread in 
adult tissues from mice of both genders, including the eye, brain, lung, heart, liver, stomach, 
pancreas, kidney and genital organs. Increased Cish expression was observed in the mammary 
gland, brain and ovary of pregnant and lactating mice compared to virgin mice.  
   CishlacZ/lacZ mice were viable, healthy and fertile with no major defects identified. However, 
male CishlacZ/lacZ mice showed a statistically significant decrease in weight due to reduced 




blood cell indices and a trend for increased spleen weight in both gender compared to their 
wild-type counterparts, which prompted further investigation.   
   Ablation of CISH resulted in perturbed fetal erythropoiesis consistent with the high level of 
Cish expression in the fetal liver. CishlacZ/lacZ mice also exhibited mild steady-state anaemia in 
adult mice, with suppression of bone marrow erythropoiesis that was largely compensated by 
enhanced splenic erythropoiesis. At steady state, CishlacZ/lacZ mice showed increased immature 
erythroblasts with reduced erythroid progenitors in the bone marrow, with elevated erythroid 
progenitors, and immature erythroblasts in the spleen compared to their wild-type 
counterparts.  Cish was demonstrated to be strongly induced by EPO in adult erythroblasts. 
However, EPO-induced erythropoiesis was blunted in the bone marrow, but enhanced in the 
spleen of CishlacZ/lacZ mice, again associated with expansion of immature erythroblasts at the 
expense of more mature cells. Peripheral blood analysis showed a significant increase in 
MCV, and reduction in MCHC at steady-state condition compared to wild-type group. EPO 
injection of CishlacZ/lacZ mice led to a delayed and blunted elevation of these parameters, 
although these continued to increase after EPO injection was stopped. 
    Ablation of Cish caused no significant change in peripheral total white blood cell count, but 
neutrophils, monocytes and eosinophils were significantly higher in CishlacZ/lacZ mice with a 
concomitant decrease in lymphocytes. Elevated levels of Gr-1+ cells and CD11b+ cells were 
observed in both the bone marrow and spleen of CishlacZ/lacZ mice compared to their wild-type 
counterparts. G-CSF injection caused a significantly higher increase in the cellularity of  the 
bone marrow but not spleen of CishlacZ/lacZ mice, with a significant elevation in total and 
relative number of GR-1+ and CD11b+ cells as well as CFU-G and CFU-M colonies in the 
bone marrow compared to wild-type counterparts. CishlacZ/lacZ mice also showed increased 




treatment, along with decreased circulating neutrophils and lymphocytes compared to their 
wild-type counterparts. 
   These data presented in this thesis point to CISH as an important physiological regulator of 
cytokine receptor signalling in vivo, with a role in the regulation of EPO-mediated red blood 
cell development, as well as impacting on white blood cell development. Recent studies have 
also reported the involvement of Cish in the regulation of CD4+ T cells, CD8+ T cell, and NK 
cells in response to IL-4, TCR and IL-15 respectively. This collectively suggests CISH is a 
broad regulator of cytokine and other signals important for maintaining appropriate levels of 
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1.1 Cytokines and their receptors  
1.1.1 Cytokines 
 Multicellular organisms represent intricate biological systems reliant on a myriad of signals 
that coordinate embryogenesis, growth, homeostasis, reproduction and defence. A major part 
of this coordination is mediated by a network of cytokines (Thomson 2003).  These are low-
molecular weight proteins secreted by different cell types in response to external stimuli, 
which mediate cell-cell communication by binding to specific receptors on the surface of 
target cells (Baker et al. 2007). Cytokines are involved in a range of developmental and 
physiological processes, including haematopoiesis, mammary gland development, lactation, 
growth dimorphism, stem cell maintenance, tissue protection and repair (Resch et al. 2011). 
Cytokines are classified into a number of families according to their structure and function. 
Class I cytokines, or haematopoietins, comprise interleukins (ILs) and haematopoietic 
colony-stimulating factors (CSFs), as well as hormones such as erythropoietin (EPO) and 
prolactin (PRL) (Lotze et al. 2003; Turner et al. 2014). Class II cytokines comprise the 
interferons (IFNs) and related molecules, with the other families of cytokines comprising 
tumour necrosis factor (TNF)-related molecules and chemokines (Krause et al. 2005; Renauld 
2003). Cytokines are firmly regulated at the transcriptional level, with dysregulation of 
cytokine expression contributing to diseases such as immunodeficiency, inflammatory 
disorders, asthma, solid tumours and leukaemia (Rowell et al. 2008; Victotatos et al. 1997). 
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1.1.2 Cytokine receptors  
 Cytokines exerts their effects via specific cognate receptors located on the cell surface 
(Elliott et al. 2014). Most cytokine receptors contain multiple subunits, typically including a 
specific ligand-binding subunit and a signal-transducing subunit (Baker et al. 2007).  
Cytokine receptors fall into two groups: class I and class II (Drachman et al. 1995). Cytokine 
receptor chains consist of an extracellular, a transmembrane and an intracellular domain (Ihle 
1994). The class I receptors have a conserved extracellular domain comprising around 200 
amino acids, with a WSXWS motif toward the C-terminus of this domain necessary for 
recognition, along with four positional conserved residues toward the upper N-terminus of 
this domain important for maintaining structure (Mackiewics et al. 1995). The extracellular 
domains of class II receptor have some similarities in their ligand-binding region, with the 
intercellular domains having several conserved motifs (Krause et al. 2005).   
Class I cytokine receptors are classified into three main families: IL-2R, IL-3R and IL-6R, 
each of which consist of receptors that share a common receptor chain (O'Sullivan et al. 
2007). The IL-2R family comprises of IL-2R, IL-4R, IL-7R, IL-9R, IL-15R and IL-21R 
(Ozaki et al. 2002) and is principally involved in the growth and maturation of lymphoid 
cells. The IL-3R family consist of IL-3R and IL-5R important for the production of 
myelomonocytic cells with broad roles in immunity and haematopoiesis (Boulay et al. 2003). 
The IL-6R family comprises IL-6R, IL-11R, leukaemia inhibitory factor receptor (LIFR), 
oncostatin M receptor (OSMR), ciliary neurotrophic factor receptor (CNTFR) and the 
cardiotrophin (CT) receptor (Krause et al. 2005). These are also a group of homomeric 
receptors, including erythropoietin receptor (EPOR), thrombopoietin receptor (TPOR), 
prolactin receptor (PRLR) and growth hormone receptor (GHR), which are involved in 
haematopoiesis, growth and metabolism (Boulay et al. 2003). Class II receptors represent the 
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IFN receptors and molecules related to IL-10R. These are mainly involved in the induction of 
antiviral activity and inflammatory responses (O'Sullivan et al. 2007). 
1.2 Cytokine receptor signalling 
Binding of a cytokine to its receptor initiates dimerization of receptor chains (Maruyama 
2015) and other changes in receptor conformation that activates tyrosine kinases such as 
Janus kinases (JAKs) and other proteins associated with the receptor cytoplasmic domain 
(Fig. 1.1). This leads to phosphorylation of tyrosine residues on the receptor complex, which 
serve as docking sites for cytoplasmic signalling proteins, including latent Signal transducer 
and activator of transcription (STAT) proteins. STATs then dimerize and enter the nucleus, 
where they activate gene transcription via specific promoter elements (Seif et al. 2017). A 
number of physiological regulators of cytokine signalling exist, especially the Suppressor of 
cytokine signalling (SOCS) family of proteins, which are induced by cytokines to provide a 
negative feedback loop to repress further signalling (O'Sullivan et al. 2007). Other regulators 
include various protein tyrosine phosphatases (PTPs), including Src-homology phosphatase 
type-1 (SHP-1) and type-2 (SHP-2), CD45, PTP1B and T-cell PTP, and members of the 
protein inhibitor of activated STAT (PIAS) family (Hendriks et al. 2013). 
1.3 Janus kinases (JAKs) 
1.3.1 JAK structure 
 There are four mammalian JAKs: JAK1, JAK2, JAK3 and the alternatively named tyrosine 
kinase 2 (TYK2). The genes encoding the JAK family members are located on three different 
chromosomes. In mice, JAK1 is located on chromosome 4, JAK2 on Chromosome 19, and 
JAK3 and TYK on chromosome 8 (Pritchard et al. 1992). Analysis of the JAK sequences has 
 Chapter 1: Literature review 
5 
 
revealed seven conserved regions across the four JAK proteins, named JH1-JH7 (Aaronson et 
al. 2002; Yamaoka et al. 2004) (Fig. 1.2). 
 The JH1 domain lies at the carboxyl-terminus and has tyrosine-kinase activity. The JH2 
domain is a pseudo-kinase domain that lacks enzymatic activity, but is suggested to serve a 
regulatory function for the tyrosine kinase domain (Ihle 2001). The more N-terminal domains 
have been implicated in the specificity of binding to the cytokine receptor. The JH7, JH6, 
JH5 and half of the JH4 domain constitute a so-called FERM domain, which has been shown 
to mediate interactions with proline-rich sequences in the cytoplasmic region of cytokine 
receptors (Ferrao et al. 2017). The other half of the JH4 plus JH3 domain comprise a SH2 
domain, which contributes to recognition and binding to specific phosphotyrosine residues in 
cytoplasm (Kisseleva et al. 2002) and is likely to have structural role as well (Ragimbeau et 
al. 2003). 
1.3.2 Signalling by JAKs   
 Different cytokine receptor complexes preferentially utilize specific JAKs (Ortmann et al. 
2000).  For example, JAK1 is involved in signalling by members of the IL-2 receptor family, 
the IL-4 receptor family, the GP130 receptor family, and various class II cytokine receptors 
(Kisseleva et al. 2002). JAK2 is involved in signalling by members of the single chain 
receptor family, such as EPOR, GHR, PRLR and G-CSFR, the IL-3R family, the GP130 
receptor family and the class II receptor cytokine family (Parganas et al. 1998). JAK3 is 
mainly limited to receptors that employ the common gamma (γc) receptor chain, while TYK2 
is involved in signalling via IL-6R, IL-10R and IL-12R (Jatiani et al. 2010). 
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1.3.3 Role of JAKs in vivo 
    Jak1 knockout mice are small at birth and show early postnatal lethality due to 
neurological damage, which results in a failure to suckle (Imada et al. 2000), likely due to 
decreased responses to leukaemia inhibitory factor (LIF) and IL-6 as a result of impairment 
of GP130-mediated signalling (Kisseleva et al. 2002) (Table 1.1). These mice exhibit defects 
in lymphopoiesis, with reduced T cell and B cell production caused by impaired 
responsiveness to IL-7, a cytokine important in early lymphocyte development. The loss of 
JAK1 also produces defective responses to type I and type II interferons, as well as IL-10 
(Muller et al. 1993). Jak1 null mice also show a range of hematopoietic defects, including 
reduction in thymocyte production, lymphoid development and B cell differentiation 
impairment, and lack of responsiveness to G-CSF, IL-2, IL-4, IL-7, IL-9, IL-13 and IL-15 
(Rodig et al. 1998). 
     Jak2 knockout mice demonstrate embryonic lethality, with death 12.5 days post-
conception due to a defect in definitive erythropoiesis resulting in severe anaemia (Neubauer 
et al. 1998; Parganas et al. 1998).  This phenotype is similar to that observed with Epor 
knockout mice (Neubauer et al. 1998; Wu et al. 1995). Cells from Jak2 knockout embryos are 
not responsive to EPO, TPO, IL-3, GM-CSF or IFN , while the responses to G-CSF, IFN/β 
and IL-6 are normal (Neubauer et al. 1998; Parganas et al. 1998). Mice lacking JAK2 show 
severe haematopoietic phenotypes, suggesting a critical role for JAK2 in erythroid/myeloid 
lineage differentiation (Neubauer et al. 1998) likely important role in downstream signalling, 
EPO, TPO and IL-3 (Ortmann et al. 2000).   
    JAK3 is mainly expressed in haematopoietic tissues, with high expression in thymocytes 
and NK cells (Witthuhn et al. 1994). Jak3 knockout mice exhibit extensive failure in 
lymphopoiesis, resulting in a SCID-like phenotype that includes a smaller thymus and spleen, 
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and reduced number of lymphocytes in the peripheral blood (Nosaka et al. 1995). This 
phenotype is similar to that observed in mice lacking the c receptor chain (Johnston et al. 
1994). This protein is a component of the receptors for IL-2, IL-4 and IL-7, with Jak3 
knockout mice impaired in response to these cytokines (Nosaka et al. 1995; Park et al. 1995).  
   Tyk2 knockout mice develop normally, but show an increased sensitivity to pathogens due 
to defective responsiveness to IL-12 and IFN/β (Matsuda et al. 2000). Consequently these 
mice are susceptible to viral and bacterial infections due to defects in T helper 1 (Th1) and T 
helper 17 (Th17) differentiation (Karaghiosoff et al. 2000).  
 
1.4 Signal transducers and activators of transcription (STAT) 
1.4.1 STAT structure  
   There are seven STATs protein in mammals: STAT1, STAT2, STAT3, STAT4, STAT5A, 
STAT5B and  STAT6, which range in size from 750 to 850 amino acids (Strehlow and 
Schindler 1998). STAT proteins consist of seven conserved regions that include the NH2-
terminal,  coiled-coil, DNA binding , linker, tyrosine activation, C-terminal transactivation 
and SH2 domains (Fig 1.3).  
The NH2-terminal domain is a well-conserved region and very important for STAT function. 
It contributes to the recognition of receptors, the regulation of nuclear translocation, 
dephosphorylation as well as cooperation with the DNA-binding domain (Mertens et al. 
2006). The coiled-coil domain plays a role in protein-protein interactions, and has also been 
implicated in receptor binding and nuclear export (Kisseleva et al. 2002). The DNA binding 
domain  has an important role in effective transcriptional activity by binding to specific 
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sequences in the promoters of responsive genes (McBride et al. 2000). The linker domain acts 
as a spacer to retain conformation and  contributes to  transcriptional regulation and 
phosphotyrosine binding, whereas the SH2 domain, which is the most highly conserved 
domain,  has the  essential role of conferring selectivity of STAT binding to specific 
phosphotyrosines on cytokine receptor components and other STATs (Kisseleva et al. 2002). 
The carboxyl-terminal transactivating domain (TAD), which is divergent and largely specific 
for each STAT protein, mediates the transcriptional responses (Schindler et al. 2007). 
Activated JAKs  phosphorylate a conserved tyrosine adjacent to the SH2 domain, facilitating  
STAT dimerization via interaction  between the phosphotyrosine and the SH2 domain of a 
partner STAT (Ward et al. 2000b). STAT1, STAT3, STAT4, STAT5A and STAT5B can also 
be modified by serine phosphorylation that affects transactivation. In addition, STATs can be 
modified by methylation, acetylation, ubiquitylation, ISGylation and sumoylation (Zhuang 
2013).   
 
1.4.2 Signalling by STATs 
   Specific STATs are utilized by different cytokine receptors to mediate their effects (Fig. 
1.4). STAT1 is involved in IFN signalling, with IFN stimulation leading to the formation of 
STAT1 homodimers, which induce transcription from GAS (gamma-activated site) sequences 
in key immune genes (Ramana et al. 2000). STAT1 is also activated by IFN-α/β, leading to 
formation of STAT1 homodimers and STAT1/STAT2 heterodimers (Ivashkiv et al. 2014). 
   STAT2 is involved in IFN signalling, including IFN, IFNβ, and IFN-, in particular IFN 
/β (Sheppard et al. 2003). After stimulation by IFN/β, both STAT1 and STAT2 are 
activated and subsequently heterodimerize, enabling interaction with p48 in the nucleus to 
create a transcriptional complex (Li et al. 1996). Among all STAT family members, STAT2 
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is unique in not directly binding to DNA after activation, instead binding to GAS sequence 
using IRF-9 for binding (Park et al. 2000). 
  STAT3 is expressed in most tissue and was first identified as an acute-phase response factor 
downstream of IL-6 (Duncan et al. 1997). However, STAT3 is also activated by many other 
cytokines, including IL-7, IL-9, LIF and OSM (Akira et al. 1994). Furthermore, STAT3 has 
been shown to be constitutively activated in many cancer cell lines and solid tumours can 
also activate STAT3 (Bowman et al. 2000).  
   STAT4 is only expressed in NK cells, dendritic cells and T lymphocytes, where it is 
induced by IL-12, which has an essential role in the Th1 subset of T cells (Liu et al. 2005). 
STAT4 has been shown to be activated by IL-12 and IL-23 in a rodent cell line (Oppmann et 
al. 2000) as well as IFNα in human cell lines through recruitment via interaction with STAT2 
(Farrar et al. 2000).  
    STAT5 was initially identified as a mammary gland factor activated by prolactin 
(Gouilleux et al. 1994). It was later discovered that there are actually two closely related 
STAT5 proteins, STAT5A and STAT5B, showing 96% identity and only differing markedly 
at their carboxyl terminal (Mui et al. 1995). STAT5A and STAT5B genes are localised on 
chromosome 11, and functionally linked and overlapping each other yet harbour a distinct 
function (Teglund et al. 1998). Both STAT5A and STAT5B are also induced by many factors 
including members of the IL-3 family (IL-3, IL-5 and GM-CSF) and the IL-2 family (IL-2, 
IL-7, TSLP, IL-9, IL-15 and IL-21), as well as growth hormone (GH), erythropoietin (EPO) 
and thrombopoietin (TPO) (Liao et al. 2014; Wang et al. 2011; Yu et al. 2011). While 
expression of both STATs is broad, STAT5A is expressed at higher levels in mammary 
tissue, but STAT5B is more highly expressed in muscle and liver (Hennighausen et al. 2008). 
STAT5 is a key factor in myeloid cell mobilization and survival (Wang et al. 2013).  
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STAT6 is also expressed in a wide range of tissues (Hou et al. 1994) and is activated by IL-4 
and IL-13, which share a common receptor chain, and are both important in acquired 
immunity, especially the production and activation of Th2 cells (Khaled et al. 2007). IFNα 
can also activate STAT6, and STAT6 target genes in B cells, such as those encoding CD23, 
GATA3, MHC class II and immunoglobin heavy chain ε (Shimoda et al. 1996). 
 
1.4.3 Role of STAT proteins in vivo  
   Stat1 knockout mice are viable and fertile (Table 1.2). However, they are impaired in 
responses to viral and microbial agents. This is due to defective signalling by both IFN and 
IFN, which play critical roles in moderating innate and acquired immunity (Durbin et al. 
1996). Stat1 knockout animals are also more susceptible to chemical-induced tumours when 
compared with wild-type animals (Schreiber et al. 2009). Stat1 null mice develop a chronic 
pulmonary inflammatory condition that leads to death following alleviated influenza infection 
whereas wild-type mice are able to clear the infection (Durbin et al. 2000). In addition to a 
role for STAT1 in the immune response, STAT1 can also have non-immune functions such 
as bone homeostasis, with mice lacking STAT1 exhibiting increased bone mass, mineral 
content of bone and other related bone growth factors due to a significant in vivo elevation of 
fibroblast growth factor (FGF) expression in osteoblasts compared to osteoclasts (Kim et al. 
2003; Xiao et al. 2004).  
   Stat2 knockout mice are also viable and fertile and similar to Stat1 knockout mice, show 
reduced microbial responses as well as increased susceptibility to viral infection (Park et al. 
2000). Stat1/Stat2 double null mice are not able to respond to any IFNs, and exhibited greater 
susceptibility to infection compared to single knockout mice (Perry et al. 2011). 
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   Stat3 deficient mouse embryos are normal up to 6.5 day post conception (dpc), but 
subsequently die at 7.5 dpc due to severe defects in development (Takeda et al. 1997). Mice 
in which Stat3 is specifically knocked out in T cells show impaired IL-2 and IL-6-dependent 
proliferation, presenting suppression of apoptosis in these cells (Alonzi et al. 2001). STAT3-
deficient macrophages and neutrophils show an elevated level of cytokine production and 
defects in the regulation of immune responses, presumably due to lack of responsiveness to 
IL-10 signalling (Imada et al. 2000). Mice lacking STAT3 in the mammary gland 
demonstrate programmed cell death deferment during mammary gland involution, leading to 
inhibition of responses in the mammary gland (Chapman et al. 1999).  STAT3 deletion in 
keratinocytes causes both skin and hair impairment due to defect in migration of 
keratinocytes (Sano et al. 1999). STAT3 deficiency in haematopoietic cells results in myeloid 
cell abnormalities, and the development of augmented innate immune response leading to 
inflammatory bowel disease (Welte et al. 2003).  
  Stat4 knockout mice are viable and fertile. STAT4 deficiency confirms the essential role for 
this STAT in IL-12 signalling. Cells from Stat4 null mice are also unresponsive to IL-12 
signalling (Imada et al. 2000) and consistent with Il-12R null mice, lymphocytes from Stat4 
knockout are not able to differentiate into Th1 cells and produce IFN- in response to IL-12, 
and so displayed strong Th2 polarization (Kaplan et al. 1998). The cooperation of IL-12 
versus IL-23 to STAT4 activation in vivo requires more clarification as IL-23 shows a 
significant role in certain autoimmune disease (Cua et al. 2003).   
Stat5a or Stat5b single knockout mice are also viable. Stat5a single knockout mice develop 
normally and do not show any distinct phenotype in terms of size, weight and fertility 
compared to their wild-type littermates, but show impairment in mammary gland 
development and lactation due to defective prolactin signalling (Liu et al. 1997; Teglund et 
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al. 1998). In contrast, Stat5b single knockout mice exhibit a defect in sexual dimorphic 
growth due to defective growth hormone signalling (Teglund et al. 1998; Udy et al. 1997). 
Stat5b knockout mice also display an impairment in insulin-like growth factor-1 (IGF-1) 
production, which was not compensated by normal Stat5a expression (Kofoed et al. 2003). 
Patient with STAT5B mutations develop GH insensitivity, suggesting a conserved role for 
STAT5B in GH signalling (Rosenfeld et al. 2007). One patient with a STAT5B mutation 
demonstrate susceptibility to infections, suggesting an immune defect (Kofoed et al. 2003). A 
mutant mouse in which the N-terminus of both STAT5A and STAT5B was deleted 
(Stat5abN/N) has been generated and although the mice are viable, adult female suffer from 
infertility and most pups from Stat5abN/N mice die after a few weeks of birth (Socolovsky et 
al. 1999; Teglund et al. 1998). These female mice form a small epithelium alveoli-like 
structure with a defect in proliferation and differentiation of PRL-dependent mammary gland 
development. The peripheral blood counts are normal but demonstrate a reduction in myeloid 
and lymphoid lineages (Miyoshi et al. 2001). Stat5a/b null bone marrow cells exhibit 
perturbed lineage expansion by IL-3, IL-5, IL-7, G-CSF, TPO and GM-CSF and show a 
defect in erythropoiesis during mid-gestation (Teglund et al. 1998). Stat5a-/- Stat5b-/- mice, 
with a complete deletion in STAT5A/STAT5B locus, have also been produced although they 
are embryonic lethal (Cui et al. 2004). This is attributed to anaemia due to reduced responses 
to EPO, resulting in high level apoptosis in cells of the erythroid cell lineage (Socolovsky et 
al. 1999). Stat5a-/- Stat5b-/- mice show a total lack of T cells and decreased CD4+ T cells 
(Villarino et al. 2016). Moreover, some phenotypes in these mice resemble severe combined 
immunodeficiency (SCID) seen in mice lacking IL-7R, γc, or JAK3 with IL-2 induced 
proliferation blocked (Yao et al. 2006). Mice with Stat5a-/- Stat5b-/- hematopoietic cells show 
hypochromic anaemia due to defective iron homeostasis (Zhu et al. 2008). These mice also 
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exhibit a substantial reduction in the number of peripheral neutrophils, and are unresponsive 
to GM-CSF during emergency situations such as myelosuppression (Kimura et al. 2009).  
 Stat6 knockout mice are viable and fertile. However, they display a significant impairment in 
the capacity to develop Th2 cells (Takatori et al. 2005), which is even more severe than that 
seen in IL-4 deficient mice, suggesting that the additional absence of IL-13 signalling in Stat6 
knockout mice is responsible for the increased severity observed (Kaplan et al. 1996; Takeda 
et al. 1996). Moreover, mice lacking STAT6 in B cells fail to carry out class switching and 
generate IGE (Shimoda et al. 1996). 
 
1.5 Suppressor of cytokine signalling (SOCS): 
1.5.1 SOCS structure  
  There are eight mammalian SOCS proteins: CISH (Cytokine-inducible SH2-containing 
protein), SOCS1, SOCS2, SOCS3, SOCS4, SOCS5, SOCS6, and SOCS7 (Kile et al. 2001; 
Starr et al. 1998) (Fig 1.5). All members of the SOCS family share common structural 
features, including a variable N-terminal region, a central SH2 domain, and a highly 
conserved C-terminal SOCS box (Liongue et al. 2012).  The function of the N-terminal 
region is not clear, although in SOCS1 and SOCS3, it contains the kinase inhibitory region 
(KIR) (Yasukawa et al. 1999) and in SOCS4 and SOCS5, the N-terminal conserved region 
(NTCR) domain (Feng et al. 2012). The KIR is required for cytokine receptor inhibition, 
which is dependent on JAKs (Croker et al. 2008), but the role of the NTCR has not been 
clarified. The SH2 domain is necessary for interaction with phosphotyrosines on target 
proteins, including cell surface receptors (O'Sullivan et al. 2007). This region in the SOCS 
proteins is longer than the typical SH2 domain, with the addition of an extended SH2 
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sequence (ESS), which has also been found in STAT1 and STAT3 and where it is necessary 
for their function (Yasukawa et al. 1999). Finally, the C-terminal domain, which consists of a 
SOCS box, is involved in proteasome degradation (Kamura et al. 2004; Kile et al. 2002). The 
SOCS box consists of two functional sub-domains including a BC box and a Cul box. 
Elongin B and C are recruited by the BC box and Cullin 5 is modulated by the Cul box. 
Collectively, this complex is able to attach to Ring box protein 2 (RBX2), also known as 
SAG (sensitive to apoptosis gene), leading to the recruitment of the residual element of an E3 
ubiquitin ligase complex (Kamura et al. 2004). 
 
1.5.2 Mechanisms of SOCS action 
   SOCS expression is stimulated by various signalling pathways (Table 1.3), including Th1 
and Th2 cytokines (IL-4, IL-13, and IFN), and a range of other ILs and growth factors 
(Dalpke et al. 2001; Stoiber et al. 1999). CISH expression is induced by IL-2, IL-3, EPO, 
GM-CSF and prolactin (Matsumoto et al. 1999). SOCS1 expression is largely induced by 
lipopolysaccharide (LPS), insulin (INS), IL-2 and IL-4, as well as by IFN (Endo et al. 1997; 
Losman et al. 1999), whereas expression of SOCS2 is mainly induced by IL-6, IFN and GH 
(Farabegoli et al. 2005; Naka et al. 1997). SOCS3 expression is dependent on various 
interleukins, including IL-1, IL-2, IL-6, IL-9 and IL-13, as well as G-CSF (Croker et al. 
2004).  Data regarding SOCS 4 to 7 is very limited (Fujimoto et al. 2003) but they are more 
likely to be induced by growth factor receptors (Yoshimura et al. 1997).  SOCS5 has also 
been shown to be induced in vitro by IL-6 (Tan et al. 2005). 
SOCS proteins can inhibit cytokine signalling via a number of different mechanisms. All 
SOCS proteins can inhibit signalling by targeting proteins for degradation. This is mediated 
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via the conserved SOCS box, which is able to bind to Elongins B and C.  These are able to 
recruit the remaining components of the E3 ubiquitin ligase complex, which can mediate 
protein ubiquitination and proteasome degradation of associated proteins (Yasukawa et al. 
1999; Yoshimura et al. 1997). SOCS proteins can also directly inhibit JAK activity, as is the 
case for SOCS1 and SOCS3, with the KIR domain critical for JAK inhibition. In addition, 
SOCS proteins can inhibit cytokine signalling by competing with other proteins for binding 
to activated receptors, such as observed with CISH and SOCS2 with respect to STAT5, and 
SOCS3 with respect to SHP2 recruitment (Dalpke et al. 2008).  Finally, SOCS proteins can 
also directly affect the nuclear translocation of STATs, for example SOCS1 and SOCS3 (but 
not SOCS2) can inhibit the nuclear translocation of STAT1 in response to IFN stimulation 
(Song et al. 1998). 
1.5.3 Role of SOCS proteins in vivo  
1.5.3.1 SOCS1 
    Studies on Socs1 knockout mice has revealed a key negative regulatory function of SOCS1 
in IFN signalling (Alexander et al. 1999a) (Table 1.4). Socs1 null mice show no obvious 
developmental defect during embryogenesis and are born normally, but they demonstrate 
clear phenotypes at birth, including low body weight and a complex pathology, leading to 
neonatal death within the first 3 weeks after birth. The mortality is due to major liver, lung, 
heart and pancreas damage caused by massive inflammation (Larsen et al. 2002). Analysis of 
peripheral blood in Socs1 null mice reveal a decreased haematocrit and reduced numbers of 
lymphocytes, eosinophils and platelets, along with a very large increase in the number of 
neutrophils (Alexander et al. 2004). The majority of these phenotypes in Socs1 null mice are 
dependent on IFN and can be ameliorated either by crossing with Ifng knockout mice or 
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using anti-IFN antibodies (Lei et al. 2004). This suggests that SOCS1 is a key negative 
regulator of IFN signalling, with unregulated IFN signalling leading to the lethal 
phenotypes. However, mice lacking both SOCS1 and IFN  eventually die after 6 months due 
to polycystic kidney diseases and kidney inflammation (Alexander et al. 1999b; Naka et al. 
1998). Mice lacking SOCS1 also exhibit a defect in osteoblast differentiation (Abe et al. 
2006), as well as elevated insulin signalling (Jamieson et al. 2005). Transgenic mice 
overexpressing SOCS1 are unable to respond to LPS, suggesting an inhibitory role for 
SOCS1 in TLR/NK-kB signalling in vivo (Kinjyo et al. 2002). Socs1 knockout mice also 
show a high level of dendritic cell and macrophage activation (Hanada et al. 2003), caused by 
increased interferon-γ or type I interferon receptor components (IFNRAR1) Signalling 
(Fenner et al. 2006). SOCS1 knockdown in zebrafish results in a decrease in specific myeloid 
populations as well as T cell reduction during embryogenesis, indicating that SOCS1 has an 
interaction with the zebrafish JAK2/STAT5 pathway (O’Sullivan et al. 2011). Mice with 
SOCS1-deficient T cells show a significant increase in the level of Treg cells in the thymus 
(Zhan et al. 2009), with SOCS1 shown to have an important role in Treg function and 
regulation by protecting them from excessive inflammatory cytokines such as IL-6 and IFN 
(Sekiya et al. 2016).  
1.5.3.2 SOCS2 
  Analysis of Socs2 knockout mice has revealed an essential role for this SOCS protein in the 
regulation of signalling by growth hormone (GH). SOCS2 mutant mice display a gigantism 
phenotype, with an increase of 30-40% in body size compared to their wild-type littermates. 
This augmentation in body size becomes obvious after weaning, with substantial increase in 
size of most visceral organs, including liver, as well as the lung, heart, muscle, bone and fat 
(Metcalf et al. 2000). However, the haematocrit, blood peripheral cell counts and the number 
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of T and B cells in the spleen, bone marrow and thymus are not changed in Socs2 null mice 
(Metcalf et al. 2000). Interestingly, mice lacking SOCS2 also display increased GH 
signalling, with a gigantism phenotype as observed in the Socs2 knockout mice, suggesting 
that SOCS2 might have a dual role in controlling GH-signalling (Greenhalgh et al. 2002). 
Socs2 knockout mice showed extended STAT5B activation in response to GH. However, 
Socs2/Stat5b knock out mice have a diminished growth phenotype, suggesting a specific role 
on GH/STAT5B signalling (Metcalf et al. 2000). Pancreatic β-cells of Socs2 knockout mice 
exhibit normal insulin and glucose tolerance levels compared to their wild-type counterparts 
(Puff et al. 2010). In contrast, transgenic mice that constitutively produce SOCS2 in 
pancreatic beta cells show hyperglycaemia and glucose intolerance in these cells (Lebrun et 
al. 2010). SOCS2 deletion in dendritic cells led to defective DC, with reduced responsive to 
LPS stimulation, suggesting a critical role for SOCS2 in TLR-induced DC activation (Hu et 
al. 2009). Finally, mice lacking SOCS2 in CD4+ T cells display an increase in the level of 
Th2 differentiation (Knosp et al. 2011).  
1.5.3.3 SOCS3 
   Socs3 knockout mice display embryonic lethality due to placental function defects, 
including lack of spongiotrophoblast formation, perturbed labyrinthine layers and elevated 
number of giant trophoblastic cells (Roberts et al. 2001). However, the embryos can be saved 
by tetraploid rescue. This observation indicates that SOCS3 is critical for the development of 
the placenta but is not necessary for embryo development (Takahashi et al. 2006). 
Furthermore, a knockout of Socs3 on a LIFR-deficient background ameliorated the survival 
defect, suggesting SOCS3 is a critical regulator of LIFR signalling (Takahashi et al. 2003). 
These mice failed to live longer than 190 days due to neutrophilia along with inflammatory 
tissue infiltration (Robb et al. 2005). Conditional Socs3 knockout mice reveal additional 
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negative regulatory roles for SOCS3 in IL-6 and G-CSF signalling (Takahashi et al. 2003). 
Mice lacking SOCS3 in hematopoietic cells exhibit a range of inflammatory pathologies and 
neutrophilia due to enhanced IL-6R and G-CSFR signalling respectively, with G-CSF 
injection of these mice resulting in neutrophilia, increased spleen size, and mobilization of 
progenitor cells, along with neutrophil infiltration into numerous tissues (Croker et al. 2004). 
SOCS3 deletion reveals embryonic lethality at 12.5 dpc with increased number of 
erythroblasts indicating that SOCS3 has an important negative regulatory role on fetal liver 
haematopoiesis (Marine et al. 1999). Socs3 knockout embryos show a slight decreased size 
compared to their wild-type counterparts, and this phenotype is also observed in fetal liver of 
SOCS3 null embryo, with the normal erythroblasts and BFU-E and CFU-E number at 11.5 
dpc suggesting both wild-type and Socs3 knockout mice are able to respond to EPO 
signalling (Roberts et al. 2001). Absence of SOCS3 results in altered STAT3 function 
converting from anti-apoptotic to pro-apoptotic in mammary epithelial cells, suggesting 
SOCS3 has a pivotal role in regulating this balance (Lu et al. 2006). SOCS3 deletion in T cell 
leads to increased proliferation of CD8+ T cells, which is associated with enhanced IL-6 and 
IL-27 signalling (Brender et al. 2007). Various roles for SOCS3 outside of the 
haematopoietic and immune lineage have also been identified. SOCS3 deletion in mammary 
stem progenitors results in defective lactation with reduced proliferation of luminal cell 
during lactation. This also caused increased STAT3 activation leading to imbalance of 
proliferation and apoptosis (Robinson et al. 2007). Moreover, SOCS3 silencing in endothelial 
cells produces severe pathological consequences similar to arthritis models due to increased 
responses to IL-6 and G-CSF signalling (Wong et al. 2006). Finally, mice with Socs3 
knocked out conditionally in neural tissue show considerably decreased food intake and body 
weight following leptin administration in comparison with wild type mice, suggesting leptin 
signalling is negatively modulated by SOCS3 in the brain (Mori et al. 2004).  




  Socs4 knock out mice are more susceptible to infection with influenza virus compared to 
wild-type mice. SOCS4 deficiency leads to greater weight loss, impairment of pro-
inflammatory cytokine regulation and production of chemokines in the lung, resulting in 
impaired CD8+ T cell trafficking and prolonged viral clearance. This suggests a possible role 
for SOCS4 in TCR signalling (Kedzierski et al. 2014). 
1.5.3.5  SOCS5 
   Socs5 knockout mice have no overt abnormalities, with normal Th1 and Th2 responses 
(Brender et al. 2004). However, SOCS5 transgenic mice show inhibited Th2 differentiation 
of T cells due to repression of IL-4 signalling, including activation of STAT6 with elevated 
peritoneal IL-2 and IFN that are important in development of Th1 differentiation (Watanabe 
et al. 2006). It is possible that the differences between the knockout and transgenic mice are 
due to compensation by another SOCS, such as SOCS4, since SOCS4 and SOCS5 share 
considerable homology (Seki et al. 2002). 
1.5.3.6  SOCS6 
   Socs6 knockout mice do not display any defects in fertility, placental development or 
postnatal survival (Krebs et al. 2001). However, Socs6 knockout mice exhibit a 10% decrease 
in body weight in comparison with their wild-type littermate, probably due to impairment of 
IGF-1 signalling (Krebs et al. 2002). SOCS6 transgenic mice show increased AKT activation 
in response to INS and enhancement of glucose metabolism, suggesting an in vivo role for 
SOCS6 in regulating INS signalling (Li et al. 2004).  




    The role of SOCS7 has been shown to vary between mouse strains due to genetic 
background differences (Krebs et al. 2002). One SOCS7 knockout mice line show 7 to 10% 
smaller body size compared to the wild-type littermate controls at birth, but no change in 
circulating glucose or INS (Krebs et al. 2004). Around half of these Socs7 null mice die by 15 
weeks of age due to hydrocephalus and growth retardation, with mice exhibiting cranial 
distortion, reduction in cerebral cortex thickness and disruption of the sub-commissural 
organ, suggesting that SOCS7 has an essential role in neuronal cell formation (Krebs et al. 
2004). However, the hydrocephaly phenotype is not reproduced in another Socs7 knockout 
generated on the 129/SvJ background, which exhibits elevated insulin signalling with 
improved glucose tolerance suggesting a role in INS signalling (Banks et al. 2005). 
Regulation of various body system and responses is mediated by small secreted proteins 
called cytokines or growth factors. The JAK/STAT pathway is the principal downstream 
signalling mechanism for a wide array of cytokines and growth factors (O’Shea et al. 2015). 
The JAK proteins selectively bind to different cytokine receptors and then activate a specific 
subset of STAT proteins (Villarino et al. 2015) (Fig. 1.4). This pathway is negatively 
regulated by suppressor of cytokine signaling (SOCS) proteins. The SOCS proteins 
selectively bind to specific receptors and/or JAKs and/or downstream molecules to negatively 
regulate specific cytokine pathways (Tamiya et al. 2011) (Table 1.3). 
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1.6 Cytokine inducible Src homology 2 protein (CISH) 
1.6.1 Introduction 
The Cish gene was first identified as a gene induced by IL-2, IL-3 and EPO, but not by a 
mutant IL-2 receptor unable to activate STAT5, thereby implicating STAT5 in the cytokine-
inducible expression of CISH (Matsumoto et al. 1997). CISH has also been shown to be 
induced by GH (Adams et al. 1998), PRL (Pezet et al. 1999), IL-9 (Lejeune et al. 2001), TPO 
(Okabe et al. 1999), GM-CSF (Yoshimura et al. 1995), and G-CSF (Hunter et al. 2004), all of 
which activate STAT5 and are direct STAT5 target genes, with conserved tandem STAT5 
binding sites (Moriggl et al. 1999). This association is confirmed in STAT5abN/N mice, 
which display no CISH expression (Teglund et al. 1998). Likewise, JAK2-deficient 
mammary epithelial cells that are impaired in their ability to activate STAT5 following PRL 
stimulation, also show reduced CISH expression (Sakamoto et al. 2007). CISH has been 
identified to negatively regulate signalling induced by IL-2 (Aman et al. 1999), IL-3 
(Yoshimura et al. 1995), GH (Ram et al. 1999), EPO (Matsumoto et al. 1997), and PRL (Dif 
et al. 2001). STAT5 activity can be inhibited by CISH using two distinct mechanisms: firstly, 
direct competition with STAT5 for docking sites on cytokine receptors and secondly, 
targeting tyrosine phosphorylated signalling proteins for ubiquitin/proteasome-dependent 
degradation (Yasukawa et al. 2000). 
 Cish expression in mice has been observed in the liver, kidney, and to a lesser extent in the 
lung during embryonic development, with the expression of Cish in other fetal tissues 
reported to be very low. In adult tissues, the expression of Cish is observed mostly in liver 
and kidney, with modest expression in lung (Uchida et al. 1997). 
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Additional studies have revealed CISH induction by IL-10 (Shen et al. 2000), IL-6 (Starr et 
al. 1997), IFNα (Brender et al. 2001), IFNγ (Starr et al. 1997), TNFα (Starr et al. 1997), 
TSPL (Isaksen et al. 1999), and leptin (Emilsson et al. 1999). CISH is also induced quickly 
by T cell receptor signalling (TCR) through a pathway not involving STAT5 (Li et al. 2000). 
1.6.2 Role of CISH in vivo  
1.6.2.1  Cish knock out studies 
  Cish knockout mice spontaneously develop lung inflammation, with a greater susceptibility 
to allergic asthma (Yang et al. 2013). T cells from Cish null mice show an elevated 
differentiation of Th2 and Th9 subsets. In this case, CISH is shown to be induced by IL-4 and 
can negatively regulate the activation of STAT3, STAT5, and STAT6 in T cells. This 
indicates an important role for CISH in regulating the generation of pro-allergic helper T cells 
and a negative feedback regulatory role on IL-4 (Yang et al. 2013). Mice lacking CISH in 
CD8+ T cells show expansion and increased function of this population, resulting in 
regression of stablished tumours. CISH is involved in regulation of TCR signalling via 
binding to the TCR intermediate PLC-γ1 leading to TCR inhibition (Palmer et al. 2015).This 
suggests a novel target regulation site in CD8 + T cells that can be used to improve cancer 
therapy (Palmer et al. 2015). Cish knockout mice are resistant to prostate, melanoma, and 
breast cancer metastasis in vivo due to enhanced NK cell responses, as a result of 
hypersensitivity to IL-15, leading to enhancement of NK- cell proliferation, survival and 
cytotoxicity toward tumours (Delconte et al. 2016). IL-15 has been shown to induce CISH, 
which selectively interacts with JAK1 to promote proteosomal degradation (Delconte et al. 
2016). Conditional Cish knockout in pancreatic cells produces no change in beta cell 
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differentiation or glucose homeostasis, however as the Socs2 gene expression is elevated, 
compensation by this SOCS member is possible (Jiao et al. 2013).  
CISH has also been shown to be important for the development of type 1 dendritic cells 
(DCs) and DC-associated CTL (cytotoxic T lymphocytes) from mouse bone marrow by GM-
CSF. CISH knockdown results in a decline in MHC class I, pro-inflammatory cytokines, and 
co-stimulatory molecule expression, which occurrs concurrently with a substantial increase in 
the production of DC via increased proliferation and reduced apoptosis. This is associated 
with CISH-mediated feedback inhibition of STAT5 activation by GM-CSF. Therefore, 
expression of CISH at the later stage of DC development appears to initiate a reduction DC 
progenitor cell proliferation to allow differentiation to proceed effectively (Miah et al. 2012). 
Knockdown of a zebrafish CISH homologue produced a range of haematopoietic phenotypes, 
including an increase in the numbers of erythroid cells, myeloid cells as well as increased T 
cells, with functional studies supporting a role for CISH in regulation of JAK2/STAT5 
(Lewis et al. 2014). 
1.6.2.2   CISH transgenic studies  
Analysis of CISH transgenic mice has implicated CISH in the in vivo regulation of the JAK2-
STAT5 signalling pathway (Marine et al. 1999). Mice expressing CISH under the control of 
the β-actin promotor show a defect in mammary gland development and growth retardation 
due to impaired GH and PRL signalling, with decreased NK and NK-T cell numbers 
(Matsumoto et al. 1999). Each of the phenotypes substantially resemble those seen in 
Stat5a/b knockout mice (Fitzgerald et al. 2009). Apoptosis of erythroid progenitor cells is 
also increased by enforced expression of CISH, consistent with an antagonistic role on 
STAT5 activation, a known anti-apoptotic factor (Ketteler et al. 2003). EPO-dependent 
STAT5 activation is inhibited by overexpression of CISH in vitro and partially suppressed 
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EPO-mediated cell proliferation, suggesting that CISH has specific negative role in STAT5 
signal transduction (Matsumoto et al. 1997; Yoshimura et al. 1995). Analysis of transgenic 
mice that selectively express CISH in CD4+ T cells revealed TCR signalling inhibition via 
independent signalling pathway from STAT5 (Li et al. 2000).  
1.6.3    Role of CISH in humans  
Dysregulation of CISH has been observed in patients with rheumatoid arthritis (RA) and 
systemic lupus erythematous (SLE). The level of CISH mRNA in peripheral blood 
mononuclear cells (PBMCs) from SLE patients in acute phase is higher than normal 
individuals and patients with inactive phase of disease, in contrast to SOCS2 and SOCS3 that 
do not change. It has been suggested that CISH represents a marker of SLE disease and may 
be involved in SLE pathogenesis. In contrast, basal CISH expression in RA patients is 
equivalent between unaffected individuals and RA patients. However, RA patients treated 
with a TNF- blocking agent show increased CISH expression but reduced SOCS2 
expression in PBMCs, suggesting a possible role for TNF- in CISH and SOCS2 expression 
regulation in PBMCs in vivo (Tsao et al. 2008).  
Genome-wide SNP analysis has identified an association between CISH polymorphisms and 
susceptibility to infectious diseases, such as bacteraemia, malaria, and tuberculosis. A single 
nucleotide polymorphism (SNP) at position -292(AT) is the most highly associated, 
increasing the overall risk of infectious diseases by at least 18% among persons carrying this 
variant CISH allele. This allele reduces the induction of CISH following IL-2 stimulation, 
suggesting enhanced IL-2 signalling might be responsible for increased susceptibility to 
infectious diseases (Khor et al. 2010). This CISH SNP is also associated with HBV infection 
in a Vietnamese population (Tong et al. 2012). This result in an increased chance of infection 
but no effect on peripheral blood levels of IL-2 is observed, nor is there an effect on total 
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bilirubin, alanine transaminase and alanine transaminase levels (Tong et al. 2012). Some 
other studies have suggested an association between CISH and expansion of regulatory T 
cells in response to pathogens (Periasamy et al. 2011). CISH mRNA levels has also been 
reported to correlate with osteoarthritis, with 10 fold lower level of CISH mRNA in the 
diseased compared to control group of patient (de Andrés et al. 2011). 
1.7 Haematopoiesis  
Haematopoiesis describes the process of blood and immune development that supplies the 
requisite number of blood cells throughout the life span (Reya et al. 2001). Haematopoiesis 
occurs in two stages:  the primitive stage and definitive stage. Primitive haematopoiesis 
occurs at very early stage of development and it is mainly limited to the production of two 
cell populations: nucleated erythrocytes and primitive macrophages (Zambidis et al. 2005). 
Definitive haematopoiesis begins in the fetal liver with hematopoietic stem cell (HSC) 
progenitors that originate in the aorta gonad mesonephros (AGM) and continues in the bone 
marrow for the rest of life under steady state conditions (Rieger et al. 2012). These 
multipotential HSCs are able to generate both new HSCs (self-renewal) as well as daughter 
cells capable of differentiating, specifically the lineage-restricted common myeloid 
progenitor (CMP) and common lymphoid progenitor (CLP) cells (Fig. 1.6). The myeloid 
progenitors differentiate to produce thrombocytes, erythrocytes, basophils, neutrophils 
eosinophils and macrophages (Rosenbauer et al. 2007). Thrombocytes or platelets have an 
important role in blood coagulation and erythrocytes play a key role in transportation of 
oxygen as well as of nutrients and wastes. Basophils are responsible for allergy response and 
blood coagulation (Karasuyama et al. 2011). Neutrophils have critical roles in restriction of 
bacterial and fungal pathogens as well as roles in inflammatory reactions (Mócsai 2013). 
Eosinophils are well known to be play an important role in parasitic infections and also 
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release immune modulators (Lee et al. 2012). Macrophages phagocytise cells and debris and 
present antigens along with dendritic cells (Hume 2008). On the other hand, the CLPs can 
differentiate to generate all mature lymphoid cells, which comprise B, T and Natural killer 
(NK) cells (Mansson et al. 2008). B cells are responsible for antibody production against 
pathogenic antigens (Blom et al. 2006). T cells play an important role in protecting against 
tumour cells and invading microorganisms (Sakaguchi 2004). T cells are divided into four 
main groups based on their function, including helper (Th), memory, cytotoxic, regulatory T 
cells (Zhu et al. 2008).  
There are many cytokines and growth factors that are involved in the process of 
haematopoiesis, which regulate the proliferation and differentiation of hematopoietic cells 
through binding to their cognate cell surface receptors (Cluitmans et al. 1997) (Fig 1.6). The 
different cell subsets found in a specific haematopoietic lineages can be detected by utilising 
various cell surface markers followed by flow cytometry. For example, CD44, CD71 and 
Ter119 are utilised in combinations as markers for the erythroid lineage surface (Liu et al. 
2013), while Gr-1, CD11b and CD11c serve as important markers for the myeloid lineage 
(Rose et al. 2012) . 
1.7.1 Erythropoiesis  
1.7.1.1  Introduction 
Red blood cells (RBC) are the most abundant cell type in the body, with the pivotal role of 
carrying oxygen to the tissues and also facilitating the transport of carbon dioxide to the lung. 
RBC are derived from two distinct pathways, including primitive and definitive 
erythropoiesis (Palis et al. 2012).  
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Primitive erythropoiesis initiates in so-called “blood islands” inside the yolk sac, where 
mesoderm cells give rise to a unique erythroid progenitor, called EryP-CFC at E7.5. These 
reach their highest number at E8.5 and are no longer detectible at E9.0 (Palis et al. 1999). 
These differentiate into primitive proerythroblast (Pro) cells, which start to circulate at E8.5 
after cardiac contraction (Palis 2014). Primitive erythroid cells enucleate between E11.5 and 
E17.5 in the mouse (Fraser et al. 2007). Definitive erythropoiesis commences with the 
formation of HSCs in the AGM that move to the fetal liver at E11.5, with production by the 
fetal liver continuing to increase until E15.5-16.5, after which it decreases and the HSCs 
relocate to the bone marrow (Gekas et al. 2005). Definitive erythropoiesis is a sequential and 
dynamic process. However, it is widely recognized to occur in two stages that include 
progenitor proliferation and terminal differentiation. Progenitor proliferation occurs at the 
burst forming unit-erythroid (BFU-E) and colony forming unit-erythroid (CFU-E) stages, 
which can be enumerated in colony forming assay (Li et al. 2014). The first morphologically 
recognizable cell in terminal erythroid differentiation is the Proerythroblast (Pro). Murine Pro 
cells develop via three mitosis to produce successively Basophilic (Baso), Polychromatic 
(Poly) and Orthochromatic (Ortho) erythroblasts. A single Pro, therefore, can produce two 
Baso, four Poly, and eight Ortho cells. Therefore, during normal murine erythropoiesis, the 
ratio of Pro: Baso: Poly: Ortho follows a 1:2:4:8 pattern (Liu et al. 2013). 
1.7.1.2  Regulation of erythropoiesis 
Erythropoiesis is controlled at multiple levels via transcription factors and cytokines. EPO 
represents one of the key external factors regulating erythropoiesis, with a role in erythroid 
development, differentiation, apoptosis, and activation of erythroid specific genes (Jelkmann 
2011). CFU-E differentiation is extremely dependent on EPO, while later phases of 
erythropoiesis are not very EPO dependent. Similarly, expression of the EPOR is attenuated 
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as progenitors of the erythroid linage undergo their last stage of proliferation and 
differentiation (Zhang et al. 2003). EPO as well as fibronectin have been shown to have an 
important role in preventing apoptosis and expansion of proliferation of haematopoietic 
lineages through Bcl-xL expression (Lodish et al. 2010). 
Amongst the transcription factors, GATA1 is specifically expressed in erythroid cells and 
essential for normal erythropoiesis (Ferreira et al. 2005), mediating survival of erythroid 
progenitor cells, terminal differentiation of erythroid cells and anti-apoptotic function in 
erythroid maturation via inducing the expression of key genes (Pan et al. 2005). Other 
erythropoietic transcription factors, including FOG1, SCL/Tal1, EKLF and GFI-1b, have 
been identified to interact with GATA1 and play important roles in regulation of 
erythropoiesis, namely in the survival and differentiation of erythroid cells (Lowry et al. 
2006). The Myc transcription factor has also been shown to have a role in regulating 
proliferation, differentiation, cell growth and apoptosis during erythropoiesis (Jayapal et al. 
2010). Interaction of the JAK2/STAT5/EPO signalling pathway and erythroid transcription 
factors can result in generation of necessary transcriptional responses to underpin 
erythropoiesis (Cantor et al. 2002).   
 Bim and Bcl-xL are two important anti-apoptotic regulators of the Bcl-2 family. Activation 
of EPOR in early erythroblasts results in Bim suppression and Bcl-xL production (Koulnis et 
al. 2012). Bcl-xL level increase dramatically in early erythroblasts in response to acute stress 
conditions such as EPO injection, reaching a peak after 12-18 h, and then decreasing to basal 
levels by 48 h. In contrast, the decline of Bim is slower than Bcl-xL as it peaks at 48-72 h 
following stimulation. This indicates that induction of the Bcl-2 family is time dependent 
following EPO stimulation rather than determined by the level of EPO or stress, and EPOR 
activated by phosphorylated STAT5 can also stimulate Bcl-xL induction (Liu et al. 2006). 
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1.7.1.3  Erythropoietin signalling   
Erythropoietin (EPO) is produced in the fetal liver during embryonic development (Tamura et 
al. 2000). In adults, EPO is produced by the kidney in response to hypoxia to maintain 
production of RBCs in the bone marrow (Fisher 2003). EPO synthesis can also occur in other 
mouse tissues such as spleen, brain, liver, and reproductive organs (Marzo et al. 2008). EPO 
is important for proliferation, differentiation, and survival of erythroid progenitors in the bone 
marrow to maintain the daily requirement of RBC production, which is necessary throughout 
life since the RBC lifespan is limited to 120 days in human and 45 days in mice (Alnaeeli et 
al. 2012). Epo knockout mice are embryonic lethal, and die at 14.5 days of gestation due to 
anaemia (Lin et al. 1996), while overproduction of EPO can cause erythrocytosis (Jelkmann 
2011). EPO exerts its functions through a cognate cell-surface receptor, EPOR that mediates 
its effect to trigger downstream signalling cascades (Watowich 2011). The EPOR is a 
member of the cytokine receptor superfamily expressed in a number of tissues, including the 
cardiovascular system and brain as well as erythropoietic cells (Brines et al. 2006). EPOR has 
been reported to exist as a dimer when un-liganded, with high affinity EPO-EPOR binding 
leading to changes in the extracellular domain of EPO including the fibronectin type III 
domains (Livnah et al. 1999), which causes an intracellular conformational change. EPOR 
deficient mouse show severe defects in the production of RBCs, and die at mid-gestation due 
to anaemia (Lin et al. 1996).  
 EPOR signalling is dependent on the protein kinase JAK2, with the FERM domain of JAK2 
responsible for binding to the EPOR (Huang et al. 2001). Interaction of EPO and its receptor 
results in JAK2 autophosphorylation, which then initiates phosphorylation of the STAT 
proteins, which then dimerize and enter the nucleus, upon where they activate transcription of 
key genes (Ihle 2001). The critical importance of JAK2 to erythropoiesis is demonstrated by 
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the fatal embryonic anaemia resulting from Jak2 deletion in mice (Miura et al. 1994). 
Conversely, activating mutations within the pseudo-kinase domain of JAK2 has been 
implicated in a spectrum of myeloproliferative disorders including Polycythaemia Vera 
(Baxter et al. 2005), with mutant JAK2 protein mediating EPO-independent erythroid 
progenitor growth and development leading to erythroid linage expansion in vivo (Zaleskas et 
al. 2006).  
There are eight tyrosine residues within cytoplasmic tail of EPOR, which once 
phosphorylated, act as docking site for intracellular signalling molecules that can stimulate 
multiple transduction pathways including the STAT5, phosphatidylinositol -3 kinase (PI3K) 
/Akt, and Shc/Ras/mitogen-activated protein kinase (MAPK) pathways(Chin et al. 1996). 
Loss of PIP3 can result in apoptosis of early progenitors and reduced number of erythroblasts 
(Lodish et al. 2009), while lack of MAPK produces a minor effect on terminal erythropoiesis 
(Zhang et al. 2007). The Bcl-xL gene is known to be a direct STAT5-responsive gene 
resulting in increased levels of anti-apoptosis in erythroid cells (Socolovsky et al. 1999). 
Adult Stat5abN/N mice show close to normal steady-state haematocrit with high levels of 
EPO in the blood and increased size of spleen, while Stat5a−/−Stat5b−/− embryos are anaemic 
with low number of erythroblasts and high levels of apoptosis suggesting they have less 
response to EPO  (Socolovsky et al. 1999). Analysis of erythroblasts from adult 
Stat5a−/−Stat5b−/− mice revealed an elevated number of early erythroblasts that fail to 
differentiate and undergo apoptosis with decreased Bcl-xL expression. This suggests that the 
level of CFU-E is high enough in these mice that even with poor erythroblast differentiation, 
still show close to normal haematocrit. (Socolovsky et al. 2001). 
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1.7.1.4  Negative regulation of EPOR signalling 
SOCS1, SOCS3 and CISH have all been implicated in the negative regulation of RBC 
production (Constantinescu et al. 1999). Quantification of SOCS gene expression during 
maturation of normal red cell progenitors revealed a difference in the level of SOCS1, 
SOCS3 and CISH, with changes to CISH inversely related to the alterations of SOCS1 and 
SOCS3 cells. At immature stages of differentiation showed increased SOCS1 and SOCS3 
mRNA expression, while in more mature cell lines SOCS1 and CISH were induced only after 
EPO stimulation (Sarna et al. 2003). CISH has been shown to be associated with tyrosine 
phosphorylated EPOR (Yoshimura et al. 1995), especially tyrosine residue 401 (Tyr401) of 
EPOR. This is the same site that STAT5 docks to, suggesting binding site competition 
between STAT5 and CISH. The CISH/EPOR complex is also a target of proteasome 
degradation (Verdier et al. 1998). In addition to the SOCS proteins, the mitogen-activated 
protein kinases (MAPKs), specifically extracellular signal-regulated kinase 1 (ERK1), has 
been shown to have a role in negative regulation of basal adult level erythropoiesis in the 
bone marrow and spleen (Guihard et al. 2010). In addition, the tyrosine phosphatase SHP-1 
binds to conserved tyrosine on the cytoplasmic tail of EPOR and also contributes to the 
negative regulation of EPOR signalling (Jiao et al. 1996). 
1.7.2 Myelopoiesis  
1.7.2.1 Introduction  
Primitive myelopoiesis occurs at 10.5 dpc in haemogenic sites, providing a transient 
population of myeloid cells mainly involved in macrophage and megakaryocyte generation 
(Tober et al. 2007). Definitive myelopoiesis initiates with the differentiation of HSCs to the 
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CFU-GEMM at and then to committed myeloid precursors, the granulocyte/macrophage 
colony-forming units (CFU-GM) in the bone marrow (Traver et al. 2001). CFU-GM give rise 
to more lineage-restricted, typified by CFU-G, CFU-M, CFU-Eo, and CFU-Baso, that in turn 
differentiate into neutrophils, macrophages, eosinophils, and basophils, respectively (Manz et 
al. 2002) (Fig. 1.6). Bone marrow neutrophil precursors comprise of two main populations 
including mitotic and post-mitotic. The mitotic compartment contains the cells that have 
ability to proliferate, including myeloblasts, promyelocytes, and myelocytes (Summers et al. 
2010). The post-mitotic compartment consist of cells that are incapable of proliferation, such 
as metamyelocytes, band neutrophils and segmented neutrophils, which are more 
differentiated (Mackey et al. 2003). The circulating granulocytes are divided into the 
marginating granulocyte pool (MGP) and the circulating granulocyte pool (CGP). The MGP, 
adhere to the blood vessel endothelium, but can move quickly into the blood circulation when 
they are required (Berkow et al. 1987). Maturation of monocytes starts with the formation of 
monoblasts that differentiate into promonocytes and ultimately monocytes, which are 
released into the blood circulation (Ohradanova-Repic et al. 2016).  Circulating monocytes 
can egress into different tissues and become specific types of tissue macrophages and 
dendritic cells, including pulmonary alveolar macrophages, hepatic Kupffer cells, pleural and 
peritoneal macrophages, osteoclasts, Langerhans and interdigitating dendritic cells in various 
tissues, and microglial cells in the central nervous system (Jakubzick et al. 2017).  
1.7.2.2 Regulation of myelopoiesis 
Myelopoiesis is controlled by cytokines. G-CSF is the primary extracellular regulator of 
granulopoiesis, affecting the proliferation, survival, and differentiation of all cells within the 
granulocytic lineage, from hematopoietic stem cells through to mature neutrophils (Lieschke 
et al. 1994). M-CSF can control proliferation, differentiation, and functional activation of 
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monocytes with an additional important role in elevating the effector functions of mature 
monocytes and macrophages (Jakubzick et al. 2017). IL-3 and IL-5 also play an important 
role in the growth, differentiations, and activation of cells from the myeloid linage (Burdach 
et al. 1998). In vivo studies have shown that GM-CSF can regulate the function of mature 
monocyte/macrophage, granulocytes, and dendritic cells through promoting antigen 
presentation (Robertson et al. 2000). Furthermore, GM-CSF and IL-5 play a major role in the 
development of the eosinophilic lineage, while SCF, IL-3, IL-4, IL-9, and IL-10 regulate 
basophil development (Naeim et al. 2009). 
Myelopoiesis is also regulated by various types of transcription factors, including PU.1, 
RAR, CBF, c-Myb, IRF8, C/EBPα and RUNX1/AML (Friedman 2002a). PU.1 and IRF8 are 
responsible for monocyte development, with a role in enhanced expression of numerous 
myeloid genes (Smith et al. 1996).  c-Myb, and  PU.1 cooperate together in order to restrict 
immature myeloid cells, resulting in progressive differentiation (Trauth et al. 1994).  Retinoic 
acid receptors (RARs) are also involved in myelopoiesis, with overexpressing of a dominant-
negative RAR in bone-marrow cells, highlighting an important role in differentiation of both 
pre-CFU-GM and neutrophilic promyelocytes (Wolff et al. 1995). One of the most important 
transcription factor involved in myelopoiesis is C/EBPα, which is mainly involved in 
regulating neutrophil maturation (Avellino et al. 2017). Numerous myeloid genes are also 
regulated by RUNX1/AML1, including This include GM-CSF, M-CSF, IL-3 and neutrophil 
elastase (Peterson et al. 2005). 
1.7.2.3  Cytokine receptor signalling in myelopoiesis 
GM-CSF receptor is involved in various cell signalling pathways and has critical roles in 
cellular functions, including anti-apoptosis, cell cycle progression, early commitment to 
myelopoiesis, differentiation or maturation of committed progenitors, and multiple activation 
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and motility functions in mature cells (Nishinakamura et al. 1996). GM-CSF receptor 
signalling is mediated by JAK2, leading to dimerization and transphosphorylation of the 
receptor and initiation of signal transduction (Lilly et al. 2001). GM-CSF can induce the 
tyrosine phosphorylation of STAT3 and STAT5 but not of STAT1, STAT2, STAT4, or 
STAT6. GM-CSFR signalling pathways is mainly mediated by JAK2, which activates 
downstream signalling pathway of STAT3, and STAT5B by phosphorylating the receptor and 
cytoplasmic signalling proteins resulting in increased differentiation and proliferation of both 
granulocytes and monocytes (Al-Shami et al. 1998). 
Granulocyte colony-stimulating factor (G-CSF), also known as colony stimulating factor 3 
(CSF3), is produced in response to infection, particularly those of a bacterial nature (Hermans 
et al. 2003). G-CSFR exists on precursor cells in the bone marrow and has an essential role in 
proliferation, survival, and differentiation of neutrophilic progenitor cells after G-CSF 
stimulation. G-CSF interaction with its receptor also leads to the release of neutrophils into 
the peripheral blood (Colotta et al. 1992). Both G-csf and G-csfr knockout mice show a 
reduction in blood neutrophils compared to wild-type as well as a significant decline in the 
number of myeloid progenitor cells (Semerad et al. 2002). These observations have 
confirmed the role of G-CSFR in maintaining neutrophil levels (Lieschke et al. 1994). 
Downstream signalling of G-CSFR leads to activation of several JAKs including JAK1, 
JAK2, and Tyk2 (Avalos et al. 1997). Activated JAKs then initiate phosphorylation of 
multiple STATs including STAT1, STAT3, and STAT5 (Panopoulos et al. 2008) via 
conserved tyrosines located in the C-terminal region of G-CSFR, which act as docking sites 
(Ward et al. 1999). 
G-csfr and Gm-csfr knockout mice develop increased susceptibility to infection including to 
Listeria monocytogenes. However, G-csfr knockouts show greater susceptibility compared to 
Gm-csfr knockout mice (Panopoulos et al. 2008). In keeping with this, the deficiency of 
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neutrophils is more marked in G-CSFR mice, which display a more pathological phenotype. 
In contrast, phagocytosis by cells from Gm-csfr knockout mice is normal compared to wild-
type mice (Hibbs et al. 2007). 
Colony stimulating factor 1 (CSF1), also known as macrophage colony-stimulating factor 
(M-CSF) can regulate proliferation, differentiation and survival of macrophages/monocyte s 
(Kelley et al. 1999). The key signalling pathway downstream of M-CSFR is the 
RAS/ERK1/2 pathway, inhibition of which leads to significant reduction in monocyte 
development (Hu et al. 2015). M-CSF signalling is also mediated by JAK1, JAK2, STAT3, 
STAT5, and STAT6 (Chen et al. 2002), as well as through the PI3K/Akt signalling pathway, 
leading to survival of monocytes (Stanley et al. 2014). Mice lacking M-CSF show a 
significant decrease in number of monocytes and macrophages and these cell populations 
survived following injecting exogenous M-CSF (Wiktor-Jedrzejczak et al. 1991). 
1.7.2.4 Negative regulation of myelopoiesis  
SOCS1 has been reported as an important negative regulator of GM-CSFR and M-CSFR 
signalling. In the case of GM-CSFR this is via ubiquitylation of βc signalling subunit to 
promote the proteasome degradation resulting in attenuation of GM-CSFR downstream 
signalling (Bunda et al. 2013). SOCS3 is a key negative regulator of G-CSF signalling in 
myeloid cells and is of particular significance during G-CSF-driven emergency 
granulopoiesis (Croker et al. 2004). Following G-CSF stimulation in vitro, SOCS3-deficient 
cells of the neutrophilic granulocyte lineage exhibit prolonged STAT3 activation and 
enhanced cellular responses to G-CSF, including an increase in cloning frequency, survival, 
and proliferative capacity. Consistent with the in vitro findings, mutant mice injected with G-
CSF display enhanced neutrophilia, progenitor cell mobilization, and splenomegaly, but 
unexpectedly also developed inflammatory neutrophil infiltration into multiple tissues 
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(Croker et al. 2004). Finally, CISH also has been shown to bind to the phosphotyrosine 
residues of G-CSFR at locations Tyr729 and Tyr744 to negatively regulate this signalling 
pathway (Hunter et al. 2004). 
 
1.8 Project rationale, hypothesis and aims  
 The evolution of multicellular organisms has required the development of systems that allow 
cells to respond to external signals. Cytokine signalling represents one of these, and is 
involved in key biological processes, including blood and immune development and function. 
The ability to subsequently extinguish these signals is important to avoid pathogenic 
outcomes. The Suppressor of cytokine signalling (SOCS) family of proteins represents an 
important mechanism to achieve this. The Cytokine Inducible SH2 domain-containing 
(CISH) protein was the first identified member of the SOCS family. In vitro studies have 
suggested the involvement of CISH as a negative regulator of signalling by EPO, IL-2, GH 
and G-CSF. Recent genetic studies have also implicated CISH in the susceptibility of humans 
to infectious disease, as well as for a zebrafish homologue in embryonic haematopoiesis. 
However, at the commencement of this project the precise physiological role of CISH 
remained obscure, largely due to the absence of a Cish-deficient mouse model. 
 The hypothesis of this project was that CISH acts as an important physiological regulator of 
cytokine receptor signalling in vivo.  This hypothesis was addressed by investigating a 
number of specific aims: (i) to generate a Cish targeted mouse; (ii) to examine the expression 
of CISH during embryonic development and in adult mice, and (iii) to analyse in detail key 
phenotypic changes in the Cish knockout mice, with an emphasis on haematopoiesis and the 
role of hematopoietic cytokines. It was anticipated that this project would provide new 
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molecular insights into the negative regulation of cytokine receptor signalling pathway by 
CISH, particularly its role in blood cell development.  
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Figure 1.1: Signaling via the JAK-STAT-SOCS pathway   
Activation of the JAK-STAT pathway following binding of ligand to its cognate cytokine 
receptor, leading to stimulation of JAK kinase function followed by STAT phosphorylation 
facilitating changes in gene transcription leading to various biological responses, including  
subsequent JAK/STAT regulation by SOCS family members. Adapted from (O’Sullivan et 
al. 2007). 
  









Figure 1.2 JAK structure  
Seven JAK homology (JH) domains are conserved among JAKs including JH1 to JH7, which 
make up the kinase, pseudo-kinase, SH2, and FERM domains. The FERM domain is 
responsible for binding to the cytokine receptor, the SH2 domain serves a structural role, the 
pseudo-kinase domain serves a regulatory role, while the kinase domain mainly mediates 
phosphorylation of substrate proteins. Adapted from (Baker et al. 2007).  
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Figure 1.3: STAT structure  
STATs share several conserved domains, including amino-terminal (NH2),  coiled-coil, DNA 
binding, linker, SH2, and transactivating domains. The site of tyrosine phosphorylation is 
indicated. Adapated form (Baker et al. 2007).  








Figure 1.4: JAKs and STATs activated by cytokine receptors 
 Schematic showing the preferential cytokine usage of different JAKs and STATs, based on 
gene-targeting studies in mice. Emphasis in bold indicates the dominant JAK of the pair and 
colour coding links the individual cytokine/growth factors with their requisite JAK and 
STAT(s). Adapted from (Kiu et al. 2012). 
  






 Chapter 1: Literature review 
47 
 
Figure 1.5 : SOCS structure  
All eight members of the SOCS protein family contain an N-terminal region of varying 
length and sequence, a central SH2 domain, and a C-terminal SOCS box.  A kinase inhibitory 
region (KIR) is present in SOCS1 and SOCS3 and an N-terminal conserved region (NTCR) is 
present in SOCS4 and SOCS5. Adapted from (Fujimoto et al. 2003).  









Figure 1.6: Haematopoiesis, regulatory cytokines, and cell surface markers used for the 
detection of different cell populations via flow cytometry  
Schematic of haematopoiesis showing the differentiation of HSC to haematopoietic 
precursors. Cytokines involved in the regulation of, and commonly used cell surface markers 
for the various hematopoietic cells are shown in green and red respectively. HSC differentiate 
to CMP and CLP. CMP yield CFU-GEMM which give rise to Plt, Ery, Mono and Neut, 
CFU-Eo and CFU-Baso which differentiate into eosinophils and basophils respectively. CLPs 
give rise to all the lymphoid cells lineage consisting of T-cell and B-cell and NK-cells. 
Abbreviation list:  HSC: hematopoietic stem cell, CMP: common myeloid progenitor, CFU-
GEMM: colony forming unit-granulocyte/erythrocyte/macrophage/megakaryocyte, CFU-
Meg: colony forming unit-megakaryocyte, Meg: megakaryocyte, plt: platelet, BFU-E: burst 
forming unit-erythroid, CFU-E: colony forming unit-erythroid, Ery: erythrocyte, CFU-GM: 
colony forming unit-granulocyte/macrophage, CFU-M: colony forming unit-macrophage, 
Mono: monocyte, CFU-G: colony forming unit-granulocyte, Neut: neutrophil, CFU-Eo:  
colony forming unit-eosinophil, Eos: eosinophil, CFU-Baso: colony forming unit-basophil,  
Baso: basophil, CLP: common lymphoid progenitor, NK-cell: natural killer cell,  GM-CSF: 
Granulocyte-macrophage colony stimulating factor, G-CSF: Granulocyte-colony stimulating 
factor,  M-CSF: Macrophage-colony stimulating factor,  IL: Interleukin, TPO: 
thrombopoietin, EPO:  erythropoietin. Adapted from (Warr et al. 2011).  
 
  










Figure 1.7: Primitive and definitive erythropoiesis  
The progressive development of cells from erythroid progenitors to erythroblast precursors, 
and finally mature red blood cells (RBCs). Erythroid progenitors including BFU-E, CFU-E 
and EryP-CFC have the capacity to form maturing erythroid cell colonies. Erythroid 
precursors are defined according their morphology as Pro, Baso, Poly and Ortho. Ortho 
enucleated to form Retic which matures into a RBC. Definitive erythropoiesis in fetal liver 
and bone marrow is derived from HSC, while primitive erythropoiesis in the yalk sac of early 
embryos occurs just once from mesoderm.  
Abbreviation list: BFU-E: burst forming unit-erythroid, CFU-E: colony forming unit-
erythroid, EryP-CFC: erythroid progenitor colony forming unit, Pro: proerythroblast, Baso: 
basophilic erythroblast, Poly: polychromatophilic erythroblast, Ortho: orthochromic 
erythroblast, Retic: reticulocyte, HSC: hematopoietic stem cell. Adapted from (Palis 2014). 
  










Figure 1.8: Regulation of erythropoiesis 
The formation of RBCs from HSCs is regulated by both external growth factors and 
cytokines (purple) and intracellular transcription factors (black).  
Abbreviation list: CFU-GEMM: colony forming unit-
granulocyte/erythrocyte/macrophage/megakaryocyte, BFU-E: burst forming unit-erythroid, 
CFU-E: colony forming unit-erythroid, IL: Interleukin. Adapted from (Palis 2014). 
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Table 1.1: Phenotypes of Jak knockout mice  
Gene 
 
phenotype of null mice References 
Jak1 Perinatal lethality 
 Neurological defect 
 Defective lymphoid development 
Defective IL-6, LIF, IL-7, IL-10 and IFN signalling 
(Imada et al. 2000) 
(Rodig et al. 1998) 
 (Kisseleva et al. 2002)   
(Kisseleva et al. 2002) 
Jak2 Embryonic lethality 
 Defective  erythropoiesis with severe anemia 
Defective EPO, TPO, IL-3, GM-CSF and IFN  signalling 
(Parganas et al. 1998) 
(Neubauer et al. 1998) 
(Neubauer et al. 1998) 
Jak3 SCID (Severe combined immunodeficiency) 
Dysregulated myelopoiesis 
Defective signaling from c containing receptors  
(Nosaka et al. 1995) 
 (Park et al. 1995) 
 (Park et al. 1995) 
Tyk2 Hypersensivity to pathogens  
Defective  IFN and IL-12 signalling  
(Matsuda et al. 2000) 
(Karaghiosof et al. 2000) 
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Table 1.2: Phenotypes of Stat knockout mice  
Gene Phenotype of null mice References 
Stat1 Defective in viral and microbial agents    
Defective IFN and IFN signalling 
Increased susceptibility to tumours 
(Durbin et al. 1996) 
(Durbin et al. 2000) 
(Schreiber et al. 2009) 
Stat2 Reduced microbial responses 
Defective IFN , IFNβ and IFN signalling 
(Park et al. 2000)  
(Perry et al. 2011) 
Stat3 Impaired responses to pathogens 
Embryonic lethality 
Defective in IL-2, IL-6, and IL-10 
(Takeda et al. 1997) 
(Takeda et al. 1997) 
(Alonzi et al. 2001) 
Stat4 Impaired Th1-cell differentiation 
Defective Il-12 signalling 
(Kaplan et al. 1998) 
(Imada et al. 2000) 
Stat5a Impaired mammary-gland development 
Defective PRL signalling 
(Liu et al. 1997) 
(Teglund et al. 1998) 
Stat5b Impaired NK cell proliferation and activity 
Defective growth-hormone signalling via IGF-1 
(Udy et al. 1997) 
(Kofoed et al. 2003) 
Stat5a/b Intense impairment of PRL and GH (Stat5abN/N) 
Impaired erythropoiesis (Stat5abN/N) 
Decreased CD4+ T cell (Stat5a-/- Stat5b-/-) 
Hypochromic anaemia  (Stat5a-/- Stat5b-/-)  
Impaired IL-2 signalling  (Stat5a-/- Stat5b-/-) 
(Fallon et al. 1999)  
(Teguld et al 1998) 
(Villarino et al. 2016).  
(Zhu et al. 2008) 
(Yao et al. 2006) 
Stat6 Impaired Th2-cell differentiation 
Defective IL-4 and IL-13 signalling 
(Takatori et al. 2005) 
(Kaplan et al. 1996)   
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IL-2, IL-3, IL-6, IL-9, IFN-, 
TNF- 
EPO, TSLP GH, PRL (Matsumoto et al. 1999) 
Inhibits IL-2, IL-3 EPO GH, PRL 
SOCS1 Induced 
by 
IL-2, IL-4, IL-6, IL-7, IL-9, 
IL-13, 
IFN-/β, IFN-, LIF, TNF- 
EPO, TPO, TSLP, 
G-CSF, GM-CSF, 
M-CSF 
GH, PRL, insulin, 
CNTF, 
TSH 
 (Endo et al. 1997) 
 (Losman et al. 1999) 
 (Crespo et al. 2000) 
 
(Wang et al. 2000) 
(Sporri et al. 2001) 
Inhibits IL-2, IL-4, IL-6, IL-7, IL-12, 
IL-15, 
IFN-/β, IFN-, LIF, TNF- 








GH, PRL, insulin, 
CNTF 
(Naka et al. 1998) 
(Matsumoto et al. 1999) 
(Ram et al. 1999) 
(Brender et al. 2000) 
(Dogusan et al. 2000) 
(Greenhalgh et al. 2002) 
(Tannahill et al. 2005) 
Inhibits IL-2, IL-3, IL-6 
 
GH, PRL, IGF-1 
SOCS3 Induced 
by 
IL-1, IL-2, IL-6, IL-9, IL-10, 
IL-13, IFN-a, IFN-, LIF 
EPO, GM-CSF 
TPO, LIF 
GH, PRL, insulin, 
leptin, 
TSH,EGF 
(Cohney et al. 1998) 
(Losman et al. 1999) 
(Bjorbaek et al. 1998) 
(Sasaki et al. 2000) 
(Fedral et al. 2003) 
(Magrangeas et al. 2001) 
(Croker et al. 2004) 
Inhibits IL-2, IL-4, IL-6, IL-9, IL-11, 
IFN-/β, IFN-, LIF 




Unknown Unknown EGF (Kairo et al. 2005)  
(Nicholson et al. 2005) 
Inhibits Unknown Unknown EGF 
SOCS5 Induced 
by 
IL-4, IL-6 Unknown EGF (Kairo et al. 2005) 
(Nicholson et al. 2005) 
(Callus et al. 2002) 
(Seki et al. 2002) Inhibits IL-4, IL-6 Unknown EGF,IL-4 
SOCS6 Induced 
by 
Unknown Unknown Insulin 
IGF-2 
(Krebs et al. 2002) 
(Fenner et al. 2006) 
Inhibits Unknown Unknown IGF-1,INS 
SOCS7 Induced 
by 
Unknown Unknown GH,PRL, IGF-1 (Matuoka et al. 1997) 
(Dogusan et al. 2000) 
(Kremer et al. 2007) 
Inhibits Actin cytoskeleton Unknown PRL, Leptin 
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Cish Spontaneous allergic lung 
inflammation 
Enhanced expansion of 
CD8+ T cell  
Enhanced NK mediated 
antitumor immunity 
Increased IL-4, TCR, and 
IL-15 signalling 
  (Yang et al. 2013) 
  (Palmer et al. 2015) 




Altered IL-2 signalling 
Fewer NK and NK T cells 
(Matsumoto et al. 1999) 
 
Socs1 Neonatal lethality 




Increased IFN- signalling 
Osteoblast differentiation 
  (Larsen et al. 2002) 
  (Alexander et al. 2004) 
  (Lei et al. 2004) 
  (Abe at al. 2006) 
   
Disturbed lymphocyte 
development 
Decreased number of  T-
cells 
Unresponsive to LPS 
(Kinjyo et al. 2002) 
 
Socs2 Gigantism 
Increased GH and IGF-1 
signalling 
  (Metcalf et al. 2000) 
  (Greenhalgh et al. 2002) 
 
Gigantism 
Increased GH signalling 
Hyperglycaemia and glucose 
intolerance 
(Puff et al. 2010) 
(Lebrun et al. 2010) 
Socs3 Embryonic lethality 
Placenta defects 
Disturbed erythropoiesis 
Increased IL-6, EPO, G-
CSF and LIF signalling 
  (Roberts et al. 2001) 
  (Takatashi et al. 2003) 
Embryonic lethality 
Increased Th2 differentiation 
Altered IL-2/ NFAT 
signalling 
(Brender et al. 2007) 
 




  (Kedizierski et al. 2014) Unknown (Fitzgerald et al. 2009) 
 
Socs5 Unknown   (Brender et al. 2004) Disturbed Th2 differentiation (Seki et al. 2002) 
 
Socs6 Slightly decreased growth 
Increased INS signalling 
  (Krebs et al. 2002) Increased glucose 
metabolism 
Enhanced INS signalling 
 
(Li et al. 2004) 
Socs7 Decreased growth  
Postnatal lethality due to 
hydrocephalus 
Increased INS signalling 
  (Kerbs et al. 2004) 
  (Banks et al. 2005) 
Unknown (Krebs et al. 2002) 
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2.1  Materials 
2.1.1  Suppliers 
The following companies supplied reagents and equipment used in this work:  
Agilent Technologies, Mulgrave, VIC, Australia 
Ambion, Austin, TX, USA 
Amgen Australia, Kew, VIC, Australia 
Amresco, Solan, OH, USA 
Applied Biosystems, Warrington, UK  
Astral Scientific, Gymea, NSW, Australia  
Australian Genome Research Facility, North Melbourne, VIC, Australia 
BD Biosciences, North Ryde, NSW, Australia  
Biogen, North Ryde, BC, NWS, Australia 
Biolegend Technology, San Diego, CA, USA 
Bio-Rad Laboratories, Hercules, CA, USA 
Cell Signaling, Danvers, MA, USA  
Chem-Supply, Port Adelaide, SA, Australia 
Eppendorf, Hamburg, Germany  
GE Healthcare, Parramatta, NSW, Australia 
Gene Codes Corporation, Michigan, USA  
Invitrogen, Mount Waverley, VIC, Australia  
In vitro Technologies, Noble Park, VIC, Australia 
Janssen, North Ryde, NSW, Australia 
Labtech Service & Supplies, Windsor, NSW, Australia 
Leica Microsystems GmbH, Wetzlar, Germany  
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Life sciences, Silverwater, NSW, Australia 
Millennium Science, Mulgrave, VIC, Australia 
Millipore, Billerica, MA, USA  
Olympus, Shinjuku, Tokyo, Japan  
PerkinElmer, Glen Waverly, VIC, Australia 
Promega, Annandale, NSW, Australia  
ProSciTech , Kirwan, QLD, Australia 
Qiagen, Melbourne, VIC, Australia 
Roche Molecular Biochemical, Indianapolis, IN, USA 
R&D System, Minneapolis, MN, USA 
Santa cruz Biotechnology, Dallas, TX, USA 
Sigma-Aldrich, Castle Hill, NSW, Australia  
Sigma Chemical Co., St Louis, MO, USA 
Thermo Scientific, Waltham, MA, USA 
Thermofisher, Scoresby, VIC, Australia 
2.1.2 Oligonucleotides 
Oligonucleotides used for variety of applications, including polymerase chain reaction (PCR) 
and reverse transcription-polymerase chain reaction (RT-PCR), quantitative real time-RT-
PCR (qRT-PCR) and sequencing, were designed using the NCBI Primer-BLAST design tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) or NetPrimer primer analysis software 
(http://www.premierbiosoft.com/netprimer/index.html). These oligonucleotides were 
synthesized by Sigma-Aldrich and are listed in Table 2.1. 
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Table 2.1: List of oligonucleotides used in this study 
Number Description * Ori #                        Sequence 5’-3’ Application 
AW024 βactin  S TGGCATCACACCTTCTAC qRT-PCR, RT-PCR 
AW025 βactin  AS AGACCATCACCAGAGTCC qRT-PCR, RT-PCR 
AW1125 Cish P1 S GACAGGTTCCCCATTCTTGTGG PCR 





AW1127 Cish P3 AS CAACGGGTTCTTCTGTTAGTCC PCR 
AW1380 Cish forward S GGACATGGTCCTTTGCGTACAG qRT-PCR 
AW1381 Cish reverse AS GGAGAACGTCTTGGCTATGCAC qRT-PCR 
AW1382 Cish  S GACTGGACCTCCTGAGCTTG PCR 
AW1383 Cish  AS GCATAGGTGGCCTTGATGTT PCR 
AW1131 Gapdh S GGATTTGGTCGTATTGGG   qRT-PCR, RT-PCR 
AW1132 Gapdh AS GGAAGATGGTGATGGGATT qRT-PCR, RT-PCR 
AW11379 Cish S1 S GAAGGGCGAGTATAGAAC  Sequencing 
AW11378 Cish S2 AS AGATGCCAAGATGATGAG Sequencing 
*: All oligonucleotides are directed against sequences from Mus musculus. 
#: Ori = orientation, S = sense, AS = antisense 
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2.2 Methods  
2.2.1 Bioinformatics application 
2.2.1.1  Sequence analysis 
 Sequence analysis and alignment were carried out using the Sequencher program version 
4.10.1 (GeneCodes Corporation). 
2.2.2  RNA applications 
2.2.2.1  Total RNA isolation 
At least 25 mg of mouse tissue of interest were physically minced into small pieces using a 
scalpel, and then homogenized in 1 ml Trizol reagent (Invitrogen). Following addition of 200 
µl chloroform (Qiagen), vortexing and a brief incubation at room temperature, the Trizol-
chloroform mix was centrifuged at 12000×g for 10 min at 4ºC. RNA present in the upper 
aqueous phase was precipitated with the addition of 500 µl isopropanol and incubation at 
room temperature (RT) for 10 min, followed by centrifugation at 12000×g for 10 min at 4ºC. 
The RNA pellet was washed with 75% (v/v) ethanol and centrifuged at 7500×g for 10 min at 
4ºC, with the purified RNA subsequently resuspended in an appropriate volume (20-25 µl) of 
sterile nuclease-free water (Ambion) depending on the size of RNA pellet.  
2.2.2.2  Reverse Transcription – Polymerase Chain Reaction (RT-PCR) 
Total RNA (200 ng) was reverse transcribed to complementary DNA (cDNA) with an iScript 
cDNA Synthesis Kit (Bio Rad) according to the manufacturer’s guidelines. A 2 µl aliquot of 
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this was used in a PCR reaction containing GoTaq Green Master Mix (Promega) and 0.4 µM 
of each gene-specific oligonucleotide (Sigma-Aldrich) (Table 2.1). Typical PCR was 
performed with conditions of an initial 2 min cycle of 95°C, followed by 35 cycles at 95°C 
for 1 min, 55°C for 30 sec and 72°C for 2 min. This was followed by 1 cycle at 72°C for 10 
min, after which the sample was held at 4°C (Bio Rad). These typical conditions and cycle 
numbers were modified as necessary. 
 For quantitative RT-PCR (qRT-PCR), cDNA was used with iQ SYBR Green (Bio-Rad) 
Supermix and 0.1 µM of each gene-specific oligonucleotide. All reactions were performed 
with 5 replicates using the Stratagene MX3000P system (Agilent), with data analysed using 
the Livak method (Livak et al. 2001) and expressed as a fold-change. The β-actin gene was 
used as housekeeping gene to normalise the relative expression between samples.  
2.2.2.3  RNA electrophoresis  
RNA was analysed on 1.2% (w/v) agarose gels prepared using a Formaldehyde-Free RNA 
Gel Kit (Amresco), as per the manufacturer’s protocol. Electrophoresis was carried out at 80 
V for between 1-1.5 h in a mini-tank apparatus (Bio Rad). Gels were post-stained in 
SYBR®Safe (Invitrogen), with RNA fragments visualised under UV illumination on a 
ChemiDoc XRS system (Bio Rad). 
2.2.2.4  Ultraviolet spectrophotometry 
UV spectrophotometry with a NanoVue Plus Spectrophotometer (GE Heathcare) was used to 
determine nucleic acid concentrations, using the relationships that 1 A260 absorbance unit 
equals 40 µg/µl RNA and 50 µg/µl DNA, with confirmation of purify based on the following 
ratios: Abs (260nm)/Abs (280nm)= 2.0 (RNA) and 1.8 (DNA)  
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2.2.3 DNA applications 
2.2.3.1  Total DNA isolation 
DNA was isolated from tissues or embryos using Quick Extract Solution (Invitrogen) 
following the manufacturer’s guidelines, and resuspended in nuclear-free water.  
2.2.3.2  Polymerase Chain Reaction (PCR)  
A 200-500 ng DNA template was used in a PCR reaction containing 1× GoTaq Green 
polymerase (Promega) reaction mix and 0.4 µm of each gene-specific oligonucleotide 
(Sigma- Aldrich) (Table 2.1). Typical PCR conditions were an initial 2 min cycle of 95°C, 
followed by 25 cycles at 95°C for 1 min, 61°C for 1 min and 72°C for 2 min. This was 
followed by 1 cycle at 72 °C for 10 min, after which the sample was held at 4°C. These 
typical conditions and cycle numbers were modified as necessary. 
2.2.4  Protein applications 
2.2.4.1  Protein isolation 
Approximately 20 mg of tissue was harvested then homogenised with 500 µl PBS to make a 
cel suspension. Following this, 0.5 mL of RIPA Lysis Buffer containing 20 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% (v/v) NP-40, 1% (v/v) sodium 
deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 
μg/mL leupeptin and 5 mg/mL phosphatase inhibitor cocktail (Sigma Chemical) were added. 
After a brief incubation of 5 min on ice, the lysate was centrifuged at 14,000×g for 15 min at 
4°C. The supernatant, which contains extracted proteins, was collected and stored at -80oC. 
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2.2.4.2  Protein concentration determination 
The total protein content was determined using a Pierce-BCA Protein Determination Kit 
(Pierce) following the manufacturer’s instructions, with bovine serum albumin (Sigma) as the 
standard. The absorbance at a wavelength of 570 nm was read using a VICTOR X Multilabel 
Plate Reader (PerkinElmer). 
2.2.4.3  SDS-PAGE 
Protein lysates were denatured by adding 1× SDS-PAGE loading buffer (62.5 mM of 1M Tris 
HCl (BioRad) (pH: 6.8), 2.5% SDS (BioRad), 10% glycerol (Invitrogen), 0.002% bromo 
phenol blue (BioRad)), mixed with 5% β-mercaptomethanol (Sigma Chemical) in a 4:1 ratio, 
and heating the mixture for 5 min at 100oC. Samples were then immediately cooling on ice 
for 5 min. The protein was separated on 4–20% Mini-PROTEAN® TGX Stain-Free™ 
Protein Gels (Biorad) at a voltage of 30 mA. 
2.2.4.4 Western blotting 
Following electrophoresis, proteins were electroblotted to nitrocellulose membrane 
(Millennium Science) in 20% (v/v) methanol, 25 mM Tris base, 192 mM glycine, pH 8.0. 
The membranes were then blocked with 5% (w/v) dried skim milk in 0.1% TBST, pH 7.6 (20 
mM Tris base, 200 mM NaCl and 0.05% (v/v) Tween-20). Following this, the membrane was 
incubated with rabbit anti-CISH (D4D9) mAb (Cell Signalling) at 1:1000, according to the 
manufacturer’s instruction overnight at 4oC. Membranes were then washed with 0.1% TBS, 
pH 7.6 for 3 × 15 min and then incubated with goat anti-rabbit HRP-conjugated secondary 
antibodies (Thermofisher) in 10 ml blocking buffer (5% BSA, 0.1% TBST), and proteins 
were detected using the Fujitsu imaging system. 




2.2.5 Cytochemistry and histology applications 
2.2.5.1  β-galactosidase  staining 
Harvested tissues or embryos were fixed with 4% (v/v) paraformaldehyde (PFA) (Sigma 
Aldrich) in 0.1 M phosphate buffer (pH 7.3) (Sigma Aldrich), for 1 h. The samples were then 
washed with 0.1 M phosphate buffer (pH 7.3) for 30 min, a total of three times. After 
washing, tissues or embryos were stained by incubation with 100 mg of X-gal (5-bromo-4-
chloro-3-indolyl-β-D-galactoside) (Roche Molecular Biochemical) in 0.1 M phosphate (pH 
7.3) buffer supplemented with 2 mM MgCl2,
  
5 mM potassium ferrocyanide 
(K4(Fe(CN)6).3H2O) (Sigma-Aldrich) and 5 mM potassium ferricyanide (Sigma-Aldrich) in 
the dark for 12 h. After staining, samples were washed with 0.1 M phosphate buffer (pH 7) 3 
times for 30 min each, and post-fixed with 4% PFA, either at 4°C overnight or 4 h at room 
temperature. Before storage in PBS at 4°C, samples were washed with 0.1 M phosphate 
buffer, pH 7.3 for 3 × 10 min.  
2.2.5.2 Tissue and embryos processing 
Tissues and embryos were fixed with 4%(v/v) PFA as described in Section 2.2.5.1 and 
transferred to 70% (v/v) ethanol and stored at 4°C until processing. Samples were subjected 
to 2 × 15 min washes with 1×PBS, followed by a series of 15 min ethanol washes (30%, 
50%, 70%, 90%, 95%, and 100% (v/v)) to dehydrate the samples. This was followed by 2 × 
30 min washes in 100% (v/v) Histosolve (Chem-Supply), and then subsequent 2 h and 
overnight washes in 100% (v/v) paraffin at 60oC. Samples were then embedded in 100% 
(v/v) paraffin and embedded in plastic histology cassettes (ProSciTech). 
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2.2.5.3  Sectioning tissues 
Sections were cut at 7 μm or 15 μm (depending on the tissue) using a microtome (Leica 
Microtome RM2125 RTS) and mounted on standard glass slides (ProSciTech).  
2.2.5.4   Eosin staining 
Slides were rehydrated in alcohol (100% (v/v), 95% (v/v), and 70% (v/v)) 3 min each. Slides 
were washed before staining with the 1% (w/v) Eosin solution (Sigma-Sigma-Aldrich) for 5 
min. Slides were then rinsed in tap water to remove the excess stain. Finally, slides were 
cleared in Histoclear (Sigma-Aldrich) and mounted in DePex (Thermofisher).  
2.2.5.5  Slide imaging 
Histology images and blood smears were captured on a Leica DFC290 digital camera 
controlled by the Leica Application Suite for Windows (Leica Microsystems). 
2.2.6  Cell analysis 
2.2.6.1  Mouse cell extractions 
Mice were euthanized by CO2 prior to obtaining specific organs or embryos for cell isolation 
using sterile technique throughout. 
2.2.6.2  Bone marrow 
The tibia and femur were flushed with RPMI (Thermofisher) containing 10% (v/v) FCS 
(Invitrogen), using a sterile 1 ml insulin syringe (BD Bioscience).  The contents were 
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collected and passed through 50 micron cell strainer (BD Bioscience), pelleted at 1600 rpm 
for 5 min, and the cells resuspended in fresh media.  
2.2.6.3  Spleen 
The spleen was sliced into small pieces, placed in 2ml PBS and homogenised using the 
plunger of a 1 ml syringe and then passed through a 50 micron cell strainer (Astral Scientific) 
attached to a 50-ml falcon tube. The cell suspension was pelleted at 1600×g for 5 min, and 
the cells resuspended in fresh IMDM media containing 10% (v/v) FCS.  
2.2.6.4  Liver 
The excised liver was sliced into small pieces, to which IMDM media (Thermofisher) 
containing 10 mg collagenase (Sigma Chemical) was added. Following incubation at 37ºC for 
4 h, the liver suspension was filtered through a 70-75 micron cell strainer (Astral Scientific), 
pelleted at 1600×g for 5 minutes, and the cells were resuspended in fresh IMDM media 
containing 10% (v/v) FCS. 
2.2.6.5  Fetal Liver 
The fetal liver harvested from E12.5 to E15.5 embryos and was disrupted by pipetting up and 
down, and passed through 50 micron cell strainer (BD Pharminogen), the cells pelleted at 
800×g for 5 min, and then resuspended in fresh media. 
2.2.6.6 Colony forming assay  
Bone marrow cells and splenocytes were derived from mice aged between 6-12 weeks, and 
fetal liver cells from embryos between 12.5 to 15.5 dpc. Colony forming assays were 
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performed using 5 ml of methylcellulose media (R&D System) in a 35 mm dish, with bone 
marrow (5×104), spleen (3×104) or fetal liver (5×104) added to each dish (Thermofisher). 
Cultures were incubated for 8-14 days at 37ºC with 5% CO2. The number of CFU-E scored at 
day 4, and CFU-GEMM, CFU-GM, CFU-G, CFU-M and BFU-E at day 8 or 14. 
2.2.6.7 Flow cytometry  
Approximately 2×106 cells from the tissue of interest was suspended in FACS buffer solution 
comprising 2% (v/v) fetal bovine serum and 0.1% (w/v) EDTA in PBS. Samples were placed 
on ice and ≤ 1.0 µg per 106 cells in 100 µl volume of Fc block solution (CD32, FC block 
antibody, BD Bioscience) was added to each tubes. Then cells were stained with specific cell 
surface marker antibodies, including CD44 (APC fluorophore, BD Pharminogen), Ter119 
(PE fluorophore, BD Pharminogen), Gr-1 (FITC fluorophore, BD Pharminogen), CD11b 
(APC-Cy7, BD Pharminogen) and CD60 (PE fluorophore, BD Pharminogen) (all diluted 
1:100) for 30 min at 4°C. Samples were washed three times for 5 min with FACS buffer 
solution. A minimum of 100,000 events were recorded for each sample from three 
independent experiments with a BD FACS-Canto II flow cytometer and analyzed using BD 
FACSDiva software (v6.0).  
2.2.6.8 Blood cell analysis 
 Mouse blood was collected from the tail and stored in mini tubes (Thermofisher) containing 
1% EDTA in PBS. Samples were analysed for WBC count, RBC count with all RBC indices 
including HCT, Hb, MCV, MCH and MCHC as well as platelets number with ABX Micros 
60 - HORIBA (Invitro Technologies).  
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2.2.6.9 Blood cell differentiation 
Slides containing cells from blood, bone marrow, and spleen samples were prepared with a 
Cytospin funnel (Thermofisher). The slides were fixed with 100% (v/v) methanol and stained 
with Wright-Geimsa according to the manufacturer’s protocol (Thermo Scientific) prior to 
viewing on a Leica Microsystem DME stereomicroscope. Differential count of the various 
cell populations were performed on a minimum of 100 cells. 
2.2.7  Animal methods 
2.2.7.1  Ethics statement 
This project involved the use of mice and was conducted in accordance with the regulations 
of the Deakin University Animal Ethics Committee under the following approval numbers:  
A44/2011: The role of cytokine signalling in development and immunity (Principal 
investigator: Alister Ward; Project duration: 3 years, Application approval date: 31/06/2011) 
G34/2014: The role of cytokine signalling in development and immunity (Principal 
investigator: Alister Ward; Project duration: 3 years, Application approval date: 31/09/2014). 
2.2.7.2  Animal housing 
Animals were maintained at 18-23°C temperature and humidity of 40-60% with a daily 14 h 
lights on/10 h lights off cycle. Mice had constant access to food and fresh water, which was 
replenished weekly, with soft fibrous material provided for security and nesting. All activities 
were performed in a manner aimed to reduce stress on the animals. 
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2.2.7.3  Breeding   
Mice were typically mated between 6 weeks to 3 months old. Following a gestation period of 
21 days for both C57BL/6J and BALB/c mice, litters of typically between 6 to 10 pups were 
produced, and weaned at 21 days. 
2.2.7.4  Timed pregnancies   
In order to produce embryos of defined age, matings were set up before 7.00 pm. The 
following day before 9.00 am mating was confirmed by the presence of a milky white to 
yellow vaginal plug, using a magnifying loop and a small probe. This was defined as 0.5 days 
post-conception (dpc). 
2.2.7.5  Mouse and embryo genotyping 
DNA was extracted from small piece of embryos tail or pups ear punch samples according to 
protocols in section 2.2.3.1. Then, PCR were performed using Cish primers (P1, P2, P3) 
listed in table 2.1 according to protocols in section 2.2.3.3. 
2.2.7.6 Mouse identification  
An ear punch device was used after weaning time for genotyped pups to create a unique 
identifier following a standard ear numbering system. To track mice breeding or other 
purposes, a metal identification tag was placed in the ear pinna with a special applicator. 
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2.2.7.7  Size and weight measurement 
Mice were measured from nose to tail using a Traceable™ Digital Caliper (ProSiTech). Total 
body and organ weight were measured using Mettler Toledo™ NewClassic ME Precision 
digital scale (Fisher Scientific). 
2.2.7.8  Body composition 
 Body composition was measured weekly by magnetic resonance imaging (EchoMRI™ 
Whole Body Composition Analyzer, Biogen), which allowed the determination of whole 
body fat mass, lean mass, free and total water content. 
2.2.7.9 Cytokine injection 
Intraperitoneal (IP) injection of specific cytokines was performed on mice at 11 weeks old of 
age. Restrained mice were injected with 100 U hEPO (Eprex 1,000 epoetin alfa 1000I/U) 
(Janssen) for either 4 or 6 consecutive days or 6 µg of hG-CSF (Neulasta, pegfilgrastim) 
(Amgen) for 5 consecutive days in 150 μl of sterile PBS for each mouse, using insulin 
syringe. The day after the last injection, mice was humanely culled and organs harvested. 
2.2.8 Statistical analysis 
All statistical analyses were performed using GraphPad Prism 7.0. An unpaired 2-tailed t test 
was used for comparisons between two experimental groups, and one-way analysis of 
variance (ANOVA) was used for comparisons of more than two groups. Unless otherwise 
indicated, all results were averaged from biological triplicates and values are reported as 
mean ± SEM. A p value < 0.05 was considered statistically significant. 














Chapter 3. Creation and characterization of 
mice bearing a Cish lacZ allele 
  




3.1  Introduction 
The suppressor of cytokine signalling (SOCS) family of proteins play important roles in the 
control of signalling from cytokine and other receptors. Individual SOCS members are 
induced by specific cytokines and serve to switch off cytokine receptor signalling, 
constituting a negative feedback regulatory loop (Alexander et al. 2004). Several show quite 
specific in vivo roles, for example, SOCS1 in regulating IFNγR signalling (Metcalf et al. 
2002), SOCS2 in regulating GHR signalling (Greenhalgh et al. 2002), and SOCS3 in 
regulating G-CSFR (Croker et al. 2004) and LIFR (Takahashi et al. 2003) signalling.  
The cytokine-inducible SH2 domain-containing (CISH) protein was the first member of the 
SOCS family identified (Yoshimura et al. 1995). A range of in vitro studies suggested that 
CISH negatively regulates signalling from several cytokine receptors, including IL-2R 
(Aman et al. 1999), IL-3R (Yoshimura et al. 1995), EPOR (Matsumoto et al. 1997), GHR 
(Ram et al. 1999) and PRLR (Dif et al. 2001), as well as the T cell receptor (Li et al. 2000). 
The mechanism by which CISH controls cytokine signalling has been investigated 
biochemically. These studies revealed a significant functional connection between STAT5 
and CISH with STAT5 stimulating CISH expression in response to activation of these 
receptors (Ram et al. 1999; Verdier et al. 1998) and CISH acting to limit STAT5 activation 
by blocking receptor docking sites or causing degradation of receptor complexes (Piessevaux 
et al. 2008).  
 However, at the time of commencement of this project the in vivo role of CISH remained 
poorly understood, with no Cish knockout mouse available. Therefore, this Chapter aimed to 
generate global Cish knockout mouse lines containing a lacZ knock-in allele and to 
commence their characterisation, including investigating Cish expression during embryonic 




development and in adult organs through use of the inserted β-galactosidase lacZ gene, and 
examining overall health  growth and fecundity.  
3.2  Generation of Cish mutant mouse lines 
3.2.1  Cish-targeted ES cells 
The Cish gene in mice is located on Chromosome 9, position 107,296,026-107,301,987. It 
contains 3 exons and 4 introns with a transcript length of 2,850 bp that encodes for a protein 
of 257 amino acid residues (Fig. 3.1A). A genomic clone containing the Cish gene from a 
mouse 129/SV genomic library was used to construct a targeting vector that contained a lacZ-
neo cassette, such that the lacZ gene was placed under the control of the endogenous Cish 
promoter to facilitate analysis of native Cish expression, and the neo gene was placed under 
control of the β-actin promoter to allow for selection of recombinants (Fig. 3.1B). 
The targeting vector was introduced into ES cells derived from the C57/BL6 mouse strain by 
electroporation, and recombinants selected in the presence of neomycin (Fig. 3.2A), with 
successful targeting confirmed by Southern blot analysis (data not shown). These targeted ES 
cells were sourced from the International Knockout Mouse Consortium. 
3.2.2 Generation of targeted Cish mice 
The Cish-modified ES cells were injected into C57BL/6 mouse blastocysts that were 
implanted into pseudo-pregnant female C57BL/6 mice to generate chimeric offspring (Fig. 
3.2B). These chimeric mice were then crossed with wild-type (C57BL/6) mice, with the 
offspring screened for the successful transmission of the modified CishlacZ allele (Fig. 3.2B). 
This was performed by the Australian Phenomics Network at Monash University. 




3.2.3  Generation of genetically pure Cish mutant lines  
To facilitate the accurate and sensitive analysis of CISH function in a range of assays, mice 
harbouring the targeted CishlacZ allele were repeatedly crossed with both C57/BL6 and Balb/c 
mice for 8 generations to ensure the allele was on a genetically ‘pure’ background (Fig. 
3.3A). Each generation required a minimum of 10 weeks (Fig. 3.3B), representing 80 weeks 
of breeding in total. 
3.3 Characterisation of Cish targeted mice 
3.3.1  Generation and analysis of Cish mutant mice 
To obtain homozygous Cish mutant mice, heterozygous (Cish+/lacZ) mice were in-crossed to 
generate a hypothetical 1:2:1 mix of wild-type (Cish+/+):heterozygous 
(Cish+/lacZ):homozygous (CishlacZ/lacZ) mice (Fig. 3.4A). Mice were genotyped using a three-
primer PCR that included primers P1 (forward primer; located at the 3’ end of the 5’ 
homology arm, P2 (reverse primer; located at the 5’ end of exon 2), and P3 (reverse primer; 
located in the En2 intron) (Fig. 3.1A&B). This amplified a product of 505 bp from the wild- 
type allele and a product of 237 bp from the targeted allele, and identified progeny of all 
genotypes were present (Fig. 3.4), thereby confirming homozygous CishlacZ/lacZ mice were 
viable. 
To examine the effect of the lacZ-neo insertion on CISH expression, Western blot analysis 
was performed on liver samples using an anti-CISH antibody. This detected bands at 36 and 
39 kDa in Cish+/+ mice, consistent with the two isoforms of CISH observed in other studies 
(Yoshimura et al. 1995). These bands were not observed in CishlacZ/lacZ mice indicating that 
the targeted Cish gene likely represents a knockout allele. 




3.3.2  Fecundity and survival 
Cish+/lacZ in-crosses on both the Balb/c (Fig. 3.5A) and C57/BL6 (Fig. 3.5B) background 
yielded good litter sizes, with no significant differences in the number of male or female 
progeny, and with Cish+/+ (wild-type), Cish+/lacZ (heterozygote) and CishlacZ/lacZ (knockout) 
progeny generated at close to Mendelian ratios. Subsequent comparison of Cish+/+ and 
CishlacZ/lacZ in-crosses revealed similar litter sizes, with no significant difference in sex ratios 
on either the Balb/c (Fig. 3.5C) or C57/BL6 (Fig. 3.5D) backgrounds. All mice displayed 
generally good health throughout life (data not shown). 
3.3.3  Body composition and organ weight 
Further analysis of Cish+/+ and CishlacZ/lacZ mice revealed that CishlacZ/lacZ males on either 
background showed a statistically significant decrease in total weight compared to their 
Cish+/+ counterparts (Fig. 3.6A& C), that was not evident in female CishlacZ/lacZ mice (Fig. 
3.6B& D). However, analysis of individual tissues revealed a significant decrease in the 
abdominal fat in both male and female CishlacZ/lacZ mice on the Balb/c (Fig. 3.6E& F) and 
C57/BL6 (Fig. 3.6G& H) backgrounds. There was also a trend for increased spleen weight in 
CishlacZ/lacZ males (Fig. 3.6E&G) that reached statistical significance in CishlacZ/lacZ females on 
both background (Fig. 3.6F& H). 
Analysis of the body composition of Balb/c mice from 4-22 weeks of age using Echo-MRI 
confirmed a reduction in overall fat weight in both male and female CishlacZ/lacZ mice 
compared to their Cish+/+ counterparts, whereas lean weight and overall weight were not 
statistically different, except overall weight in younger male (Fig. 3.7 A& B). Detailed 
assessment of specific fat deposits revealed that all were significantly decreased in 
CishlacZ/lacZ mice, with the exception of white fat in females (Fig. 3.7 C& D). 




3.3.4  Further analysis of aged mice 
Balb/c mice were further examined at 27 weeks of age. This revealed a small but significant 
decrease in body weight and size in male CishlacZ/lacZ mice compared to Cish+/+ mice, 
although femur length was normal (Fig. 3.8A), but no such differences were noted in females 
(Fig. 3.8B). Analysis of dissected tissues revealed that fat deposits were again consistently 
decreased. In addition, spleen and liver weight were increased in CishlacZ/lacZ of both sexes 
(Fig. 3.8C& D), while heart weights were higher specifically in CishlacZ/lacZ males (Fig. 3.8C) 
and kidney weight in CishlacZ/lacZ females (Fig. 3.8D). Full blood analysis revealed alterations 
in red blood cell indices, with haemoglobin (HGB) and haematocrit (HCT) significantly 
decreased in males (Fig. 3.8E), with a non-significant trend in females (Fig. 3.8F), while 
mean cell volume (MCV) was elevated and mean cell haemoglobin content (MCHC) was 
decreased significantly in both sexes (Fig. 3.8E& F). 
3.4  Expression of Cish 
Insertion of the lacZ gene under the control of the endogenous Cish promotor (Fig. 3.1B) 
enabled Cish expression to be monitored from embryonic development to adult tissues by β-
galactosidase staining. 
3.4.1  Embryonic expression of Cish 
A time course of β-galactosidase staining of Cish+/lacZ embryos was performed from 10.5 to 
18.5 days post conception (dpc) compared to Cish+/+ embryos as negative controls. No 
staining was observed in embryo of either genotype at 10.5 dpc (Fig. 3.9A). However, 
staining was identified in Cish+/lacZ embryos at 11.5 dpc in the fetal liver (Fig. 3.9B), which 
increased dramatically at 12.5 dpc (Fig. 3.9C), with some staining observed in vertebrae and 




areas of the brain at this time point (Fig. 3.9C). Staining of brain and vertebrae continued at 
13.5 dpc (Fig. 3.9D), and increased by 14.5 dpc (Fig. 3.9E) with additional staining seen in 
hair follicles at this time point. Staining in vertebrae, skin and brain further increased in 15.5 
dpc and 16.5 dpc embryos (Fig. 3.9 F, G). Additional staining was observed in the developing 
ear, abdomen, tail, forelimb and digits at 17.5 dpc and 18.5 dpc (Fig.  3.9 H, I). 
3.4.2 Expression of Cish in adult tissues 
β-galactosidase staining was performed on dissected tissue from 11 week-old male and 
female CishlacZ/lacZ mice, with Cish+/+ mice used as negative controls. No staining was 
observed in the spleen of either male or female CishlacZ/lacZ mice compared to wild-type 
controls. In contrast, strong staining was observed in the lobes, lobules and septa of the 
thymus of both male and female CishlacZ/lacZ mice (Fig. 3.10). Staining was also present in the 
left and right lobe of the lung, with additional staining in the trachea and bronchi, and in the 
ventricle, auricle and aorta of the heart in both male and female CishlacZ/lacZ mice, although 
the intensity of staining was greater in female compared to male mice (Fig. 3.10). Some 
staining was seen in the cornea, lens and vitreous body of the eye in both male and female 
CishlacZ/lacZ mice, with additional staining present in certain genital organs including the 
ovary, uterus and testicle (Fig. 3.10). Staining was observed in specific areas of the brain, 
with significant staining detected in various cerebrocortical regions, including basal ganglia, 
hippocampus and thalamus, with greater intensity in female mice compared to male mice. On 
the ventral surface of the brain significant staining was identified in the occipital and 
temporal lobes, hypothalamus, lateral reticular nuclei and pontine nuclei. Male CishlacZ/lacZ 
mice showed greater staining in the lateral reticular nuclei compared to females. Staining was 
also observed in visceral organs, including liver lobes, the cortex, papilla and calyx of the 
kidney, the pancreas oesophagus, as well as the cardia, fundus, body, pylorus and duodenum 




of the stomach with intensity of staining again greater in female mice. Staining was also 
observed within the abdominal fat, with no significant difference in staining between male 
and female CishlacZ/lacZ mice (Fig. 3.10). 
3.4.3 Expression of Cish in pregnant and lactating mice 
Expression of Cish was investigated in pregnant, lactating and virgin CishlacZ/lacZ mice, with 
virgin Cish+/+ mice used as negative control. Increased staining was observed in the brain, 
liver, kidney and mammary gland of pregnant and lactating mice compared to virgin 
CishlacZ/lacZ mice, with a greater increase observed in lactating mice compared to pregnant 
mice (Fig. 3.11A). Histological examination of organs from pregnant mice revealed that Cish 
was expressed in glial cells in the brain, epithelial cells in the mammary gland, 
juxtaglomerular cells in the kidney, and hepatocytes in the liver (Fig. 3.11B). 
  




3.5  Discussion 
Despite CISH being the first SOCS family member identified (Yoshimura et al. 1995), no 
Cish deficient mouse lines had been published when this project was initiated. Therefore, the 
major goal of this Chapter was to generate such lines to facilitate in vivo functional analysis. 
An ES cell line carrying a Cish allele targeted with a lacZ-neo cassette was obtained from the 
International Knockout Mouse Consortium and used to generate mice carrying this CishlacZ 
allele on both C57/BL6 and Balb/c backgrounds. Western blot analysis of the liver from mice 
homozygous for this allele failed to detect CISH protein indicating that this likely represents 
a knockout (KO) allele. There was no obvious phenotype in CishlacZ/lacZ mice compared to 
Cish+/+ mice on both backgrounds, being healthy and fertile, and generated in close to 
Mendelian ratios from Cish+/lacZ in-crosses. Collectively, this was consistent with 
unpublished reports of CISH-deficient mice lacking a phenotype (Matsumoto et al. 1999). 
More detailed analysis, however, revealed differences between Cish+/+ and CishlacZ/lacZ mice, 
including reduced body weight in male CishlacZ/lacZ mice, reduced fat content as well as 
increased spleen and liver weight, and elevated MCV but reduced MCHC in CishlacZ/lacZ  mice 
of both sexes compared to Cish+/+ controls.  
The health and viability of CishlacZ/lacZ mice contrasted with Socs1 knockout mice that died 
neonatally due to excessive IFNγ signalling (Starr et al. 1998) and Socs3 knockout mice that 
displayed embryonic lethality at 13 dpc due to unrestrained LIFR signalling leading to 
placental defects (Roberts et al. 2001). CishlacZ/lacZ mice also showed no major difference in 
body size, lean mass or bone length, compared with Socs2 knockout mice that exhibited 
gigantism due to enhanced GH receptor signalling (Metcalf et al. 2000) or Socs6 and Socs7 
mice that showed growth defects due to perturbation of IGF-1R signalling (Krebs et al. 2004; 
Krebs et al. 2002). Moreover, CishlacZ/lacZ mice showed high fecundity and were able to raise 




offspring, processes critically dependent on PRL receptor signalling (Kelly et al. 2001). 
Collectively, this suggest CISH does not exert a major non-redundant role in LIF, IFNγ, 
IGF1-R or PRL signalling.  
CishlacZ/lacZ mice did display some phenotypic differences to their wild-type counterparts. 
Firstly, spleen sizes were consistently increased with evidence for altered red blood cell 
parameters in CishlacZ/lacZ mice. This suggests a role for CISH in haematopoiesis, which is 
explored in detail in Chapter 4 and Chapter 5. Secondly, male CishlacZ/lacZ mice showed 
reduced body weight compared to Cish+/+ mice. Interestingly, Cish transgenic mice showed 
growth retardation leading to reduced body weight in both males and females due to reduced 
GHR signalling (Matsumoto et al. 1999). However, the low body weight in male CishlacZ/lacZ 
mice is unlikely to be caused by altered GH signalling since lean mass and bone length (data 
not shown) were not affected. Thirdly, CishlacZ/lacZ mice showed reduced fat deposits across 
both sexes and backgrounds. Leptin has a negative regulatory role in appetite control (Perry 
et al. 2012), with both CISH and SOCS3 shown to be induced by leptin (Emilsson et al. 
1999). Socs3 knockout mice showed lower levels of food intake compared to wild-type 
controls, consistent with elevated leptin-induced inhibition of appetite in the Socs3 knockout 
mice (Mori et al. 2004). CISH has been shown to interact with the leptin receptor (Lavens et 
al. 2006) and so it may also regulate leptin receptor signalling in a manner similar to SOCS3. 
However, this was not pursued further in this project. Lastly, aged CishlacZ/lacZ mice exhibited 
an increased liver weight in both sexes, which was not investigated further.  
The lacZ gene insertion afforded an opportunity to utilize β-galactosidase staining to detect 
Cish expression. This identified expression during embryogenesis in the fetal liver, the site of 
embryonic haematopoiesis, as well as the brain, vertebrae, tail, skin, digits and forelimb. 
Previous studies have identified CISH expression in fetal liver, kidney, and to a lesser extent 




lung during embryonic development, with expression in other fetal tissues reported as very 
low (Uchida et al. 1997). Both SOCS2 (Dey et al. 1998), SOCS3 (Marine et al. 1999) are 
expressed in the fetal liver, indicating the potential for redundant or overlapping function 
with CISH. There is also potential for redundancy of CISH with SOCS6, which is expressed 
ubiquitously during mouse embryonic development (Krebs et al. 2002).  
In adult tissues, CISH expression was identified in the hippocampus, thalamus, hypothalamus 
and lateral reticular nuclei region of the brain, liver hepatocytes, the cortex, papilla and calyx 
of the kidney, the lobes, lobules and septa of the thymus, the trachea, bronchus and ventricle 
of the lung, the auricle and aorta of the heart, the cornea, lens, and vitreous body of the eye, 
pancreas, abdominal fat, stomach, and certain genital organs. Other research has identified 
CISH expression in the liver and kidney, with modest expression in lung (Uchida et al. 1997). 
Socs1 was shown to be highly expressed in the thymus and spleen (Kato et al. 2006), with a 
lesser extent in the lung and testis (Starr et al. 1997). Socs2 expression was demonstrated in 
the kidney, lung and liver (Metcalf et al. 2000; Starr et al. 1997), pancreatic islet (Santangelo 
et al. 2005), and to a lesser extent in the heart and brain (Metcalf et al. 2000). Socs3 
expression was also identified in the spleen, thymus and lung (Starr et al. 1997), with high 
expression of Socs4 additionally seen in the thymus and intestine (Delgado-Ortega et al. 
2011). Socs5 was expressed in a variety of adult tissues including heart, brain, eye, lung, 
testis and skeletal muscle (Magrangeas et al. 2000; Nicholson et al. 2005). Socs6 expression 
has been detected in the bone marrow (Krebs et al. 2002) and the retina (Liu et al. 2008), and 
Socs7 has been shown to be highly expressed in the pancreas and brain, and at lower levels in 
the liver, perigonadal fat, spleen, and testis (Banks et al. 2005; Krebs et al. 2002). There is 
thus considerable opportunity for redundancy with other SOCS family members in a number 
of tissues. For example, in the thymus where SOCS1 plays a key regulatory role on IFNγ 
signalling and T cell development (Cornish et al. 2003; Metcalf et al. 2002), and CISH 




transgenic mice studies have highlighted a potential regulatory role of Cish in T cells (Li et 
al. 2000; Matsumoto et al. 1999).  
The wide range of Cish expression is consistent with broad expression of JAK/STAT 
components with critical roles in cytokine receptor signalling. For example, JAK1/JAK2, 
STAT3 and STAT6 show overlapping expression in the cerebral cortex, hippocampus, and 
cerebellum of the brain (De‐Fraja et al. 1998) while JAK2 and STAT5B were also expressed 
in the liver to mediate the effects of growth hormone (Herrington et al. 2000). This 
collectively indicates that Cish has the potential to regulate JAK/STAT counterparts in these 
organs. 
Expression of Cish was increased in the liver, brain and mammary gland of pregnant and 
lactating CishlacZ/lacZ mice. PRL plays a key role during pregnancy, including direct 
involvement in mammary gland development and lactation as well as mediating behavioural 
effects through its action in the brain (Grattan et al. 2001). SOCS2 has been shown to be 
required for the attenuation of the PRL receptor signalling pathway during pregnancy and 
lactogenesis (Ramanathan et al. 2008; Riley et al. 2010), while SOCS3 has been implicated in 
the regulation of mammary tissue through programmed cell death and tissue remodelling, that 
is initiated after the termination of lactation (Sutherland et al. 2007). Moreover, CISH 
transgenic mice showed defected mammary gland development leading to defective lactation 
due to disrupted PRL receptor signalling (Matsumoto et al. 1999). Collectively, this suggests 
CISH may work with other SOCS family members in controlling PRL signalling during 
pregnancy and lactation, as well as transitioning from lactation.   
 




Figure 3.1:  Targeting of Cish locus 
A. Wild-type mouse Cish locus, showing the position of the 3 exons and the genotyping 
primers P1 and P2. 
B. Cish targeting vector, showing the 5’ and 3’ homology arms derived from the endogenous 
Cish locus flanking a lacZ-neo cassette. The lacZ gene is flanked by En2SA, IRES and pA 
sequence to ensure efficient transcription from the endogenous promotor, with the neo gene 
under the control of the constitutive hbactP. The position of FRT and loxP site as well as the 
genotyping primers P1 and P3 are shown. 
Abbreviation list: lacZ: β-galactosidase, neo: neomycin, En2SA: En2 splice acceptor, IRES: 
internal ribosome entry site, pA: polyadenylation, hbactP: human beta-actin promoter, FRT: 
flippase recognition target, loxP: locus of crossover in P1. 
  











Figure 3.2: Generation of targeted Cish mice 
A. Generation of modified ES cells by electroporation of the Cish targeting vector (KOMP) 
followed by homologous recombination, with selection of clones using neomycin. 
B. Generation of Cish targeted mice by injection of the modified ES cells into blastocysts for 
implantation into pseudo-pregnant females to generate chimeric mice, which were crossed to 
wild-type mice to identify heterozygous progeny with germline transmission of the targeted 
Cish allele. 










Figure 3.3: Generation of genetically pure targeted Cish lines 
A. Cish+/lacZ mice were back-crossed for 8 generations onto either a Balb/c or C57/BL6 
background. 
B. Breeding timeline, showing 10 weeks generational time, with 3 weeks gestation and 7 
weeks to reach sexual maturity. During this time, pups were genotyped (2 weeks old) and 
weaned (3 weeks old). 










Figure 3.4: Generation of homozygous CishlacZ/lacZ mice and their analysis 
A. In-crossing of Cish+/lacZ mice was performed to generate Cish+/+, Cish+/lacZ and CishlacZ/lacZ 
progeny. 
 B. Genotyping of Cish+/+, Cish+/lacZ and CishlacZ/lacZ littermates using a 3-primer PCR on 
genomic DNA extracted from ear clips, with the size of wild-type and targeted alleles 
indicated. 
 C. Western blot analysis of serial-diluted protein lysates from adult livers of Cish+/+ and 
CishlacZ/lacZ mice using anti-CISH antibody, with the position and size of CISH protein 
isoforms indicated.  
  









Figure 3.5: Breeding outcomes of crossing of various Cish lines  
A-B. Analysis of litter size (black), sex (grey) and genotype (Cish+/+: green, Cish+/lacZ: 
orange, CishlacZ/lacZ: red) outcomes for Cish+/lacZ in-crosses on a Balb/c (A) or C57/BL6 (B) 
background. N=40, showing mean with the error bars representing SEM: * P<0.05. 
C-D. Analysis of litter size and sex outcomes for Cish+/+ (green) and CishlacZ/lacZ (red) in-
crosses on a Balb/c (C) or C57/BL6 (D) background. N=32, showing mean with the error 
bars representing SEM: * P<0.05. 
  









Figure 3.6: Body and organ weight comparisons in young adult mice 
A-D. Body weight of 12 week-old Cish+/+ (green) and CishlacZ/lacZ (red) male (A& C) and 
female (B, D) mice on Balb/c (A& B) or C57/BL6 (C& D) background. N=24, showing 
mean with error bars representing SEM: * P<0.05. 
E-H. Weight of indicated organs from 12 week-old Cish+/+ (green) and CishlacZ/lacZ (red) male 
(E, G) and female (F, H) mice on a Balb/c (E& F) or C57/BL6 (G& H) background. N=20, 
showing mean with the error bars representing SEM: ** P<0.01, * P<0.05. 
  









Figure 3.7: Body composition comparisons in young adult mice 
A-B. Echo-MRI analysis of total, fat and lean weight as indicated in 12 week-old Cish+/+ 
(green) and CishlacZ/lacZ (red) Balb/c male (A) and female (B) mice. N=12, showing mean 
with the error bars representing SEM:  ** P<0.001, * P<0.05. 
C-D. Weight of indicated fat deposits from 12 week-old Cish+/+ (green) and CishlacZ/lacZ (red) 
Balb/c male (C) and female (D) mice. N=12, showing mean with the error bar representing 
SEM:  ** P<0.001, * P<0.05. 









Figure 3.8: Body, organ and blood parameters in aged mice 
A-B. Selected body parameters of 27 week-old Cish+/+ (green) and CishlacZ/lacZ (red) Balb/c 
male (A) and female (B) mice. N=12, showing mean with the error bar representing SEM:  * 
P<0.05. 
C-D. Weight of indicated organs and fat deposits from 27 week-old Cish+/+ (green) and 
CishlacZ/lacZ (red) Balb/c male (C) and female (D) mice. N=12, showing mean with the error 
bar representing SEM:  * P<0.05.  
Abbreviation list: Epi: epidermal fat, Ing: inguinal fat, and Mes: mesodermal fat. 
E-F. Blood parameters of 27 week-old Cish+/+ (green) and CishlacZ/lacZ (red) Balb/c male (E) 
and female (F) mice. N=12, showing mean with the error bar representing   SEM:  * P<0.05.  
Abbreviation list: RBC: red blood cell; Hb: haemoglobin; HCT: haematocrit; MCV: mean 
cell volume; MCH: mean cell haemoglobin; MCHC: mean cell haemoglobin content; WBC: 
white blood cell; PLT: platelets 
  









Figure 3.9: Embryonic expression of Cish  
β-galactosidase staining of Cish+/+ and Cish+/lacZ embryos at 10.5 (A), 11.5 (B), 12.5 (C), 13.5 
(D), 14.5 (E), 15.5 (F), 16.5 (G), 17.5 (H), and 18.5 (I) days post conception (dpc), as 
indicated. N=3. 
 Abbreviation list: a: abdomen, b: brain, d: digits, f: forelimb, l: liver, t: tail, v: vertebrae. 
  









Figure 3.10: Expression of Cish in adult tissues 
β-galactosidase staining of dissected tissues from 11 weeks old male and female of Cish+/+ 
and CishlacZ/lacZ Balb/c mice. N=6. 
 Abbreviation list: g: ganglia, h: hippocampus, hy: hypothalamus, l: lateral reticular nuclei, p: 
pontine nuclei, t: thalamus, lo: lobes, lob: lobules, s: septa, ll: left lobe, rl: right lobe, tr: 
trachea, v: ventricle, au: auricle, ao: aorta, co: cornea, le: lens, vb: vitreous body, ut: uterus, o: 
ovary, te: testicle, co: cortex, ca: calyx, pa: papilla, os: oesophagus, f: fundus, bo: body, py: 
pylorus.  
  









Figure 3.10: (cont) 
  












Figure 3.11: Expression of Cish in pregnant and lactating mice 
A. β-galactosidase staining of dissected tissue from virgin Cish+/+, as wells as virgin, 
pregnant, and lactating CishlacZ/lacZ mice (A). N=3. 
B. Section of β-galactosidase-stained kidney, mammary gland, brain, and liver from pregnant 
CishlacZ/lacZ mice. N=3. 
 Abbreviation list: h: hepatocytes, g: glial cells, j: juxtaglomerular cells, e: epithelial cells. 
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4.1  Introduction 
Erythropoietin (EPO) is a cytokine that mediates embryonic erythroid development and 
maintains appropriate adult red blood cell numbers in response to environmental signals, such as 
hypoxia (Wojchowski et al. 2010). EPO acts through its cognate cell-surface receptor, EPOR, 
which activates a number of intracellular pathways to mediate its effects. These notably include 
the highly related signal transducer and activator of transcription 5 (STAT5) proteins, which are 
latent cytoplasmic transcription factors that becomes tyrosine phosphorylated following EPOR 
ligation. This in turn facilitates STAT5 dimerization and nuclear translocation, where the STAT5 
dimers can modulate the expression of key target genes that mediate the requisite biological 
effects (Kuhrt et al. 2015). An important facet of signalling via cytokine receptors such as EPOR 
is their tight negative regulation, including by members of the suppressor of cytokine signalling 
(SOCS) family of proteins, which act to extinguish signalling in a regulated manner (Trengove et 
al. 2013).  
The cytokine-inducible SH2-containing (CISH) protein was the first member of the SOCS family 
identified, being an immediate-early gene induced by EPO (Yoshimura et al. 1995), as well as by 
other haematopoietic cytokines that activate STAT5 (Wang et al. 2013). The encoded CISH 
protein was found to bind via its SH2 domain to phosphorylated tyrosine residues found on 
activated cytokine receptors, where it could suppress downstream signalling through several 
mechanisms. Firstly, CISH was able bind to the same receptor phosphotyrosine residues as 
STAT5 and thereby physically block STAT5 docking, including to EPOR (Verdier et al. 1998). 
Secondly, CISH could facilitate proteasomal degradation of activated receptor complexes through 
recruitment of an E3 ubiquitin ligase complex via interactions with its SOCS box (Piessevaux et 
al. 2008). Enforced CISH expression in vitro partially suppressed EPO-mediated cell 
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proliferation (Matsumoto et al. 1997; Yoshimura et al. 1995) and promoted apoptosis of erythroid 
progenitor cells ex vivo (Ketteler et al. 2003). 
Transgenic mice that expressed CISH under the control of the β-actin promoter exhibited altered 
T and NK cell responses, growth retardation and defective mammary gland development 
(Matsumoto et al. 1999). More recent studies of alternative Cish knockout mice lines has 
revealed roles in the development and homeostasis of T cells (Palmer et al. 2015; Yang et al. 
2013) and NK cells (Delconte et al. 2016) but no erythroid phenotypes have been noted in any of 
these studies. However, ablation of a zebrafish CISH homologue resulted in increased early 
erythropoiesis, including the EPOR-positive cell population (Lewis et al. 2014), suggesting CISH 
may represent a physiological regulator of EPOR. Thus, to directly examine this aspect of CISH 
biology further, developmental, steady-state and EPO-induced erythropoiesis were investigated in 
the Balb/c CishlacZ/lacZ mice generated in Chapter 3. 
4.2 Role of CISH in steady-state and developmental 
erythropoiesis 
Examination of red blood cell parameters in female CishlacZ/lacZ mice revealed subtle alterations 
when compared to Cish+/+ mice. A significantly increased mean cell volume (MCV) and 
decreased mean cell haemoglobin content (MCHC) was observed (Table 4.1). This suggested 
alteration in steady-state erythropoiesis in the absence of CISH. 
To investigate this further, bone marrow was extracted from the mice and analysed using lineage-
specific markers. The overall cellularity was not significantly different between the Cish+/+ and 
CishlacZ/lacZ genotypes (Fig. 4.1A). However, CishlacZ/lacZ mice possessed reduced Ter119+ 
erythroid cells compared to Cish+/+ mice in terms of both total number (Fig. 4.1B-C) and relative 
                         Chapter 4: CISH regulation of erythropoiesis 
115 
  
percentage (Fig. 4.1D-E). Analysis of specific erythroid populations using a Ter119+/CD44+ 
staining strategy (Liu et al.  2013) identified elevation of specific erythroblast populations in 
CishlacZ/lacZ mice, with a significant increase in basophilic and polychromatic cells in terms of 
total (Fig. 4.2A-B) and relative (Fig. 4.2C-D) number, with the increase in orthoblasts reaching 
significance for relative number (Fig. 4.2C-D). Differential counts confirmed a significant 
increase for pro-erythroblasts, basophilic and polychromatic erythroblast (Fig. 4.2E-F). In 
contrast, the more mature reticulocyte and RBC populations were significantly reduced in total 
and relative number in CishlacZ/lacZ compared to Cish+/+ mice (Fig. 4.2A-D). Analysis of early 
precursors using a colony-forming assay demonstrated a trend for reduced frequency of CFU-E 
and BFU-E in CishlacZ/lacZ mice, but this failed to reach significance (Fig. 4.3A-D). Collectively, 
this suggests a major disruption in the erythroid differentiation program. Whilst measurement of 
other haematopoietic cell populations in the bone marrow was also performed, these will be 
discussed later in Chapter 5. 
In contrast, the spleens of CishlacZ/lacZ mice were increased in cellularity (Fig. 4.4A) and size (data 
not shown) compared to Cish+/+ mice, with an increase in the total number of Ter119+ cells (Fig. 
4.4B-C). Indeed, the total number of almost all erythroid cell populations (Fig. 4.5A-B) and both 
CFU-E and BFU-E precursors (Fig. 4.6A-B) were increased in the spleen in the absence of CISH. 
However, the relative number, and where applicable, the differential count of these erythroid 
populations were largely unchanged (Fig 4.5C-F), except CFU-E, which were elevated (Fig 4.6C-
D). Together, this suggests no basal differentiation defect exists in the spleen, which instead may 
be compensating for the disrupted bone marrow erythropoiesis observed. 
To examine the consequences of CISH ablation on developmental erythropoiesis, a similar 
analysis was also performed on fetal livers. This demonstrated a small but significant increase in 
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total cellularity (Fig. 4.7A) as well as Ter119+ total (Fig. 4.7B-C) and relative (Fig 4.7D-E) cell 
number in CishlacZ/lacZ mice compared to Cish+/+ mice. The pro-erythroblast, basophilic and 
polychromatic erythroblast populations were elevated in terms of total number (Fig. 4.8A-B) and 
for pro-erythroblast and basophilic erythroblast in relative number (Fig. 4.8C-D), while the 
reticulocyte and RBC numbers were unchanged  in the CishlacZ/lacZ mice (Fig. 4.8C-D). A 
decreased total BFU-E and frequency of CFU-E and BFU-E was also observed (Fig. 4.9C-D). 
This points to a basal differentiation defect also existing in the fetal liver.  
4.3  Role of CISH in EPO-induced erythropoiesis 
EPO is a critical regulator of developmental erythropoiesis with a role in maintaining red blood 
cell homeostasis (Jelkmann 2011). Moreover, in vitro studies have demonstrated strong negative 
regulation of EPOR signalling by CISH (Yoshimura et al. 1995). Thus, it is likely that altered 
EPOR-mediated responses might be responsible for many of the changes observed in the 
CishlacZ/lacZ mice. To directly investigate this potential role for CISH in regulating in vivo EPOR 
signalling, Cish+/+ and CishlacZ/lacZ mice were injected with EPO. 
Analysis of bone marrow and spleen by RT-PCR revealed that basal Cish was low in bone 
marrow cells, and not detected in spleen cells of Cish+/+ mice. Following 4 consecutive days of 
EPO injection, Cish expression was markedly increased in the bone marrow with strong 
expression also observed in the spleen (Fig. 4.10). No expression was observed in CishlacZ/lacZ 
mice. 
Injection of EPO for 4 days caused a significant increase in haemoglobin (Hb), haematocrit 
(HCT), MCV and MCH in Cish+/+ mice was (Table 4.2).  These parameters further increased 
after 6 days at which time RBC numbers were also increased significantly. These values 
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decreased slightly after EPO injection was discontinued for 2 days. In contrast, EPO injection of 
CishlacZ/lacZ mice led to a delayed and blunted elevation of these parameters, although these 
continued to increase after EPO injection was stopped. 
Analysis of the bone marrow of Cish+/+ mice following EPO stimulation revealed a large 
increase in total cellularity (Fig. 4.11A-B) and specifically the total (Fig. 4.12A-B) and relative 
Ter119+ population (Fig. 4.13A-B), all of which then waned after EPO injection was 
discontinued. Analysis of the various erythroid subpopulations by FACS revealed increased total 
number of all populations (data not shown), with the relative number of basophilic, 
polychromatic and orthochromatic erythroblasts significantly elevated after 4 days, at the expense 
of pro-erythroblasts, reticulocytes and RBCs, with all returning to close to basal proportions after 
6 days EPO treatment and following EPO cessation (Fig. 4.14A-B). This was confirmed for 
erythroblasts by differential counts (Fig. 4.15 A-B). The frequency of BFU-E, CFU-E and CFU-
GEMM increased marginally following EPO injection at the expense of CFU-G, CFU-GM and 
CFU-M (Fig. 4.16A-B).  
For the CishlacZ/lacZ mice, the bone marrow response was blunted, such that these mice showed a 
significantly lower total cellularity (Fig. 4.11C-E) and total Ter119+ cells (Fig. 4.12C-E) 
compared to Cish+/+ mice following EPO injection, although the relative proportion of Ter119+ 
cells was not significantly different after EPO injection (Fig.4.13 C-E). The change in relative 
number of immature erythroblasts following 4 days EPO injection in CishlacZ/lacZ mice were also 
similar to Cish+/+ mice (4.14 C-D). However, all erythroid subpopulations were decreased in total 
number in CishlacZ/lacZ mice compared to Cish+/+ mice (data not shown). Moreover, the trend for 
increased immature erythroblasts subpopulations and decreased mature erythroblasts 
subpopulations in CishlacZ/lacZ mice compared to Cish+/+ mice was also disrupted, as assessed by 
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either FACS (Fig. 4.14 E) or differential counts (Fig. 4.15C-E). CFU-E and BFU-E frequency 
remained consistently reduced in CishlacZ/lacZ compared to Cish+/+ mice following EPO treatment, 
which extended to CFU-GEMM, while the comparative levels of CFU-GEMM and CFU-GM 
declined (Fig. 4.16C-E). 
The effect of EPO administration was also analysed in the spleen. EPO injection resulted in a 
dramatic increase in spleen size (data not shown) and cellularity in Cish+/+ mice, both of which 
were reduced following cessation of injection (Fig. 4.17A-B). This was mirrored in the total (Fig. 
4.18A-B) and relative (Fig. 4.19A-B) number of Ter119+ cells. Basophilic, polychromatic and 
orthochromatic erythroblasts were all elevated at 4 days, but by 6 days the relative numbers of 
basophilic and polychromatic erythroblasts had decreased compared to 4 days EPO injection, 
which also applied to orthochromatic erythroblasts following cessation of injection (Fig. 4.20A-
B, Fig 4.21A-B). In contrast, reticulocytes increased over this period, while relative numbers of 
pro-erythroblasts and RBCs decreased in the first 6 days, and then began to rebound once EPO 
injection was stopped (Fig. 4.20A-B). Both CFU-E and BFU-E increased progressively after 4 
and 6 days of EPO injection (Fig. 4.22A-B).  
EPO injection of CishlacZ/lacZ mice for 4 days also resulted in an increased spleen size (data not 
shown) and cellularity (Fig. 4.17C), but the fold increase was less than for the Cish+/+ mice. 
Notably, continued injection of EPO for 6 days actually led to a reduced spleen size (data not 
shown) and cellularity, relative to 4 days with cessation of EPO injection having limited effect 
(Fig. 4.17C-D). Collectively, this meant that while the total cell number was initially significantly 
higher in the spleens of CishlacZ/lacZ mice compared to Cish+/+ mice, a small but significant 
decrease was evident at day 6 (Fig. 4.17E). This was reflected in the Ter119+ cell population to 
an even greater extent (Fig. 4.18C-E, Fig. 4.19C-E), which rebounded once EPO injection was 
                         Chapter 4: CISH regulation of erythropoiesis 
119 
  
stopped. Changes to the relative numbers of various erythroid cell populations in response to 
EPO injection were reasonably similar between CishlacZ/lacZ and Cish+/+ mice (Fig. 4.20C-E, Fig. 
4.21C-E), whereas the relative frequency of CFU-E and BFU-E followed similar kinetics to those 
observed for the overall cellularity and Ter119+ cells (Fig. 4.22C-E). Collectively, this suggests 
that depletion of precursors may be occurring at later time points in CishlacZ/lacZ mice.  
  




 EPOR signalling is important for the proliferation, differentiation, and survival of erythroid 
progenitors in the fetal liver during early development (Palis 2014) as well as in the adult bone 
marrow to maintain RBC homeostasis in the spleen in stress conditions (Jelkmann 2011). CISH 
was first identified as a negative feedback regulator of EPOR signalling in vitro (Yoshimura et al. 
1995) but the in vivo relevance of this has not been verified. Using one of the novel Cish deficient 
mouse lines generated in Chapter 3, this Chapter explored the physiological role of CISH in 
mammalian erythropoiesis. This was investigated through the analysis of erythroid precursors 
using colony forming assays, intermediate stages of erythropoiesis using flow cytometry, and 
analysis of peripheral erythrocytes in developmental, steady-state and EPO-induced 
erythropoiesis. Collectively, these studies have identified a complex role for CISH in 
erythropoiesis, likely mediated by its negative feedback regulation of EPOR signalling. 
Ablation of CISH resulted in perturbed fetal erythropoiesis, consistent with its expression in the 
fetal liver identified in Chapter 3. There was a considerably marked increase in erythroblast 
populations compared to more mature erythroid cells in CishlacZ/lacZ fetal liver, indicating an 
imbalance between proliferation and differentiation. SOCS3 has also been shown to have a role 
in fetal liver erythropoiesis, with SOCS3 ablation leading to marked erythrocytosis resulting in 
expanded numbers of mature red blood cell and erythroid precursors, whilst its enforced 
overexpression suppressed erythropoiesis and resulted in anaemia (Marine et al. 1999). This 
suggests CISH and SOCS3 may have overlapping roles in fetal erythropoiesis and could 
potentially compensate for one another. 
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CISH was also demonstrated to be expressed basally in bone marrow and strongly induced by 
EPO in both bone marrow and spleen. Ablation of CISH resulted in mild steady state anaemia in 
adult mice, with suppression of bone marrow erythropoiesis consistent with its basal expression 
in this haematopoietic organ, and which appeared to be partially compensated by enhanced 
splenic erythropoiesis. Similar to fetal erythropoiesis, there was a tendency for more immature 
and less mature erythroblasts in the CishlacZ/lacZ mice compared to wild-type mice suggesting an 
impairment in differentiation, but a reduction of CFU-E and BFU-E frequency also observed. 
Ablation of CISH also blunted EPO-induced erythropoiesis in the bone marrow, and to a lesser 
extent in the spleen, but again was associated with expansion of erythroblasts at the expense of 
more mature cells. 
 Ablation of SOCS1 in mice was also shown to lead to a reduced haematocrit, reduced total 
cellularity and number of erythroblasts in bone marrow, and increased numbers of erythroblasts 
in the spleen, although the total cellularity in the spleen of Socs1 knockout mice was lower than 
that of wild-type mice (Metcalf et al. 1999). SOCS3-deficient fetal liver stem cells could restore 
bone marrow erythropoiesis in lethality-irradiated mice (Marine et al. 1999). However, 
knockdown of SOCS3 in human HSCs induced erythroid expression whereas ectopic expression 
blocked erythroid expansion and colony formation (Liu et al. 2015).  Collectively, this suggests 
that CISH and SOCS1 may have some overlapping roles in regulating steady-state erythropoiesis, 
while SOCS3 appears to have an opposing action. 
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Data is presented as mean ± SEM for Cish+/+ mice (WT) and CishlacZ/lacZ mice (KO) (N= 10) and 
the p-value for their comparison. RBC: red blood cell; Hb: haemoglobin; HCT: haematocrit; 
MCV: mean cell volume; MCH: mean cell haemoglobin; MCHC: mean cell haemoglobin 
content; WBC: white blood cell. 
  

















Table 4.2: (cont.) 
 
 
Data is presented as mean ± SEM for Cish+/+ mice (WT) and CishlacZ/lacZ mice (KO) (N=5) and 
the p-value for their comparison, for uninjected mice (0d) or mice injected with EPO for 4 days 
(4d), 6 days (6d) or for 6 days followed by no injection for 2 days (6d+2d). RBC: red blood cell; 
Hb: haemoglobin; HCT: haematocrit; MCV: mean cell volume; MCH: mean cell haemoglobin; 
MCHC: mean cell haemoglobin content. 
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Figure 4.1: Analysis of bone marrow haematopoiesis in CishlacZ/lacZ mice 
A. Quantitation of total cell number in the bone marrow. 
B-E. Quantitation of erythroid cells (Ter119+) in the bone marrow showing total number (B) and 
its fold-change (C), as well as the relative number (D) and its fold-change (E). 
Data is presented for Cish+/+ mice (WT, green) (N=10) and CishlacZ/lacZ mice (KO, red) (N=8) 
along with fold-change between them (KO vs WT, orange). Shown is the mean ± SEM, along 
with values for individual mice in panels B and D. * P<0.05. 
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Figure 4.2: Analysis of bone marrow erythropoiesis in CishlacZ/lacZ mice 
A-D. Quantitation of specific erythroid cell populations (pro-erythroblast: PRO, basophilic 
erythroblast: BASO, polychromatic erythroblast: POLY, orthochromatic erythroblast: ORTHO, 
reticulocyte: RETIC, red blood cell: RBC) in the bone marrow, showing total number (A) and its 
fold-change (B), as well as the relative number (C) and its fold-change (D) as determined by 
FACS. 
E-F. Differential counts for various cell types (pro-erythroblast: PRO, basophilic erythroblast: 
BASO, polychromatic erythroblast: POLY, orthochromatic erythroblast: ORTHO, neutrophils: 
NEUT, eosinophil; EOS, monocyte: MON, lymphocyte: LYMPH) (E) and the fold-change (F), 
which was determined by counting the respective cell populations visible in Giemsa-stained 
cytospins, with a total of 300 cells counted per sample. 
Data is presented for Cish+/+ mice (WT, green) (N=10) and CishlacZ/lacZ mice (KO, red) (N=8) 
along with fold-change between them (KO vs WT, orange). Shown is the mean ± SEM, along 
with values for individual mice in panels A, C and E. ** P<0.01, * P<0.05. 
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Figure 4.3: Analysis of bone marrow colony-forming cells in CishlacZ/lacZ mice 
Quantitation of erythrocyte colony-forming unit (CFU-E) and blast-forming unit (BFU) cell 
populations in bone marrow, showing total number (A) and its fold-change (B), as well as the 
frequency (per 105 cells) (C) and its fold-change (D) as determined by colony formation on 
semi-solid agar.  
Data is presented for Cish+/+ mice (WT, green) (N=6) and CishlacZ/lacZ mice (KO, red) (N=6) 
along with fold-change between them (KO vs WT, orange). shown as the mean ± SEM, along 
with values for individual mice in panels A and C. Shown is the mean ± SEM, along with 
values for individual mice in panels A and C. ** P<0.01, * P<0.05. 
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Figure 4.4: Analysis of spleen haematopoiesis in CishlacZ/lacZ mice 
A. Quantitation of total cell number in the spleen. 
B-E. Quantitation of erythroid cells (Ter119+) in the spleen showing total number (B) and its 
fold-change (C), as well as the relative number (D) and its fold-change (E). 
Data is presented for Cish+/+ mice (WT, green) (N=8) and CishlacZ/lacZ mice (KO, red) (N=6) 
along with fold-change between them (KO vs WT, orange). Shown is the mean ± SEM, along 
with values for individual mice in panels B and D. ** P<0.01. 
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Figure 4.5: Analysis of spleen erythropoiesis in CishlacZ/lacZ mice 
A-D. Quantitation of specific erythroid cell populations (pro-erythroblast: PRO, basophilic 
erythroblast: BASO, polychromatic erythroblast: POLY, orthochromatic erythroblast: 
ORTHO, reticulocyte: RETIC, red blood cell: RBC) in the spleen, showing total number (A) 
and its fold-change (B), as well as the relative number (C) and its fold-change (D) as 
determined by FACS. 
E-F. Differential counts for various cell types (pro-erythroblast: PRO, basophilic erythroblast: 
BASO, polychromatic erythroblast: POLY, orthochromatic erythroblast: ORTHO, 
neutrophils: NEUT, eosinophil; EOS, monocyte: MON, lymphocyte: LYMPH) (E) and the 
fold-change (F). 
Data is presented for Cish+/+ mice (WT, green) (N=10) and CishlacZ/lacZ mice (KO, red) (N=8) 
along with fold-change between them (KO vs WT, orange). Shown is the mean ± SEM, along 
with values for individual mice in panels A, C and E. ** P<0.01, * P<0.05. 
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Figure 4.6: Analysis of spleen colony-forming cells in CishlacZ/lacZ mice 
Quantitation of erythrocyte colony-forming unit (CFU-E) and blast-forming unit (BFU) cell 
populations in the spleen, showing total number (A) and its fold-change (B), as well as the 
frequency (per 105 cells) (C) and its fold-change (D) as determined by colony formation on 
semi-solid agar. Data is presented for Cish+/+ mice (WT, green) (N=6) and CishlacZ/lacZ mice 
(KO, red) (N=6) along with fold-change between them (KO vs WT, orange). * P<0.05. 
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Figure 4.7: Analysis of fetal liver haematopoiesis in CishlacZ/lacZ mice 
A. Quantitation of total cell number in the fetal liver. 
B-E. Quantitation of lineage-specific cell populations (Ter119+, CD61+, Gr-1+, CD11b+) in 
the fetal liver showing total number (B) and its fold-change (C), as well as the relative 
number (D) and its fold-change (E). 
Data is presented for Cish+/+ mice (WT, green) (N=8) and CishlacZ/lacZ mice (KO, red) (N=8) 
along with fold-change between them (KO vs WT, orange). Shown is the mean ± SEM, along 
with values for individual mice in panels B and D. ** P<0.01, * P<0.05. 
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Figure 4.8: Analysis of fetal liver erythropoiesis in CishlacZ/lacZ mice 
A-D. Quantitation of specific erythroid cell populations (pro-erythroblast: PRO, basophilic 
erythroblast: BASO, polychromatic erythroblast: POLY, orthochromatic erythroblast: 
ORTHO, reticulocyte: RETIC, red blood cell: RBC) in the fetal liver, showing total number 
(A) and its fold-change (B), as well as the relative number (C) and its fold-change (D) as 
determined by FACS. Data is presented for Cish+/+ mice (WT, green) (N=5) and CishlacZ/lacZ 
mice (KO, red) (N=5) along with fold-change between them (KO vs WT, orange). **P<0.01, 
*P<0.05. 
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Figure 4.9: Analysis of fetal liver colony-forming cells in CishlacZ/lacZ mice 
Quantitation of specific colony-forming unit (CFU) and blast-forming unit (BFU) cell 
populations (erythrocyte: E, granulocyte: G, macrophage: M, granulocyte/macrophage: GM, 
granulocyte/erythrocyte/macrophage/megakaryocyte: GEMM) in fetal liver, showing total 
number (A) and its fold-change (B), as well as the frequency (per 105 cells) (C) and its fold-
change (D) as determined by colony formation on semi-solid agar. 
Data is presented for Cish+/+ mice (WT, green) (N=5) and CishlacZ/lacZ mice (KO, red) (N=5) 
along with fold-change between them (KO vs WT, orange). Shown is the mean ± SEM, along 
with values for individual mice in panels A and C. *** P<0.001, ** P<0.01, * P<0.05. 
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Figure 4.10: Analysis of Cish mRNA expression in bone marrow and spleen  
Analysis of Cish mRNA expression in total bone marrow and spleen basally (d0) and 
following 4 days EPO injection (4d) using RT-PCR with β-actin as control. 
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Figure 4.11: Analysis of bone marrow cellularity in CishlacZ/lacZ mice following EPO 
stimulation 
Quantitation of total cell number in the bone marrow for Cish+/+ mice (WT, green) (A) and 
its fold-change (B) and CishlacZ/lacZ mice (KO, red) (C) and its fold-change, along with fold-
change between them (KO vs WT, orange) (E) for uninjected mice (0d, no pattern) or mice 
injected with EPO for 4 days (4d, horizontal stripe), 6 days (6d, vertical stripe) or for 6 days 
followed by no injection for 2 days (6d+2d, stippled). Data presented is the mean ± SEM: *** 
P<0.001, ** P<0.01, * P<0.05 (N=5). 
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Figure 4.12: Analysis of bone marrow lineage composition in CishlacZ/lacZ mice following 
EPO stimulation 
Quantitation of total number of various lineage-specific cell populations (Ter119+, CD61+, 
Gr-1+, CD11b+) in the bone marrow for Cish+/+ mice (WT, green) (A) and its fold-change (B) 
and CishlacZ/lacZ mice (KO, red) (C) and its fold-change, along with fold-change between them 
(KO vs WT, orange) (E) for uninjected mice (0d, no pattern) or mice injected with EPO for 4 
days (4d, horizontal stripe), 6 days (6d, vertical stripe) or for 6 days followed by no injection 
for 2 days (6d+2d, stippled). Data presented is the mean ± SEM: *** P<0.001, ** P<0.01, * 
P<0.05 (N=5). 
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Figure 4.13: Analysis of bone marrow lineage frequency in CishlacZ/lacZ mice following 
EPO stimulation 
Quantitation of relative number of various lineage-specific cell populations (Ter119+, CD61+, 
Gr-1+, CD11b+) in the bone marrow for Cish+/+ mice (WT, green) (A) and its fold-change (B) 
and CishlacZ/lacZ mice (KO, red) (C) and its fold-change, along with fold-change between them 
(KO vs WT, orange) (E) for uninjected mice (0d, no pattern) or mice injected with EPO for 4 
days (4d, horizontal stripe), 6 days (6d, vertical stripe) or for 6 days followed by no injection 
for 2 days (6d+2d, stippled). Data presented is the mean ± SEM: *** P<0.001, ** P<0.01, * 
P<0.05 (N=5). 
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Figure 4.14: Analysis of bone marrow erythropoiesis in CishlacZ/lacZ mice following EPO 
stimulation by FACS 
Quantitation of the relative number of specific erythroid cell populations (pro-erythroblast: 
PRO, basophilic erythroblast: BASO, polychromatic erythroblast: POLY, orthochromatic 
erythroblast: ORTHO, reticulocyte: RETIC, red blood cell: RBC) in the bone marrow for 
Cish+/+ mice (WT, green) (A) and its fold-change (B), and CishlacZ/lacZ mice (KO, red) (C) 
and its fold-change, along with fold-change between them (KO vs WT, orange) (E) for 
uninjected mice (0d, no pattern) or mice injected with EPO for 4 days (4d, horizontal stripe), 
6 days (6d, vertical stripe) or for 6 days followed by no injection for 2 days (6d+2d, stippled). 
Data presented is the mean ± SEM: *** P<0.001, ** P<0.01, * P<0.05 (N=5). 
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Figure 4.15: Analysis of bone marrow haematopoiesis in CishlacZ/lacZ mice following EPO 
stimulation by differential count 
Differential counts for various cell types (pro-erythroblast: PRO, basophilic erythroblast: 
BASO, polychromatic erythroblast: POLY, orthochromatic erythroblast: ORTHO, 
neutrophils: NEUT, eosinophil; EOS, monocyte: MON, lymphocyte: LYMPH) in the bone 
marrow for Cish+/+ mice (WT, green) (A) and its fold-change (B), and CishlacZ/lacZ mice (KO, 
red) (C) and its fold-change, along with fold-change between them (KO vs WT, orange) (E) 
for uninjected mice (0d, no pattern) or mice injected with EPO for 4 days (4d, horizontal 
stripe), 6 days (6d, vertical stripe) or for 6 days followed by no injection for 2 days (6d+2d, 
stippled). It was determined by counting the respective cell populations visible in Giemsa-
stained cytospins, with 300 cells counted per sample. Data presented as the mean ± SEM: *** 
P<0.001, ** P<0.01, * P<0.05 (N=5). 
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Figure 4.16: Analysis of bone marrow colony-forming cells in CishlacZ/lacZ mice following 
EPO stimulation 
Quantitation of specific colony-forming unit (CFU) and blast-forming unit (BFU) cell 
population (erythrocyte: E, granulocyte: G, macrophage: M, granulocyte/macrophage: GM, 
granulocyte/erythrocyte/macrophage/megakaryocyte: GEMM) frequency in the bone marrow 
for Cish+/+ mice (WT, green) (A) and its fold-change (B), and CishlacZ/lacZ mice (KO, red) (C) 
and its fold-change, along with fold-change between them (KO vs WT, orange) (E) for 
uninjected mice (0d, no pattern) or mice injected with EPO for 4 days (4d, horizontal stripe) 
and 6 days (6d, vertical stripe). Shown is the mean ± SEM: *** P<0.001, ** P<0.01, * 
P<0.05 (N=5). 
  









Figure 4.17: Analysis of spleen cellularity in CishlacZ/lacZ mice following EPO stimulation 
Quantitation of total cell number in the spleen for Cish+/+ mice (WT, green) (A) and its fold-
change (B) and CishlacZ/lacZ mice (KO, red) (C) and its fold-change, along with fold-change 
between them (KO vs WT, orange) (E) for uninjected mice (0d, no pattern) or mice injected 
with EPO for 4 days (4d, horizontal stripe), 6 days (6d, vertical stripe) or for 6 days followed 
by no injection for 2 days (6d+2d, stippled). Data presented is the mean ± SEM: *** 
P<0.001, ** P<0.01, * P<0.05 (N=5). 
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Figure 4.18: Analysis of spleen lineage composition in CishlacZ/lacZ mice following EPO 
stimulation 
Quantitation of total number of various lineage-specific cell populations (Ter119+, CD61+, 
Gr-1+, CD11b+) in the spleen for Cish+/+ mice (WT, green) (A) and its fold-change (B) and 
CishlacZ/lacZ mice (KO, red) (C) and its fold-change, along with fold-change between them 
(KO vs WT, orange) (E) for uninjected mice (0d, no pattern) or mice injected with EPO for 4 
days (4d, horizontal stripe), 6 days (6d, vertical stripe) or for 6 days followed by no injection 
for 2 days (6d+2d, stippled). Data presented is the mean ± SEM: *** P<0.001, ** P<0.01, * 
P<0.05 (N=5). 
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Figure 4.19: Analysis of spleen lineage frequency in CishlacZ/lacZ mice following EPO 
stimulation 
Quantitation of relative number of various lineage-specific cell populations (Ter119+, CD61+, 
Gr-1+, CD11b+) in the spleen for Cish+/+ mice (WT, green) (A) and its fold-change (B) and 
CishlacZ/lacZ mice (KO, red) (C) and its fold-change, along with fold-change between them 
(KO vs WT, orange) (E) for uninjected mice (0d, no pattern) or mice injected with EPO for 4 
days (4d, horizontal stripe), 6 days (6d, vertical stripe) or for 6 days followed by no injection 
for 2 days (6d+2d, stippled). Data presented is the mean ± SEM: *** P<0.001, ** P<0.01, * 
P<0.05 (N=5). 
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Figure 4.20: Analysis of spleen erythropoiesis in CishlacZ/lacZ mice following EPO 
stimulation by FACS 
Quantitation of the relative number of specific erythroid cell populations (pro-erythroblast: 
PRO, basophilic erythroblast: BASO, polychromatic erythroblast: POLY, orthochromatic 
erythroblast: ORTHO, reticulocyte: RETIC, red blood cell: RBC) in the spleen for Cish+/+ 
mice (WT, green) (A) and its fold-change (B), and CishlacZ/lacZ mice (KO, red) (C) and its 
fold-change, along with fold-change between them (KO vs WT, orange) (E) for uninjected 
mice (0d, no pattern) or mice injected with EPO for 4 days (4d, horizontal stripe), 6 days (6d, 
vertical stripe) or for 6 days followed by no injection for 2 days (6d+2d, stippled). Data 
presented is the mean ± SEM: *** P<0.001, ** P<0.01, * P<0.05 (N=5). 
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Figure 4.21: Analysis of spleen haematopoiesis in CishlacZ/lacZ mice following EPO 
stimulation by differential count 
Differential counts for various cell types (pro-erythroblast: PRO, basophilic erythroblast: 
BASO, polychromatic erythroblast: POLY, orthochromatic erythroblast: ORTHO, 
neutrophils: NEUT, eosinophil; EOS, monocyte: MON, lymphocyte: LYMPH) in the spleen 
for Cish+/+ mice (WT, green) (A) and its fold-change (B), and CishlacZ/lacZ mice (KO, red) (C) 
and its fold-change, along with fold-change between them (KO vs WT, orange) (E) for 
uninjected mice (0d, no pattern) or mice injected with EPO for 4 days (4d, horizontal stripe), 
6 days (6d, vertical stripe) or for 6 days followed by no injection for 2 days (6d+2d, stippled). 
It was determined by counting the respective cell populations visible in Giemsa-stained 
cytospins, with 300 cells counted per sample. Data presented as the mean ± SEM: *** 
P<0.001, ** P<0.01, * P<0.05 (N=5). 
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Figure 4.22: Analysis of spleen colony-forming cells in CishlacZ/lacZ mice following EPO 
stimulation 
Quantitation of specific colony-forming unit (CFU) and blast-forming unit (BFU) cell 
population (erythrocyte: E, granulocyte: G, macrophage: M, granulocyte/macrophage: GM, 
granulocyte/erythrocyte/macrophage/megakaryocyte: GEMM) frequency in the spleen for 
Cish+/+ mice (WT, green) (A) and its fold-change (B), and CishlacZ/lacZ mice (KO, red) (C) 
and its fold-change, along with fold-change between them (KO vs WT, orange) (E) for 
uninjected mice (0d, no pattern) or mice injected with EPO for 4 days (4d, horizontal stripe) 
and 6 days (6d, vertical stripe). Shown is the mean ± SEM: *** P<0.001, ** P<0.01, * 
P<0.05 (N=5). 
  
















Chapter 5. CISH regulation of myelopoiesis 
  




Myelopoiesis is the commonly used term to describe the development of monocytes, 
macrophages, neutrophils, eosinophils, basophils and mast cells from 
granulocyte/macrophage progenitors (Rosmarin et al. 2005). This process is regulated by an 
array of cytokines including GM-CSF, G-CSF, M-CSF, IL-3, IL-5 and IL-6 (Mroczko et al. 
2004; Smith et al. 2001). GM-CSF impacts on steady-state and emergency granulocyte and 
monocyte/macrophage development, with additional regulatory roles in dendritic cell and T-
cell function (Rosmarin et al. 2005). G-CSF is a regulator of neutrophil homeostasis with a 
critical role in emergency granulopoiesis (Panopoulos et al. 2008), as well as mediating stem 
cell mobilization, and impacting on T cell function and dendritic cell activation (Franzke et 
al. 2003). M-CSF plays an important role in promoting the differentiation of monocytes and 
macrophages (Hu et al. 2015). IL-3 supports the production of CFU-M (Lantz et al. 1998), as 
well as promoting terminal differentiation of neutrophils, basophils, eosinophils and 
megakaryocytes (Valent et al. 1989). IL-5 has a pivotal role in the production and function of 
cells, along the eosinophil lineage (Kouro et al. 2009). IL-6 has multiple biological activities 
on a variety of cells, including monocytes, granulocytes and neutrophils and exhibits a 
variety of actions in myelopoiesis (Hibbs et al. 2007). Several of these cytokines act via 
receptors that activate STAT5 (Guthridge et al. 1998), with GM-CSF, IL-3 and IL-5 
achieving this via JAK2 (D'Andrea et al. 2000), and G-CSF via JAK1/JAK2 (Avalos et al. 
1997), with STAT1 and STAT3 also activated (Tian et al. 1996). 
CISH has been shown to be induced by both GM-CSF (Yoshimura et al. 1995), and G-CSF 
(Hunter et al. 2004), with evidence that it is able to interact with signalling by both G-CSF 
(Hunter et al. 2004) and GM-CSF (Miah et al. 2012) in vitro. However, the in vivo role of 
CISH in myelopoiesis is unknown. This Chapter aimed to investigate the physiological role 
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of Cish in myelopoiesis. Both steady-state and G-CSF-induced myelopoiesis were studied in 
the Balb/c CishlacZ/lacZ line generated in Chapter 3 in comparison to Cish+/+ mice. 
5.2 Role of CISH in steady state myelopoiesis  
Analysis of peripheral blood revealed no significant change in total white blood cell count in 
CishlacZ/lacZ mice compared to their wild-type counterparts. However, differential counts 
showed that neutrophils, monocytes and eosinophils were significantly higher in CishlacZ/lacZ 
mice with a concomitant decrease in lymphocytes (Table 5.1).  
To investigate this further, the bone marrow and spleen was analysed by FACS using 
antibodies to Gr-1 and CD11b, which are commonly used as cell surface markers for the 
myeloid lineage cells. Gr-1 is comprised of two components, Ly6C and Ly6G, with Ly6G 
exclusively expressed on neutrophils and Ly6C highly expressed on monocytes (Rose et al. 
2012). CD11b is expressed on the surface of many leukocytes and labels 
monocytes/macrophages, neutrophils and eosinophils (Misharin et al. 2013). 
CishlacZ/lacZ mice showed no significant difference in total Gr-1+ and CD11b+ cells in the bone 
marrow compared to Cish+/+ mice (Fig. 5.1A-B), but adjustment for overall cellularity 
revealed a significant increase in the relative percentage of both populations (Fig. 5.1C-D). 
Analysis of early precursors using a colony-forming assay identified a significant increase in 
total number (Fig. 5.2A-B) and frequency (Fig. 5.2C-D) of CFU-G and CFU-M, with no 
significant change in CFU-GEMM or CFU-GM (Fig. 5.2A-D). From Chapter 4, the bone 
marrow differential count also revealed significantly increased number of neutrophils, 
eosinophils and monocytes at the expense of lymphocytes in CishlacZ/lacZ mice compared to 
Cish+/+ mice (Fig. 4.2E-F). 
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In the spleen a significant increase in both the total number (Fig. 5.3A-B) and relative 
percentage (Fig. 5.3C-D) of Gr-1+ and CD11b+ cells was observed in CishlacZ/lacZ mice 
compared to Cish+/+ mice. Colony-forming assays identified elevated total number of CFU-
GEMM, CFU-G and CFU-M (Fig. 5.4A-B) and relative number of CFU-GEMM and CFU-G 
(Fig. 5.4C-D) in CishlacZ/lacZ mice compared to Cish+/+ mice. Spleen differential counts 
performed as part of Chapter 4 also revealed increased numbers of monocytes and 
lymphocytes and decreased neutrophils in CishlacZ/lacZ mice compared to Cish+/+ mice (Fig. 
4.5E-F). This collectively indicates dysregulated steady-state myelopoiesis in both bone 
marrow and spleen.  
5.3  Role of CISH in G-CSF-induced myelopoiesis 
G-CSF represent one of the critical regulators of myelopoiesis (Semerad et al. 2002), and in 
vitro studies have indicated that Cish expression is induced by G-CSF (Hunter et al. 2004). 
This suggested that altered G-CSFR-mediated responses might be responsible for some of the 
changes observed. To directly investigate the potential in vivo role of CISH in regulating G-
CSFR signalling, Cish+/+ and CishlacZ/lacZ mice were injected with G-CSF. 
In Cish+/+ mice a significant increase in circulating WBC, total mature neutrophils was 
identified following 1 day of G-CSF injection, with appreciable band cells also observed 
(Table  5.2). These effects were further increased after 5 days G-CSF injection with the 
proportion of WBC, total neutrophils, mature neutrophils and band cells all significantly 
increased when compared to 1 day of injection. Metamyelocytes were also seen in circulation 
and in addition monocytes were significantly increased. For the CishlacZ/lacZ mice, a single G-
CSF injection again led to significant elevation of WBC and total neutrophils (Table 5.2). In 
this case, the increase in mature neutrophils did not reach significance but both band cells and 
metamyelocytes cells were observed in circulation and there was also a significant increase in 
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monocytes and eosinophils, with the relative proportion of band cells, metamyelocytes, 
monocytes and eosinophils all statistically higher in the CishlacZ/lacZ mice compared to their 
Cish+/+ counterparts (Table 5.2). Following 5 days of G-CSF injection, WBC, total 
neutrophils, mature neutrophils, and band cells had all significantly increased when compared 
to a single day G-CSF injection (Table 5.2). However, there was no longer a significant 
difference in total or mature neutrophils, metamyelocytes, monocytes or eosinophils 
percentages between Cish+/+ and CishlacZ/lacZ mice following 5 days G-CSF injection, 
although band cells remained statistically elevated (Table 5.2). 
Analysis of the bone marrow in Cish+/+mice revealed a significant increase in total cellularity 
following 5 days of G-CSF injection (Fig. 5.5A-B). A significant elevation of total cellularity 
was also observed in CishlacZ/lacZ mice at both 1 and 5 days of G-CSF injection (Fig. 5.5A-B), 
such that total cellularity in CishlacZ/lacZ mice become elevated to a statistically significant 
extent compared to Cish+/+mice following 5 days G-CSF stimulation (Fig. 5.5E). 
Analysis of lineage-specific markers in the bone marrow of Cish+/+mice revealed a 
significant increase in total (Fig. 5.6A-B) and relative (Fig. 5.7A-B) number of CD11b+ cells 
after 1 day and both Gr-1+ and CD11b+ cells after 5 days G-CSF stimulation, with a 
significant reduction in the relative number of Ter119+ cells. The effects observed in 
CishlacZ/lacZ mice were similar, but slightly augmented, with a significant elevation in total 
(Fig. 5.6C-D) and relative (Fig. 5.7C-D) number of Gr-1+ and CD11b+ cells after 1 and 5 
days G-CSF. The fold-changes in Gr-1+ and CD11b+ cells were significantly higher in 
CishlacZ/lacZ compared to Cish+/+ mice after 5 days G-CSF injection in terms of total (Fig. 
5.6E) but not relative (Fig. 5.7E) number. Analysis of various bone marrow erythroid 
subpopulations revealed a similar decrease in both relative and total number of 
polychromatic, orthochromatic erythroblasts and reticulocytes after 5 days of G-CSF 
injection in both genotypes, as analysed by FACS (data not shown).  
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Analysis of colony-forming activity in Cish+/+ mice demonstrated that both total (Fig. 5.8A-
B) and relative (Fig. 5.9A-B) number of CFU-GEMM, CFU-G and CFU-M increased 
following G-CSF injection. Total CFU-GM colonies were also increased significantly 
following G-CSF injection (Fig. 5.8A-B). The effects of G-CSF injection on colony-forming 
activity in CishlacZ/lacZ mice were similar to Cish+/+ mice, but again somewhat augmented. 
CishlacZ/lacZ mice displayed significant elevation in both total (Fig. 5.8C-D) and relative (Fig. 
5.9C-D) number of CFU-GEMM, CFU-GM, CFU-G and CFU-M colonies following G-CSF 
injection, leading to statistically-significant  elevation of total (Fig. 5.8E) and relative (Fig. 
5.9E) number of CFU-GM and CFU-G colonies in CishlacZ/lacZ mice compared to Cish+/+ 
mice following G-CSF stimulation, with relative CFU-M colonies also increased. 
Bone marrow differential counts identified statistically-significant increases in the proportion 
of cells along the neutrophil lineage in Cish+/+mice after 1 day G-CSF administration, 
including myeloblasts, promyelocytes, myelocytes, metamyelocytes, band cells, mature and 
total neutrophils, along with monocytes at the expense of lymphocytes and erythroblasts (Fig. 
5.10A-B). Following 5 days G-CSF injection in Cish+/+mice, the proportion of total and 
mature neutrophils, eosinophils and monocytes cells continued to increase at the expense of 
lymphocytes and erythroblasts, with a significant decline in the relative number of 
myeloblasts, promyelocytes and myelocytes compared to mice injected for 1 day (Fig. 5.10A-
B). In CishlacZ/lacZ mice, G-CSF injection for 1 day resulted in statistically significant 
increases in myeloblasts, myelocytes, band cells and mature neutrophils along with 
eosinophils and monocytes at the expense of lymphocytes and erythroblasts (Fig. 5.10C-D). 
The relative number of mature neutrophils, eosinophils and monocytes continued to increase 
in CishlacZ/lacZ mice following 5 days G-CSF injection, with a significant decrease in the 
relative number of myelocytes and metamyelocytes (Fig. 5.10C-D). Overall, G-CSF 
administration resulted in  significant reduction in the relative number of myelocyte, 
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metamyelocytes, band cells and mature neutrophils as well as lymphocytes in CishlacZ/lacZ 
mice compared to Cish+/+ mice, with significant increases in the proportion of  eosinophils, 
monocytes and erythroblasts (Fig. 5.10E).  
G-CSF injection of Cish+/+ mice for 1 day resulted in a significant increase in spleen size 
(data not shown) and cellularity, which continued following 5 days of injection (Fig. 5.11A-
B). This was mirrored in the total (Fig. 5.12A-B) and relative (Fig. 5.13A-B) number of Gr-
1+ and CD11b+ cells. G-CSF injection of CishlacZ/lacZ mice also caused a significant increase 
in spleen size (data not shown) and cellularity after 1 and 5 days (Fig. 5.11C-D). However, 
this effect was blunted in CishlacZ/lacZ mice, such that the difference in cellularity between 
Cish+/+ and CishlacZ/lacZ mice was no longer statistically significant after G-CSF 
administration (Fig. 5.11E).  CishlacZ/lacZ mice showed a significant increase in Gr-1+ cells 
following G-CSF injection for  1 day and 5 days in terms of total (Fig. 5.12C-D) and relative 
(Fig. 5.13C-D) number, with a significant increase in total (Fig. 5.12C-D) but not relative 
(Fig. 5.13C-D) number of CD11b+ cells. Following G-CSF injection, CishlacZ/lacZ mice no 
longer showed a significant difference in total number of Gr-1+ and CD11b+ cells compared 
to Cish+/+ mice (Fig. 5.12E) with a trend for reduced relative number of GR-1+ and CD11b+ 
cells (Fig. 5.13E). Analysis of various splenic erythroid subpopulations revealed no 
significant difference in pro-, basophilic, polychromatic and orthochromatic erythroblasts, 
reticulocytes or mature red blood cells between Cish+/+ and CishlacZ/lacZ mice after G-CSF 
stimulation in terms of total or relative number (data not shown).  
An increase of both total (Fig. 5.14A-B) and relative (Fig. 5.15A-B) number of CFU-GEMM, 
CFU-GM, CFU-G and CFU-M colonies was observed in the spleen of Cish+/+ mice 
following G-CSF stimulation for 1 and 5 days. These populations were also elevated in 
CishlacZ/lacZ mice in both total (Fig. 5.14C-D) and relative (Fig. 5.15C-D) number, except 
CFU-GEMM that became significantly decreased following G-CSF injection. However, the 
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effects were blunted in CishlacZ/lacZ mice compared to Cish+/+ mice. The basal elevation of 
CFU-GEMM, CFU-G and CFU-M was no longer significantly higher following 1 and 5 days 
of G-CSF injection, with CFU-GEMM and CFU-M becoming comparatively decreased in 
CishlacZ/lacZ compared to Cish+/+ mice (Fig. 5.15E). The comparative effects on total (Fig. 
5.14E) and relative number (Fig. 5.15E) of CFU-E and BFU-E colonies following G-CSF 
treatment were more variable but followed a similar trend.  
Spleen differential counts revealed elevation of all neutrophil populations in Cish+/+ mice 
treated with G-CSF, including myeloblasts, promyelocytes, myelocytes, metamyelocytes, 
band cells, mature and total neutrophils, as well as monocytes, at the expense of lymphocytes 
and erythroblasts (Fig. 5.16. A-B). G-CSF treatment in CishlacZ/lacZ resulted in similar effects 
on all cell populations (Fig. 5.16.C-D). However, the relative number of metamyelocytes and 
band cells became significantly higher in CishlacZ/lacZ mice compared to Cish+/+ mice 
following 5 days G-CSF stimulation, with a significant increase in the relative number of 
erythroblasts at 1 day that decreased again after 5 days of G-CSF injection (Fig. 5.16.E). 
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5.4  Discussion  
Cish has been shown to be induced by a range of cytokines that impact on myelopoiesis such 
as GM-CSF, IL-3 and G-CSF (Matsumoto et al. 1997; Verdier et al. 1998), with CISH 
identified as a regulator of signalling from the G-CSF receptor (Hunter et al. 2004) and GM-
CSF receptor (Miah et al. 2012) in vitro. Using one of the novel CISH-deficient mouse lines 
generated in Chapter 3, the experiments detailed in this Chapter investigated the 
physiological role of CISH in myelopoiesis. This was achieved through the analysis of 
myeloid precursors using colony-forming assays, specific myeloid lineages using flow 
cytometry, and analysis of white blood cells by histochemistry in both steady-state and G-
CSF-induced myelopoiesis. Collectively, these studies have identified a subtle role for CISH 
in myelopoiesis.  
As described in Chapter 4, the total cellularity of CishlacZ/lacZ bone marrow was lower 
compared to that of wild-type counterparts, but this was not statistically significant. However, 
the number of bone marrow CFU-G, CFU-M, Gr-1+ and CD11b+ cells was significantly 
higher in CishlacZ/lacZ mice than Cish+/+ mice, with a significant increase in myelocytes, 
metamyelocytes, mature neutrophils, eosinophils and monocytes. In contrast, spleen 
cellularity of CishlacZ/lacZ mice was increased compared to their wild-type counterparts to a 
statistically significant extent. Moreover, the number of CFU-G, CFU-M, Gr-1+ and CD11b+ 
cells were also higher in spleen compared to Cish+/+ mice, with an increased number of 
mature neutrophils, along with a decreased lymphocytes in CishlacZ/lacZ mice. The peripheral 
blood of CishlacZ/lacZ mice also contained elevated number of mature neutrophils, eosinophils, 
and monocytes. 
A significant decrease in total bone marrow cells has also been observed in Socs1 knockout 
mice, which displayed a higher frequency of bone marrow granulocytes and monocytes than 
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wild-type littermate (Metcalf et al. 1999). However, in contrast to the CishlacZ/lacZ mice, no 
significant change in CFU-GM, CFU-G and CFU-M colonies was observed in the Socs1 
knockout mice. Mice lacking Socs1 also showed a reduction in spleen cellularity, but with a 
higher frequency of splenic granulocyte and monocyte cells, although no significant change 
in CFU-GM, CFU-G and CFU-M precursors was observed. Peripheral neutrophil numbers in 
Socs1 knockout mice were variable but were elevated approximately 2-fold compared to 
wild-type mice, whereas monocytes were normal and eosinophils decreased. This suggests 
the potential for CISH and SOCS1 to have some overlapping roles in myelopoiesis, but with 
CISH having a more important role on myeloid precursors. The effect of SOCS1 ablation has 
been attributed to loss of regulation of GM-CSFR signalling (Metcalf et al. 1999). Given the 
overlapping phenotypes, it is possible that CISH may also regulate GM-CSFR-mediated 
myelopoiesis, consistent with its proposed role in the control of GM-CSFR-mediated DC 
development (Miah et al. 2012).   
 Mice lacking Socs3 in their bone marrow exhibited an elevated number of metamyelocytes 
and mature neutrophils, with peripheral neutrophilia (Kimura et al. 2004). They also showed 
an elevated number of neutrophil progenitors in the bone marrow as well as splenomegaly 
(Croker et al. 2004). It has been suggested this was due to SOCS3 being a pivotal negative 
regulator of G-CSFR-mediated myelopoiesis. Since CISH deficiency also resulted in 
enhanced myelopoiesis, it was possible that CISH may also impact on G-CSFR-mediated 
responses.  
G-CSF injection of CishlacZ/lacZ mice led to a greater increase in total bone marrow cellularity 
than observed with Cish+/+ mice. This was associated with a slightly higher comparative 
increase of total CFU-G and CFU-M progenitor cells, as well as Gr-1+ and CD11b+ cells but 
not the relative number of the latter. Bone marrow monocytes and eosinophils were also 
comparatively increased but a reduced increase in neutrophil population was observed 
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compared to Cish+/+ mice. G-CSF administration also caused a substantial increase in the 
total cellularity of the spleen but the relative Gr-1+ and CD11b+ cell populations were 
decreased in CishlacZ/lacZ compared to Cish+/+ mice, and CFU-GM, CFU-G and CFU-M 
precursor numbers did not show any significant change. This was associated with a slight 
relative decrease in lymphocytes, but an overall increase in cells of the neutrophil lineage, but 
this was only significantly greater for band cells and metamyelocytes, with no statistically 
significant increase in mature neutrophils, eosinophils or monocytes. The peripheral blood 
showed a transient relative increase in eosinophils and monocytes, but only total WBC and 
band cells remained elevated after 5 days. 
Following G-CSF injection, mice lacking Socs3 in bone marrow showed greatly elevated 
circulating neutrophils compared to wild-type mice due to increased proliferation of 
precursors and enhanced survival of mature neutrophils, along with splenomegaly and 
neutrophil infiltration in multiple tissues (Croker et al. 2004). This was also attributed to the 
role of SOCS3 as a key regulator of G-CSF signalling. Splenomegaly was also observed in 
CishlacZ/lacZ mice (data not shown) following G-CSF administration, but not neutrophilia, 
although the total WBC number, immature band cells, monocytes and eosinophils increased. 
This suggests CISH likely only plays a limited role in the regulation of G-CSFR-mediated 
emergency myelopoiesis. Most of the differences seen following G-CSF treatment appear to 
represent simply a compounding of steady-state defects, particularly having an increased 
progenitor pool that is able to respond G-CSF. However, it is possible that CISH plays a 
negative role in mobilization responses to G-CSF, since neutrophil precursors appeared in 
circulation earlier in Cish lacZ/lacZ mice.  
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Table 5.1: Analysis of white blood cell in peripheral blood of CishlacZ/lacZ mice 
 
Data is presented as mean ± SEM for Cish+/+ mice (WT) and CishlacZ/lacZ mice (KO) (N=10 
mice) and the p-value (as determined by students t-test) of their comparison. WBC: white 
blood cell.  
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Data is presented as mean ± SEM for Cish+/+ mice (WT) and CishlacZ/lacZ mice (KO) for 
uninjected mice (0d) or mice injected with G-CSF for 1 (1d) or 5 days (5d) (N=5 mice) and 
the p-value (as determined by student t-test) of their comparison. 
Abbreviation: WBC: white blood cell. N/A: not applicable.  






Figure 5.1: Analysis of bone marrow myelopoiesis in CishlacZ/lacZ mice 
A-D Quantitation of lineage-specific cell populations (Gr-1+, CD11b+) in the bone marrow 
showing total number (A) and its fold-change (B), as well as the relative number (C) and its 
fold-change (D). 
Data is presented for Cish+/+ mice (green) and CishlacZ/lacZ mice (red) along with fold-change 
between them (KO vs WT, orange). Shown is the mean ± SEM, along with values for 
individual mice in panels A and C. * P<0.05.  
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Figure 5.2: Analysis of bone marrow colony-forming cells in CishlacZ/lacZ mice 
Quantitation of specific colony-forming unit cell populations (granulocyte: G, macrophage: 
M, granulocyte/macrophage: GM, granulocyte/erythrocyte/macrophage/megakaryocyte: 
GEMM) in bone marrow, showing total number (A) and its fold-change (B), as well as the 
frequency (per 105 cells) (C) and its fold-change (D). 
Data is presented for Cish+/+ mice (green) and CishlacZ/lacZ mice (red) along with fold-change 
between them (KO vs WT, orange). Shown is the mean ± SEM, along with values for 
individual mice in panels A and C. ** P<0.01, * P<0.05. 
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Figure 5.3: Analysis of spleen myelopoiesis in CishlacZ/lacZ mice 
A-D Quantitation of lineage-specific cell populations (Gr-1+, CD11b+) in the spleen showing 
total number (A) and its fold-change (B), as well as the relative number (C) and its fold-
change (D). 
Data is presented for Cish+/+ mice (green) and CishlacZ/lacZ mice (red) along with fold-change 
between them (KO vs WT, orange). Shown is the mean ± SEM, along with values for 
individual mice in panels A and C. ** P<0.01. 
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Figure 5.4: Analysis of spleen colony-forming cells in CishlacZ/lacZ mice 
Quantitation of specific colony-forming unit cell populations (granulocyte: G, macrophage: 
M, granulocyte/macrophage: GM, granulocyte/erythrocyte/macrophage/megakaryocyte: 
GEMM) in spleen, showing total number (A) and its fold-change (B), as well as the 
frequency (per 105 cells) (C) and its fold-change (D). 
Data is presented for Cish+/+ mice (green) and CishlacZ/lacZ mice (red) along with fold-change 
between them (KO vs WT, orange). Shown is the mean ± SEM, along with values for 
individual mice in panels A and C. ** P<0.001, * P<0.05. 
  










Figure 5.5: Analysis of bone marrow cellularity in CishlacZ/lacZ mice following G-CSF 
stimulation 
Quantitation of total cell number in the bone marrow for Cish+/+ mice (green) (A) and its 
fold-change (B) and CishlacZ/lacZ mice (red) (C) and its fold-change (D), along with fold-
change between them (KO vs WT, orange) (E) for uninjected mice (0d, no pattern) or mice 
injected with G-CSF for 1 day (1d, horizontal), or 5 days (5d, vertical) . Data presented is the 
mean ± SEM (N=5): ** P<0.01, * P<0.05  
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Figure 5.6: Analysis of bone marrow lineage composition in CishlacZ/lacZ mice following 
G-CSF stimulation 
Quantitation of total number of various lineage-specific cell populations (Ter119+, CD61+, 
Gr-1+, CD11b+) in the bone marrow for Cish+/+ mice (green) (A) and its fold-change (B) and 
CishlacZ/lacZ mice (red) (C) and its fold-change (D), along with fold-change between them (KO 
vs WT, orange) (E) for uninjected mice (0d, no pattern) or mice injected with G-CSF for 1 
day (1d, horizontal) or 5 days (5d, vertical). Data presented is the mean ± SEM (N=5): *** 
P<0.001, ** P<0.001, * P<0.05. 
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Figure 5.7: Analysis of bone marrow lineages in CishlacZ/lacZ mice following G-CSF 
stimulation 
Quantitation of relative number of various lineage-specific cell populations (Ter119+, CD61+, 
Gr-1+, CD11b+) in the bone marrow for Cish+/+ mice (green) (A) and its fold-change (B) and 
CishlacZ/lacZ mice (red) (C) and its fold-change (D), along with fold-change between them (KO 
vs WT, orange) (E) for uninjected mice (0d, no pattern) or mice injected with G-CSF for 1 
day (1d, horizontal) or 5 days (5d, vertical). Data presented is the mean ± SEM (N=5): ** 
P<0.01, * P<0.05. 
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Figure 5.8: Analysis of total bone marrow colony-forming cells in CishlacZ/lacZ mice 
following G-CSF stimulation 
Quantitation of relative number of bone marrow colony-forming cells from total cell number 
of colony-forming unit (CFU) and blast forming unit (BFU) cell population (erythrocyte: E, 
granulocyte: G, macrophage: M, granulocyte/macrophage: GM, 
granulocyte/erythrocyte/macrophage/megakaryocyte: GEMM) frequency in the bone marrow 
for Cish+/+ mice (green) (A) and its fold-change (B), and CishlacZ/lacZ mice (red) (C) and its 
fold-change, along with fold-change between them (KO vs WT, orange) (E) for uninjected 
mice (0d, no pattern) or mice injected with G-CSF for 1 day (1d, horizontal) or 5 days (5d, 
vertical) as determined by colony forming assays. Shown is the mean ± SEM (N=5): *** 
P<0.001, ** P<0.01, * P<0.05. 
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Figure 5.9: Analysis of bone marrow colony-forming cells frequency in CishlacZ/lacZ mice 
following G-CSF stimulation 
Quantitation of specific colony-forming unit (CFU) and blast-forming unit (BFU) cell 
population (erythrocyte: E, granulocyte: G, macrophage: M, granulocyte/macrophage: GM, 
granulocyte/erythrocyte/macrophage/megakaryocyte: GEMM) frequency in the bone marrow 
for Cish+/+ mice (green) (A) and its fold-change (B), and CishlacZ/lacZ mice (red) (C) and its 
fold-change, along with fold-change between them (KO vs WT, orange) (E) for uninjected 
mice (0d, no pattern) or mice injected with G-CSF for 1 day (1d, horizontal) or 5 days (5d, 
vertical) as determined by colony-forming assays. Shown is the mean ± SEM (N=5): *** 
P<0.001, ** P<0.01, * P<0.05. 
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Figure 5.10: Analysis of bone marrow haematopoiesis in CishlacZ/lacZ mice following G-
CSF stimulation by differential count 
Differential counts for various cell types (myeloblast, promyelocyte, myelocyte, 
metamyelocyte, band cell, neutrophils, eosinophil, monocyte, lymphocyte and erythroblasts) 
in the bone marrow for Cish+/+ mice (green) (A) and its fold-change (B), and CishlacZ/lacZ mice 
(red) (C) and its fold-change, along with fold-change between them (KO vs WT, orange) (E) 
for uninjected mice (0d, no pattern) or mice injected with G-CSF for 1 day (1d, horizontal) or 
5 days (5d, vertical), which was done by counting the respective cell populations visible in 
Giemsa-stained cytospins, with a total of 300 cells counted per sample. Data presented as the 
mean from ± SEM (N=5): *** P<0.001, ** P<0.01, * P<0.05. 
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Figure 5.11: Analysis of spleen cellularity in CishlacZ/lacZ mice following GCSF 
stimulation 
Quantitation of total cell number in the spleen for Cish+/+ mice (green) (A) and its fold-
change (B) and CishlacZ/lacZ mice (red) (C) and its fold-change (D), along with fold-change 
between them (KO vs WT, orange) (E) for uninjected mice (0d, no pattern) or mice injected 
with G-CSF for 1 day (1d, horizontal), or 5 days (5d, vertical). Data presented is the mean ± 
SEM (N=5): ** P<0.01, * P<0.05. 
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Figure 5.12: Analysis of spleen lineage composition in CishlacZ/lacZ mice following G-CSF 
stimulation 
Quantitation of total number of various lineage-specific cell populations (Ter119+, CD61+, 
Gr-1+, CD11b+) in the spleen for Cish+/+ mice (green) (A) and its fold-change (B) and 
CishlacZ/lacZ mice (red) (C) and its fold-change (D), along with fold-change between them (KO 
vs WT, orange) (E) for uninjected mice (0d, no pattern) or mice injected with G-CSF for 1 
day (1d, horizontal) or 5 days (5d, vertical). Data presented is the mean ± SEM (N=5): ** 
P<0.01, * P<0.05. 
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Figure 5.13: Analysis of spleen lineage frequency in CishlacZ/lacZ mice following G-CSF 
stimulation 
Quantitation of relative number of various lineage-specific cell populations (Ter119+, CD61+, 
Gr-1+, CD11b+) in the spleen for Cish+/+ mice (green) (A) and its fold-change (B) and 
CishlacZ/lacZ mice (red) (C) and its fold-change (D), along with fold-change between them (KO 
vs WT, orange) (E) for uninjected mice (0d, no pattern) or mice injected with G-CSF for 1 
day (1d, horizontal) or 5 days (5d, vertical). Data presented is the mean ± SEM (N=5): ** 
P<0.001, * P<0.05. 
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Figure 5.14: Analysis of total spleen colony-forming cells in CishlacZ/lacZ mice following 
G-CSF stimulation 
Quantitation of relative number of spleen colony-forming cells from total cell number of 
colony-forming unit (CFU) and blast-forming unit (BFU) cell population (erythrocyte: E, 
granulocyte: G, macrophage: M, granulocyte/macrophage: GM, 
granulocyte/erythrocyte/macrophage/megakaryocyte: GEMM) frequency in the spleen for 
Cish+/+ mice (green) (A) and its fold-change (B), and CishlacZ/lacZ mice (red) (C) and its fold-
change, along with fold-change between them (KO vs WT, orange) (E) for uninjected mice 
(0d, no pattern) or mice injected with G-CSF for 1 day (1d, horizontal) or 5 days (5d, 
vertical) as determined by colony-forming assays. Shown is the mean ± SEM (N=5): *** 
P<0.001, ** P<0.01, * P<0.05. 
  





 Chapter 5: CISH regulation of myelopoiesis 
211 
 
Figure 5.15: Analysis of spleen colony-forming cells frequency in CishlacZ/lacZ mice 
following G-CSF stimulation 
Quantitation of specific colony-forming unit (CFU) and blast-forming unit (BFU) cell 
population (erythrocyte: E, granulocyte: G, macrophage: M, granulocyte/macrophage: GM, 
granulocyte/erythrocyte/macrophage/megakaryocyte: GEMM) frequency in the spleen for 
Cish+/+ mice (green) (A) and its fold-change (B), and CishlacZ/lacZ mice (red) (C) and its fold-
change, along with fold-change between them (KO vs WT, orange) (E) for uninjected mice 
(0d, no pattern) or mice injected with G-CSF for 1 day (1d, horizontal) or 5 days (5d, 
vertical) as determined by colony forming assay. Shown is the mean ± SEM (N=5): *** 
P<0.001, ** P<0.01, * P<0.05. 
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Figure 5.16: Analysis of spleen haematopoiesis in CishlacZ/lacZ mice following G-CSF 
stimulation by differential count 
Differential counts for various cell types (myeloblast, promyelocyte, myelocyte, 
Metamyelocyte, band cell, neutrophils, eosinophil, monocyte, lymphocyte and erythroblasts) 
in the spleen for Cish+/+ mice (green) (A) and its fold-change (B), and CishlacZ/lacZ mice (red) 
(C) and its fold-change, along with fold-change between them (KO vs WT, orange) (E) for 
uninjected mice (0d, no pattern) or mice injected with G-CSF for 1 day (1d, horizontal) or 5 
days (5d, vertical), which was done by counting the respective cell populations visible in 
Giemsa-stained cytospins, with a total of 300 cells counted per sample. Data presented as the 
mean from ± SEM (N=5): *** P<0.001, ** P<0.01, * P<0.05. 
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6.1  Generation of Cish knockout mice 
CISH was the first member of the SOCS family identified (Yoshimura et al. 1995). However, 
at the time that this project commenced no Cish mouse knockout had been published. A Cish 
allele targeted with a lacZ-neo cassette (CishlacZ) was introduced into two different genetic 
backgrounds, C57/BL6 and Balb/c, to facilitate a thorough analysis of CISH function. 
Western blot analysis on homozygous CishlacZ/lacZ mice failed to detect CISH expression 
suggesting this was likely a global knock out. 
CishlacZ/lacZ mice were viable and healthy, with no overt defects. This is consistent with 
unpublished reports of CISH-deficient mice lacking a phenotype (Matsumoto et al. 1999) as 
well as several recent studies reporting that Cish knockout mice were healthy, fertile and with 
no obvious phenotypic abnormality (Delconte et al. 2016; Palmer et al. 2015; Yang et al. 
2013). CISH transgenic mice were similarly viable and developed normally (Matsumoto et al. 
1999). Collectively this suggests that CISH does not exert a major effect on embryonic 
development, survival and fecundity.  
6.2 Expression of Cish knockout mice 
The presence of a lacZ insertion in the Cish locus enabled the use of β-galactosidase staining 
to monitor Cish expression, as the endogenous Cish promoter in CishlacZ/lacZ mice remained 
intact. This revealed strong expression of Cish in the fetal liver from 12.5 dpc that continued 
to 15.5 dpc with additional staining in vertebrae and brain, as well as in the tail, forelimb and 
digits later in embryonic development. 
Previous research had revealed high expression of Cish in the fetal liver and kidney, as well 
as at a moderate level in the developing lung, with expression in other fetal tissues at low 
levels (Uchida et al. 1997). Haematopoiesis commences in the mouse fetal liver from 12.5 
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dpc and continues to 16.5 dpc, being principally involved in the production of erythrocytes 
(Dzierzak et al. 1995). The EPO receptor is one of the key factors enabling embryonic 
erythropoiesis and is strongly expressed in the fetal liver during this time (McGann et al. 
1997).  This suggested that Cish may be induced by EPO receptor signalling in the tissue, 
consistent with its induction by EPO in vitro (Yoshimura et al. 1997). 
CISH has been shown to be a direct STAT5 target gene (Matsumoto et al. 1997; Moriggl et 
al. 1999). Several studies have examined expression of STAT5 during mouse development, 
which have revealed expression in the fetal liver (Bunting et al. 2002), lung (Zscheppang et 
al. 2011), brain (Yu et al. 2002), bone (Udy et al. 1997) and skin (Gallego et al. 2001). This 
may indicate the expression of Cish in several locations in the developing mouse embryo is 
potentially mediated via activation of the widely-expressed STAT5. 
Widespread expression of Cish was also observed in adult mice using β-galactosidase 
staining, including in the brain, eye, lung, heart, thymus, liver, kidney, pancreas and fat, as 
well as mammary gland and genital organs. Previous analysis of Cish expression 
demonstrated strong expression of Cish in the adult mouse kidney, lung and liver (Uchida et 
al. 1997; Yoshimura et al. 1995), and lower level expression in the heart, stomach, testis, 
spleen and thymus (Starr et al. 1997; Yoshimura et al. 1995). Within the adult mouse brain 
CISH expression has been observed in the cortex and hypothalamus (Kasagi et al. 2004). 
Collectively, this points to broad expression of Cish, with the potential to be involved in 
numerous physiological systems.  
The paradigm for SOCS genes is that steady state levels of mRNA and protein are low 
probably due to active transcriptional repression and rapid degradation of transcript and 
protein, but  they get more prominent with rapid induction typically via STAT protein in 
response to cytokines and other factors (Alexander et al. 2004). Study of transgenic mice in 
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which the expression of a lacZ reporter gene was directed by STAT5-specific response 
elements identified expression in mammary epithelial cells, liver hepatocytes, kidney, spleen, 
thymus and uterus of adult mice (Bednorz et al. 2011). Moreover, Stat5abN/N mice 
displayed negligible Cish expression (Teglund et al. 1998), suggesting STAT5 could be the 
major mediator of Cish expression. Therefore, cytokines that activate STAT5 likely 
contribute to the Cish expression observed.  
CISH has been shown to be induced by EPO, GM-CSF and G-CSF (Yoshimura et al. 1995), 
as well as PRL (Pezet et al. 1999) and GH (Adams et al. 1998), which may underpin 
expression in the spleen, mammary gland and liver, respectively. CISH mRNA has also been 
demonstrated to be induced in rat hypothalamus after human GH (hGH) administration, 
specifically in the arcuate nucleus and periventricular nucleus (Kasagi et al. 2004), providing 
a potential explanation for some of the expression in the brain. CISH has additionally been 
shown to be significantly induced by IL-2 in lymphocytes (Aman et al. 1999) via TCR 
stimulation (Palmer et al. 2015), by IL-4 via STAT5 in T cells (Yang et al. 2013), and in 
response to IL-15 in NK cells (Delconte et al. 2016), that may underpin expression of Cish 
observed in the spleen and thymus.  
Enhanced expression of Cish was observed during mid-pregnancy and lactation in the ovary, 
mammary gland and brain. Expression of Cish mRNA was previously shown to be 
augmented in the rat ovary from mid-gestation, which was associated with elevated 
endogenous tyrosine phosphorylated STAT5, presumed to be via enhanced PRL receptor 
signalling (Anderson et al. 2009). Increased CISH mRNA expression was also observed in 
the brain of lactating rats concomitant with increased STAT5 activation via PRL (Anderson 
et al. 2006). Therefore, PRL represents a likely mediator of these enhanced Cish expression 
during pregnancy and lactation. 
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6.3  CISH regulation of erythropoiesis  
6.3.1  Fetal erythropoiesis  
CISH was initially identified as a negative feedback regulator of EPOR signalling in vitro 
(Yoshimura et al. 1995). The data presented in Chapter 3 showed that Cish was highly 
expressed in the fetal liver. The results in Chapter 4 revealed that its ablation caused aberrant 
fetal erythropoiesis, with reduced CFU-E and BFU-E but more immature erythroblasts in 
CishlacZ/lacZ mice compared to their wild-type counterparts, although mature RBC were not 
elevated.  
Fetal erythropoiesis mainly relies on signal transduction through EPOR, JAK2 and STAT5. 
Mice defective in EPO or EPOR (Wu et al. 1995) or JAK2 (Neubauer et al. 1998) showed 
defective fetal erythropoiesis. Red blood cell progenitors were produced, but maturation did 
not occur (Wu et al. 1995). In addition, mice with a truncated form of EPOR (EPORH), which 
is able to activate STAT5 but not other signalling pathways, displayed no major fetal 
erythroid phenotype, suggesting STAT5 is the pivotal mediator of EPOR responses (Menon 
et al. 2006a; Menon et al. 2006b). This was confirmed in Stat5a-/- Stat5b-/- mice, which 
displayed embryonic or neonatal lethality due to severe microcytic anaemia associated with 
decreased survival of erythroid precursors (Kerenyi et al. 2008). Expression of a 
constitutively-active STAT5 in zebrafish embryos resulted in enhanced levels of embryonic 
erythroid cells (Lewis et al. 2006). It is therefore likely that the effect of CISH ablation is due 
to enhanced EPOR signalling via JAK2 and STAT5 leading to expansion of immature 
erythroblasts. However, the fact that this does not translate to more mature red cells suggests 
that the balance between production and differentiation is also impacted. Interestingly, 
ablation of the pro-apoptotic Caspase 8 gene resulted in a reduction in colony-forming cells 
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but with elevated number of erythrocytes (Varfolomeev et al. 1998). Therefore, it might be 
useful to consider if CISH ablation also effects survival of fetal erythroid cells. 
6.3.2  Steady-state erythropoiesis  
Subtle alterations in red blood cell indices were observed in the peripheral blood of adult 
CishlacZ/lacZ mice with a mild steady-state anaemia characterized by a decreased haematocrit. 
No changes in bone marrow cellularity, CFU-E or BFU-E were detected, although the 
number of immature erythroblasts was greater compared to wild-type, but a reduction in 
reticulocytes and RBC numbers was observed in CishlacZ/lacZ mice compared to wild-type. In 
contrast, the spleen showed an increase in total cellularity, CFU-E, BFU-E and erythroblasts, 
suggesting compensation for aberrant bone marrow erythropoiesis.  
EPOR is principally expressed on immature erythroblasts and plays an important role in adult 
erythropoiesis (Broudy et al. 1991). Studies using a mouse model expressing EPO in the liver 
but not in the kidney showed when erythropoietin production switches from liver to kidney 
post-weaning mice experience anaemia, suggesting EPO is indispensable for adult 
erythropoiesis (Yamazaki et al. 2013). The embryonic lethality of Stat5a-/- Stat5b-/- mice has 
prevented definitive studies on the role of STAT5 protein in adult erythropoiesis. However, 
those Stat5ΔN/ΔN mice that survived to adulthood showed no signs of anaemia, with normal 
levels of CFU-E and BFU-E, suggesting STAT5A and STAT5B were dispensable for adult 
erythropoiesis (Socolovsky et al. 2001; Teglund et al. 1998). However, these mice displayed 
an increased spleen size, with significant expansion of spleen red pulp suggesting a 
compensatory response was occurring (Teglund et al. 1998). Enhanced EPOR signalling due 
to truncating mutations in EPOR or activating downstream JAK2 mutations have been shown 
to increase red blood cells (Huang et al. 2010). Overexpression of constitutively active 
STAT5 in human erythroid progenitor cells also enhanced erythropoiesis, with increased 
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CFU-E observed (Garçon et al. 2006; Wierenga et al. 2008). The phenotype observed in 
CishlacZ/lacZ bone marrow does not fit with it being part of a simple negative regulating circuit 
leading to enhanced EPOR/STAT5 signalling throughout the erythroid lineage. Instead, it 
points again to a role in controlling the balance of proliferation versus differentiation in early 
precursors. Therefore, a possible mechanism of abnormal erythroid development in 
CishlacZ/lacZ bone marrow could be an increase rate of proliferation at early stage of 
erythropoiesis leading to significant elevation of immature erythroblasts. Moreover, it is 
possible that other negative regulators act at later stages of erythropoiesis, with both SOCS1 
(Sarna et al. 2003) and SOCS3 (Marine et al. 1999) but shown to have a regulatory role in 
erythropoiesis and therefore representing potential candidates. In addition to its potential 
effect of on EpoR signalling, it is possible that CISH would influence signalling pathways 
activated by other cytokines and/or growth factors to regulate erythropoiesis. GM-CSF has 
been reported to promote the proliferation and survival of early erythroid progenitors (Singh 
et al. 2014). Function of GM-CSF can also impact to the survival, activation and proliferation 
of erythroid lineages (Hercus et al. 2009), and facilitating the transition from BFU-E to CFU-
E formation (Sieff et al. 1989). Moreover, GM-CSF are well known as one of the growth 
factors that control macrophages development. Macrophages can impact on erythropoiesis 
(Fabrieck et al 2007). CISH has been reported to control GM-CSF signalling (Miah et al. 
2012). Therefore, absence of CISH could result in altered macrophages numbers and 
subsequently impact on erythropoiesis. 
The spleen is an important secondary site for erythropoiesis, contributing up to 10% basally, 
which is increased when required (Vacha et al. 1982). CishlacZ/lacZ mice exhibited increased 
erythropoiesis in the spleen size with elevated Ter119+ cells, CFU-E and BFU-E. This is in 
line with other studies showing that mice carrying mutations in various erythroid-regulating 
genes, including Stat5ΔN/ΔN (Teglund et al. 1998), Gata1-/- (Vannucchi et al. 2001), as well as 
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the negative regulator Shp1-/- (Van Zant et al. 1989) also showed enhanced splenic 
erythropoiesis.  
Macrophages have been shown to have an important impact on erythropoiesis in both the 
bone marrow and spleen by regulating haeme-iron homeostasis within the erythroid cell 
lineage (Soares et al. 2017). The number of CD11b+ cells, which mainly represent 
macrophages, was found to be decreased in the bone marrow of CishlacZ/lacZ mice compared to 
their wild-type counterparts as were the number of erythroid TER119+ cells. In contrast, 
there were increased numbers of CD11b+ and TER119+ cells in the spleen of CishlacZ/lacZ 
mice. This suggests the altered macrophages numbers may be impacting on erythropoiesis. 
CISH expression has been reported to be induced by GM-CSF and CISH participates in the 
control of GM-CSF signalling (Miah et al. 2012). GM-CSF has also been shown to impact on 
the proliferation and differentiation of early erythroid progenitors (Bot et al. 1989), mediated 
by macrophages in the erythroblastic islands (Manwani et al. 2008). The interaction between 
CD163+ macrophages and erythroblasts promoted the latter’s their expansion but not 
differentiation (Fabriek et al. 2007), with over-expression of GM-CSF resulting in 
impairment of bone marrow erythropoiesis (Chow et al. 2013). Therefore, the absence of 
CISH may result in loss of negative regulation of GM-CSFR signaling that could impact 
directly on macrophage numbers that could contribute to an increase in erythroid precursor 
proliferation at the expense of differentiation in the bone marrow of CishlacZ/lacZ mice 
compared to their wild-type counterparts. 
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6.3.3 EPO-induced erythropoiesis  
CishlacZ/lacZ mice showed a delayed and blunted elevation of erythroid populations in the bone 
marrow following EPO injection, although these continued to increase after EPO injection 
was stopped. The level of response in the spleen of CishlacZ/lacZ mice was greater than in wild-
type counterparts, leading to increased BFU-E, CFU-E and immature erythroblasts compared 
to wild-type mice following EPO injection. However, circulating RBC and reticulocytes in 
CishlacZ/lacZ mice did not display a significant change following EPO injection compared to 
wild-type mice, with haematocrit was lower in CishlacZ/lacZ compared to wild-type mice.  
Mice expressing the truncated EPOR (EPO-HM), that only activates low levels of STAT5 
failed to upregulate erythroblast production in the spleen following EPO injection, with the 
haematocrit unchanged (Porpiglia et al. 2012). Adult Stat5abΔN/ΔN mice showed a sluggish 
response to erythropoietic stress, producing lower numbers of circulating reticulocytes 
compared to wild-type mice (Socolovsky et al. 2001). These studies suggest that high levels 
of STAT5 activation is crucial for mediating the high levels of erythropoiesis required under 
these conditions, and presumably in response to EPO. It has also been shown that early 
erythroblasts are able to respond to EPO in a high-intensity graded manner, while later 
erythroblasts respond in a low-intensity binary manner (Porpiglia et al. 2012). The extended 
sustained erythropoiesis in CishlacZ/lacZ mice post-EPO injection in consistent with a model in 
which the absence of CISH-mediated negative regulation result in high levels of STAT5 
activation in erythroid precursors, which respond proportionally, whereas later erythroblasts 
cannot, causing a bottleneck that blunts overall erythrocyte production with EPO. This is 
alleviated post-EPO withdrawal with a spike in erythrocyte production. Perusing 
confirmation of this model biochemically would be highly valuable. 
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6.4 CISH regulation of myelopoiesis 
6.4.1  Steady-state myelopoiesis  
CishlacZ/lacZ mice displayed increased numbers of CFU-GM, CFU-G and CFU-M progenitors, 
as well as Gr-1+ and CD11b+ cells in both bone marrow and spleen. The bone marrow of 
CishlacZ/lacZ mice also possessed elevated number of immature neutrophils, mature 
neutrophils, eosinophils and monocytes, but no significant change in these cells was observed 
in the spleen when compared to wild-type mice. CishlacZ/lacZ mice also showed increased 
relative numbers of circulating neutrophils, monocytes and eosinophils at the expense of 
lymphocytes.  
Myelopoiesis is controlled by a number of cytokines that play essential roles in steady-state 
conditions. Mice lacking IL-5R exhibited decreased numbers of circulating eosinophils 
(Nishinakamura et al. 1996), those with ablated IL-3 showed abnormal mast cell 
differentiation (Lantz et al. 1998), and mice lacking M-CSFR displayed macrophage 
deficiency (Dai et al. 2002).  Ablation of G-CSF or G-CSFR resulted in a reduction in 
peripheral blood neutrophils and monocytes with decreased myeloid progenitors in the 
marrow and spleen (Lieschke et al. 1994; Liu et al. 1996). Mice expressing a hyper-
responsive form of truncated G-CSFR (Δ715/ Δ715), which show sustained signalling in 
response to G-CSFR, possessed a decreased number of circulating neutrophils compared to 
wild-type counterparts, but CFU-GM, CFU-G and CFU-M were slightly increased (Hermans 
et al. 1998). The effect of CISH ablation suggests that it plays a role in the negative 
regulation of G-CSFR signalling, but potentially could also exert effect on IL-5R or M-CSFR 
signalling.  
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Stat5a-/-  Stat5b-/-  mice showed aberrant granulopoiesis with reduced circulating neutrophils, 
and reduced CFU-GM, CFU-G and CFU-M, thought to be due to defective GM-CSF-induced 
proliferation and survival signalling (Fiévez et al. 2007; Kimura et al. 2009).   Stat5abΔN/ΔN 
(truncated hypomorphic STAT5) mice possessed decreased numbers of CFU-GM and CFU-
G with reduced white blood cell counts, although an increased proportion of neutrophils was 
observed (Yao et al. 2006), but this was likely a secondary effect from compensatory G-CSF 
production by liver endothelial cells (Fiévez et al. 2007). Moreover, expression of a gain-of-
function STAT5 mutant in hypomorphic Stat5abΔN/ΔN mice led to high numbers of circulating 
neutrophils (Lin et al. 2013). This suggests that CISH may regulate STAT5 activation during 
myelopoieis, with its ablation causing enhanced STAT5 activation. Interestingly, mice 
lacking STAT3 in their haematopoietic progenitors exhibited basal neutrophilia (Lee et al. 
2002; Panopoulos et al. 2006). It has been suggested that this STAT3-mediated negative 
regulation of neutrophil production was due to induction of SOCS3 (Croker et al. 2004). The 
data presented here suggested that CISH may work in a parallel, independent manner in the 
regulation of G-CSFR-mediated granulopoiesis as well as myelopoiesis more broadly.  
6.4.2 G-CSF-induced myelopoiesis  
Following G-CSF injection, CishlacZ/lacZ mice exhibited increased bone marrow cellularity, 
CFU-GM, CFU-G, CFU-M, monocytes and eosinophils, but with decreased relative number 
of immature and mature neutrophils compared to their wild-type counterparts. CishlacZ/lacZ 
mice also showed increased numbers of Gr-1+ cells and neutrophils, but decreased CFU-M, 
in the spleen following G-CSF treatment. Circulating monocytes and eosinophils were 
increased but neutrophils and lymphocytes decreased in CishlacZ/lacZ mice, but immature 
neutrophils appeared more rapidly in circulation. 
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Mice expressing a truncated hyper-responsive G-CSFR exhibited an exaggerated response 
following G-CSF administration, with mutant mice developing neutrophilia, with neutrophils 
levels peaking higher than in wild-type mice injected with G-CSF (Hermans et al. 1999). 
Therefore, the result with CishlacZ/lacZ mice suggests that CISH is not a major physiological 
regulator of G-CSFR signalling in emergency conditions, but may regulate the effects of G-
CSF on early precursors and during mobilisation. Once again, other negative regulators are 
likely to act at later stages, notably SOCS3, the ablation of which resulted in enhanced G-
CSF responsiveness including execerbated neutrophilia (Croker et al. 2004; Kimura et al. 
2004). 
 
6.5  Cish regulation of immunity 
Several studies have identified diverse roles for CISH in immune regulation. Transgenic 
expression of CISH from the β-actin promoter resulted in a significant reduction in the 
number of T, NK and NK T cells (Matsumoto et al. 1999). T cells were less responsive to IL-
2-mediated proliferation and STAT5 activation, suggesting CISH negative regulated IL-2R 
signalling, which may explain some of the lymphoid phenotypes. 
CISH has also been shown to act as negative feedback regulator of IL-15 signalling in NK 
cells (Delconte et al. 2016).  CISH was rapidly induced in response to IL-15 and interacted 
with JAK1, leading to its proteasomal degradation. Deletion of Cish rendered NK cells 
hypersensitive to IL-15, with enhanced STAT5 activation leading to increased proliferation 
and survival of NK cells, increased IFNγ production and heightened cytotoxicity toward 
tumours. Consequently, Cish-/- mice were resistant to melanoma, prostate and breast cancer 
metastasis that was exclusive to NK cell activity (Delconte et al. 2016). 
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CISH has been additionally shown to regulate IL-4 signalling in T cells (Yang et al. 2013). In 
this case, it was activated principally via STAT6. Ablation of CISH resulted in increased 
activation of STAT3, STAT5 and STAT6 and enhanced differentiation of TH2 and TH9 
cells, associated with spontaneous lung inflammation in aged mice caused by increased 
eosinophil influx (Yang et al. 2013).   
CISH has also been shown to be involved in TCR regulation. Mice expressing CISH 
transgenically in CD4+ T cells exhibited elevated proliferative and survival responses after 
TCR activation (Li et al. 2000), associated with increased MAPK activity. This is potentially 
mediated by interaction between CISH and activated protein kinase C (PKC) downstream of 
the TCR (Chen et al. 2003). Conversely, genetic deletion of Cish in CD8+ T cells resulted in 
increased number and function of these cells, resulting in durable regression of established 
tumours. This function of CISH was dependent on TCR, with CISH shown to interact with 
PLC-γ1, targeting it for proteasomal degradation following TCR stimulation (Palmer et al. 
2015).  
CISH additionally has been shown to regulate GM-CSFR signalling during early DC 
development (Miah et al. 2012). Cish was induced by GM-CSF, with CISH knockdown in 
bone marrow resulting in enhanced STAT5 activation. This was associated with elevated DC 
production through increased proliferation and reduced apoptosis, although these DCs 
showed reduced activation (Miah et al. 2012). This suggests that CISH can control late stage 
proliferation of DCs via a negative regulatory role on GM-CSF mediated STAT5 activation 
that facilitates DC differentiation.  
In addition to the roles that have been described for CISH in NK cells, T cells and their 
regulation, this thesis has identified additional roles for CISH in innate immune cell 
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regulation, namely a role in regulation of neutrophil and monocyte/macrophage production. 
Collectively, this suggests CISH is a major and complex regulator of global immunity. 
6.6 Non-haematopoietic roles for Cish 
Growth hormone (GH) is a multi-functional hormone that activates its cognate receptor, 
GHR, leading to JAK2 stimulation and STAT5 phosphorylation (Baik et al. 2011). Postnatal 
body growth has been shown to be regulated by GH-mediated STAT5B activation through 
induction of IGF-1 gene expression (Udy et al. 1997). Transgenic mice overexpressing GH 
exhibit increased body size with disproportionate hepatomegaly due to hyperplasia of 
hepatocytes, with higher activation of STAT5 and up-regulation of mitogenic signalling 
pathway that resulted in hepatic morphological changes (Martinez et al. 2016). CISH has 
been shown to negatively modulate GH signalling through binding to phosphotyrosine sites 
on the activated GHR to block further STAT5 connection and facilitate proteasome 
degradation (Ram et al. 1999). Transgenic expression of CISH resulted in a reduction in body 
size, suggesting a role in GH regulation (Matsumoto et al. 1999). However, CISH deficiency 
caused no major difference in body size, lean mass or bone length. This suggests that in 
contrast to SOCS2 (Metcalf et al. 2000) CISH does not exert a major non-redundant role in 
the negative regulation of GH signalling under physiological conditions. However, the result 
from Chapter 3 showed that aged CishlacZ/lacZ mice exhibited increased liver weight. While 
there are many explanations for this, it remains possible that CISH plays a specific role in 
negatively regulating GHR-mediated proliferative signalling in hepatocytes. 
Maintenance of energy homeostasis relies on the precise balancing of intake to expenditure. 
When such energy balance is maintained, stored energy is protected in the form of adipose 
mass (Friedman 2002b). Numerous CNS systems have been identified that are involved in the 
regulation of energy balance by responding to peripheral signals. The adipocyte-derived 
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cytokine leptin represents one of the peripheral signals regulating the CNS circuits 
(Faulconbridge et al. 2011). It is produced by adipose tissue to reduce appetite via action on 
leptin receptor in the CNS (Gainsford et al. 1996). GM-CSF also regulates energy balance, 
with administration of GM-CSF able to suppresses food intake and reduce body weight in 
rats and mice via GM-CSF receptors that are also expressed in the CNS (Reed et al. 2005). 
CISH has been reported to have a complex interaction with the leptin receptor (Lavens et al. 
2006) and is induced by GM-CSF and can regulate GM-CSFR action (Miah et al. 2012). 
Analysis of individual tissues revealed a significant decrease in abdominal fat in CishlacZ/lacZ 
mice of both sexes on the C57/BL6 and Balb/c backgrounds. A number of mechanisms could 
explain this phenotype, including enhanced metabolism or activity. However, reduced food 
intake due to enhanced appetite suppression by unrestrained Leptin receptor or GM-CSF 
receptor signalling due to loss of CISH-mediated negative regulation is worthy of further 
exploration.  
6.7  Future directions 
At the commencement of project, there was limited knowledge about role of CISH in vivo. In 
the meantime, several studies have added to our understanding about role of this member of 
SOCS family, particularly in the development of lymphoid cells and their immune function 
(Delconte et al. 2016; Palmer et al. 2015; Yang et al. 2013). The data presented in this thesis 
has identified additional roles for CISH in erythropoiesis and myelopoiesis, and hinted at 
broader functions beyond haematopoiesis. However, clearly more work is required to 
understand the complete physiological role of CISH. 
The Cish gene mutation was made by inserting a lacZ-neo cassette into the wild-type gene 
without deleting any part of the gene. Although Western blot confirmed an absence of CISH 
protein, this was performed on just one tissue sample. It remains possible that this is a  
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hypomorphic allele that may cause a partial loss of gene function instead of complete loss. In 
this case, this allele may not remove all activity of this gene. A complete loss of gene 
function (knockout allele) would provide the most valuable information about gene function. 
Since loxP sites flank the coding sequences, suitable Cre-lines could be used to generate a 
definitive knockout to further investigate the Cish gene. 
The presence of an inserted lacZ gene in the Cish locus allowed the evaluation of CISH 
expression using a simple colorimetric assay. Fluorescent β-galactosidase substances such as 
FDG can enable analysis of expression in specific cell populations through FACS analysis, 
including quantitatively (Knapp et al. 2003; Tan et al. 1994). This approach would be 
particularly useful in examining the cytokine-inducible regulation of CISH in particular 
lineages and indeed different stages of development within these lineages to shed additional 
light on the specific cytokines involved. 
The expression of CISH overlapped with that reported for other SOCS family members. This 
means CISH may have redundant functions with these SOCS proteins. Potential redundancy 
could be explored through the generation of combinational knockouts and investigating 
whether additional or exacerbated phenotypes were observed compared to the respective 
single knockout. Alternatively, other SOCS genes may compensate for the loss of CISH. 
Potential compensation could be explored by assessing if the expression of other SOCS 
members is altered in CISH mutant mice. Such compensation has been reported in zebrafish 
embryos in which a CISH homologue was ablated resulting in up-regulation of other SOCS 
members (Lewis et al. 2014). 
Several cytokines and growth factor are involved in erythropoiesis and myelopoiesis 
including EPO and SCF in erythropoiesis and GM-CSF, G-CSF and M-CSF in myelopoiesis. 
Examining the level of each of growth factor in circulation and also investigating of 
 Chapter 6: General discussion and future directions 
232 
 
cytokine/growth factor signaling component on both erythropoiesis and myelopoiesis would 
be helpful in future to find out whether CISH knockout affects signaling mediated by 
cytokines that are involved in erythropoiesis and myelopoiesis by using bone marrow and 
spleen from wild-type and CishlacZ/lacZ mice. 
The CishlacZ/lacZ mice were analysed extensively for myelopoiesis including colony forming 
unit assays, FACS with specific markers and differential counts performed in bone marrow, 
spleen and circulating blood. Significant differences in the number of neutrophils and 
macrophages was seen in circulation, which was reflected in Gr-1+ cells and relevant colony 
forming units in the bone marrow. G-CSF has been shown to act on HSC and also mediate 
their mobilization (Schuettpelz et al. 2014). Therefore, HSC are likely to have been affected, 
and so future studies of HSC in CishlacZ/lacZ mice is required to provide better understanding 
of the potential effects on early progenitor cells. 
STAT5 has been implicated in the control of haematopoiesis, where it plays a number of 
different roles, depending on the cell lineage and extent of differentiation. For example, it has 
been shown to mediate HSC quiescence, but enhance proliferation of more differentiated 
cells (Han et al. 2009). STAT5 has also been identified as a critical regulator of 
developmental erythropoiesis (Kerenyi et al. 2008) and EPO-induced erythropoiesis (Grebien 
et al. 2008; Menon et al. 2006a), and the CISH protein has been shown to negatively regulate 
STAT5 activation downstream of EPOR and other receptors (Matsumoto et al. 1997). STAT5 
also plays a key role in myelopoiesis, including the production of monocytes, macrophages, 
neutrophils and eosinophils by GM-CSFR, G-CSFR, IL-5 and M-CSF (Zhu et al. 2002), with 
the CISH protein demonstrated to regulate signalling by several of these receptors (Horikawa 
et al. 2006; Hunter et al. 2004). This study identified CISH as a key regulator of EPO-
induced erythropoiesis as well as playing a role in myelopoiesis Therefore, it is important to 
understand the effects of Cish ablation on STAT5 activation. This could be investigated by 
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analysing levels of pSTAT5 and STAT5 at steady state and in response to cytokine injection 
and other stress condition through use of Western blot or FACS analysis of specific 
haematopoietic cell populations in CishlacZ/lacZ compared to wild-type mice. 
Analysis of CishlacZ/lacZ mice revealed an intriguing phenotype of reduced fat content 
compared to their wild-type counterparts. Elucidating the underlying mechanism is clearly 
worthwhile. Initial work would involve analysis of key metabolic parameters including food 
intake, energy expenditure and activity levels on both normal and high fat diet. Cish 
expression was also modulated during pregnancy and lactation (Anderson et al. 2009), likely 
mediated by PRL. Transgenic CISH expression has been shown to suppress PRL-induced 
lactation (Matsumoto et al. 1999). Therefore, a closer examination of this process in 
CishlacZ/lacZ mice remains a priority. 
Previous studies revealed a correlation between human CISH polymorphisms and enhanced 
susceptibility to infectious diseases, including bacteraemia, malaria, tuberculosis and viral 
disease (Hu et al. 2014; Khor et al. 2010). The CishlacZ/lacZ mice provides an opportunity to 
better understand the role of CISH in the outcome of infection by these agents using 
developed murine models of infection. This would be further enhanced by using mouse 
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